vigabatrin carbamazepine use seizures absence
vigabatrin carbamazepine use seizures
carbamazepine use seizures absence
carbamazepine use seizures
vigabatrin Carbamazepine contraindicated seizures absence
vigabatrin Carbamazepine contraindicated seizures
Carbamazepine contraindicated seizures absence
Carbamazepine contraindicated seizures
carbamazepine two jerks myoclonic
carbamazepine two jerks
carbamazepine withdrawal resolved jerks myoclonic
carbamazepine withdrawal resolved jerks
testosterone screened basis desire low
testosterone screened basis desire sexual
testosterone screened basis desire
testosterone gynecomastia desire low
testosterone gynecomastia desire sexual
testosterone gynecomastia desire
testosterone Determining cases desire low
testosterone Determining cases desire sexual
testosterone Determining cases desire
testosterone missed Determining cases desire low
testosterone missed Determining cases desire sexual
testosterone missed Determining cases desire
testosterone determined cases desire low
testosterone determined cases desire sexual
testosterone determined cases desire
testosterone desire low
testosterone desire sexual
testosterone desire
LiCl contained diet consuming rats developed polyuria
Lidocaine induced asystole cardiac
Lidocaine induced asystole
ouabain administered tachycardias ventricular
ouabain administered tachycardias
CBDCA use cause damage peripheral
CBDCA use cause damage nervous
CBDCA use cause damage system
CBDCA use cause damage
CBDCA dose neurotoxicity peripheral
CBDCA dose neurotoxicity
cocaine kindled steroids efficacy seizures
cocaine engendered administration kindling seizure
cocaine administration kindling seizure
cocaine development seizures
cocaine administration induced seizures
doxorubicin cardiomyopathy
doxorubicin produced cardiomyopathy
doxorubicin produced cardiomyopathy CM
doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease myocardial
doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease
DXR doxorubicin produced cardiomyopathy
DXR doxorubicin produced cardiomyopathy CM
DXR doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease myocardial
DXR doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease
Adriamycin doxorubicin produced cardiomyopathy
Adriamycin doxorubicin produced cardiomyopathy CM
Adriamycin doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease myocardial
Adriamycin doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease
DXR proportional damage CM
DXR proportional damage myocardial
DXR proportional damage
DXR dose insult degree proportional damage CM
DXR dose insult degree proportional damage myocardial
DXR dose insult degree proportional damage
propranolol toxicity associated syndrome Amnestic
propranolol toxicity associated syndrome
streptozotocin vincristine induced hyperalgesia
streptozotocin vincristine induced hyperalgesia model chemotherapy diabetic
streptozotocin vincristine induced hyperalgesia model neuropathy
vincristine induced hyperalgesia
vincristine produced hyperalgesia
streptozotocin induced hyperalgesia
streptozotocin participates seemed bradykinin hyperalgesia
vincristine seemed participates streptozotocin induced hyperalgesia
vincristine seemed bradykinin hyperalgesia
Cocaine induced seizures
Antidepressant mania
Antidepressant mania patients bipolar
antidepressants associated mania
antidepressants associated mania switching risks Concerns continue interfere establishment paradigm depression bipolar
antidepressants associated mania switching risks Concerns continue interfere establishment paradigm depression
antidepressant therapy type diagnosis structured Patients experienced compared switch manic
antidepressant therapy type diagnosis structured Patients experienced compared switch manic hypomanic
antidepressant therapy type diagnosis II vs DSM
antidepressant therapy type diagnosis II vs IV
antidepressant therapy type diagnosis II vs bipolar
antidepressant therapy type diagnosis II vs I
antidepressant therapy type diagnosis II bipolar
antidepressant therapy type diagnosis II
antidepressant therapy type diagnosis number episodes manic
antidepressant drugs vs therapy type diagnosis structured Patients experienced compared switch manic
antidepressant drugs vs therapy type diagnosis structured Patients experienced compared switch manic hypomanic
antidepressant drugs vs therapy type diagnosis II vs DSM
antidepressant drugs vs therapy type diagnosis II vs IV
antidepressant drugs vs therapy type diagnosis II vs bipolar
antidepressant drugs vs therapy type diagnosis II vs I
antidepressant drugs vs therapy type diagnosis II bipolar
antidepressant drugs vs therapy type diagnosis II
antidepressant drugs vs therapy type diagnosis number episodes manic
serotonin inhibitors drugs vs therapy type diagnosis structured Patients experienced compared switch manic
reuptake inhibitors drugs vs therapy type diagnosis structured Patients experienced compared switch manic
inhibitors drugs vs therapy type diagnosis structured Patients experienced compared switch manic
serotonin inhibitors drugs vs therapy type diagnosis structured Patients experienced compared switch manic hypomanic
reuptake inhibitors drugs vs therapy type diagnosis structured Patients experienced compared switch manic hypomanic
inhibitors drugs vs therapy type diagnosis structured Patients experienced compared switch manic hypomanic
serotonin inhibitors drugs vs therapy type diagnosis II vs DSM
serotonin inhibitors drugs vs therapy type diagnosis II vs IV
serotonin inhibitors drugs vs therapy type diagnosis II vs bipolar
serotonin inhibitors drugs vs therapy type diagnosis II vs I
reuptake inhibitors drugs vs therapy type diagnosis II vs DSM
reuptake inhibitors drugs vs therapy type diagnosis II vs IV
reuptake inhibitors drugs vs therapy type diagnosis II vs bipolar
reuptake inhibitors drugs vs therapy type diagnosis II vs I
inhibitors drugs vs therapy type diagnosis II vs DSM
inhibitors drugs vs therapy type diagnosis II vs IV
inhibitors drugs vs therapy type diagnosis II vs bipolar
inhibitors drugs vs therapy type diagnosis II vs I
serotonin inhibitors drugs vs therapy type diagnosis II bipolar
serotonin inhibitors drugs vs therapy type diagnosis II
reuptake inhibitors drugs vs therapy type diagnosis II bipolar
reuptake inhibitors drugs vs therapy type diagnosis II
inhibitors drugs vs therapy type diagnosis II bipolar
inhibitors drugs vs therapy type diagnosis II
serotonin inhibitors drugs vs therapy type diagnosis number episodes manic
reuptake inhibitors drugs vs therapy type diagnosis number episodes manic
inhibitors drugs vs therapy type diagnosis number episodes manic
SSRIs -RSB- inhibitors drugs vs therapy type diagnosis structured Patients experienced compared switch manic
SSRIs -RSB- inhibitors drugs vs therapy type diagnosis structured Patients experienced compared switch manic hypomanic
SSRIs -RSB- inhibitors drugs vs therapy type diagnosis II vs DSM
SSRIs -RSB- inhibitors drugs vs therapy type diagnosis II vs IV
SSRIs -RSB- inhibitors drugs vs therapy type diagnosis II vs bipolar
SSRIs -RSB- inhibitors drugs vs therapy type diagnosis II vs I
SSRIs -RSB- inhibitors drugs vs therapy type diagnosis II bipolar
SSRIs -RSB- inhibitors drugs vs therapy type diagnosis II
SSRIs -RSB- inhibitors drugs vs therapy type diagnosis number episodes manic
SSRIs -LSB- treated subgroup % / patients % occurred Switches hypomania
SSRIs -LSB- treated subgroup % / patients % occurred Switches hypomania mania
SSRIs -LSB- treated subgroup % / patients % occurred experienced episodes manic
SSRIs -LSB- treated subgroup % / patients % occurred experienced experienced episodes hypomanic
dietary supplementation effect importantly contributes treated rats hypertensive
sodium supplementation effect importantly contributes treated rats hypertensive
chloride supplementation effect importantly contributes treated rats hypertensive
dietary supplementation effect hypertensive
sodium supplementation effect hypertensive
chloride supplementation effect hypertensive
dietary increase
dietary increase eliminated MAP in
dietary increase eliminated MAP
sodium increase
sodium increase eliminated MAP in
sodium increase eliminated MAP
chloride increase
chloride increase eliminated MAP in
chloride increase eliminated MAP
Pethidine associated seizure
pethidine associated seizure
combined contraceptives women thromboembolism thromboembolism venous
combined contraceptives women thromboembolism thromboembolism
oral contraceptives women thromboembolism thromboembolism venous
oral contraceptives women thromboembolism thromboembolism
contraceptives women thromboembolism thromboembolism venous
contraceptives women thromboembolism thromboembolism
combined contraceptives women thromboembolism thromboembolism VTE
oral contraceptives women thromboembolism thromboembolism VTE
contraceptives women thromboembolism thromboembolism VTE
COCs thromboembolism venous
COCs thromboembolism
COCs thromboembolism VTE
COCs had while VTE
COCs women years 2 years COCs 1 women risk VTE
COCs 1 women risk VTE
COCs women VTE
BZDs RDs use associated dizziness
BZDs RDs use associated sleep awaking night tiredness
BZDs RDs use associated dizziness inability
BZDs RDs use associated sleep to
BZDs RDs use associated sleep
BZDs RDs use associated sleep awaking symptoms depressive
BZDs RDs use associated sleep awaking symptoms
Puromycin aminonucleoside administered induce proteinuria
aminonucleoside administered induce proteinuria
PAN aminonucleoside administered induce proteinuria
capecitabine effects diarrhea vomiting
capecitabine effects diarrhea
capecitabine effects diarrhea stomatitis
capecitabine effects diarrhea hand
capecitabine effects diarrhea syndrome foot
capecitabine effects diarrhea syndrome
capecitabine effects diarrhea nausea
Haloperidol induced rigidity muscle
Haloperidol induced rigidity
haloperidol diminished rigidity muscle
haloperidol diminished rigidity
alfentanil increases rigidity
alfentanil rigidity
alfentanil used prevented rigidity
azidothymidine mice treatment produces myelodysplasia
AZT treatment produces myelodysplasia
AZT induced anemia macrocytic
AZT induced anemia
AZT therapy induced anemia macrocytic
AZT therapy induced anemia
AZT incorporation induced mentioned cells known seen syndrome myelodysplastic
AZT incorporation induced mentioned cells known seen syndrome
fluoxetine medication Increase disability Parkinson
fluoxetine medication Increase disability
fluoxetine exposure disease patients disability motor
fluoxetine exposure disease patients disability
ribavirin interferon therapy events one anemia Hemolytic
ribavirin interferon therapy events one anemia
interferon therapy events one anemia Hemolytic
interferon therapy events one anemia
ribavirin anemia hemolytic
ribavirin anemia
rifampicin administration subsequent Acute
rifampicin administration subsequent failure renal
rifampicin administration subsequent failure
dilevalol mechanism hepatitis
dilevalol mechanism reaction Hypersensitivity
dilevalol assess induced injury liver
dilevalol assess induced injury
dilevalol antigens containing serum assess induced injury liver
dilevalol antigens containing serum assess induced injury
dilevalol case antigens containing serum assess induced injury liver
dilevalol case antigens containing serum assess induced injury
dilevalol diagnosis woman year injury liver
dilevalol diagnosis woman year injury
dilevalol antigens prepared used injury liver
dilevalol antigens prepared used injury
dilevalol mechanism involvement suggesting prepared used injury liver
dilevalol mechanism involvement suggesting prepared used injury
cocaine Absence associated hemorrhage subarachnoid
cocaine Absence associated hemorrhage
cocaine patients angiograms obtained associated hemorrhage subarachnoid
cocaine patients angiograms obtained associated hemorrhage
cocaine patients angiograms obtained associated hemorrhage SAH
cocaine use underwent hemorrhage subarachnoid
cocaine use underwent hemorrhage
cocaine use underwent hemorrhage SAH
cocaine toxicology identified screened retrospectively SAH
cocaine use associated SAH
cocaine use associated SAH aneurysmal
nicotine role disease cardiovascular
nicotine role disease
Nicotine activates contribute disease cardiovascular
Nicotine activates contribute disease
nicotine play role atherosclerosis
5 undergoing assess incidence changes ischemic
FU infusion 5 undergoing assess incidence changes ischemic
5 infusion angina rare episodes Anginal
FU infusion angina rare episodes Anginal
5 infusion angina
FU infusion angina
5 02 0 13 0 + 0 incidence episodes ischemic
FU 0 13 0 + 0 incidence episodes ischemic
5 03 + 0 incidence episodes ischemic
FU infusion 0 incidence episodes ischemic
5 hour minutes + duration less P infusion 0 incidence episodes ischemic
FU v + minutes + duration less P infusion 0 incidence episodes ischemic
5 hour patient minutes + minutes + duration less P infusion 0 incidence episodes ischemic
FU P minutes + minutes + duration less P infusion 0 incidence episodes ischemic
5 infusion associated increase ischemia
- infusion associated increase ischemia
FU infusion associated increase ischemia
ibuprofen use associated described child developed Stevens
ibuprofen use associated described syndrome Johnson
ibuprofen use associated described syndrome
dexamethasone atorvastatin effects Anti hypertension
Dexamethasone characterized hypertension
Dex Dexamethasone characterized hypertension
clozapine associated myocarditis
clozapine commencement associated myocarditis
clozapine commencement developed onset myocarditis
clozapine use associated complication Myocarditis
paracetamol doses associated hepatotoxicity
acetaminophen BACKGROUND role alcohol development hepatotoxicity
paracetamol 3 developed failure liver
paracetamol 3 developed failure
paracetamol doses treated patients hepatotoxicity
penicillamine Immunopathology disease glomerular
penicillamine Immunopathology disease
D developed proteinuria
penicillamine D developed proteinuria
morphine trinitrate effect induced evaluated patients sphincter
morphine trinitrate effect induced evaluated patients sphincter dyskinesia of
morphine trinitrate effect induced evaluated patients sphincter dyskinesia Oddi
morphine trinitrate effect induced evaluated patients sphincter dyskinesia
prostigmine morphine trinitrate effect induced evaluated patients sphincter
prostigmine morphine trinitrate effect induced evaluated patients sphincter dyskinesia of
prostigmine morphine trinitrate effect induced evaluated patients sphincter dyskinesia Oddi
prostigmine morphine trinitrate effect induced evaluated patients sphincter dyskinesia
morphine provocation caused indicating spasm
Prostigmine RESULTS caused indicating spasm
morphine effect overcome able relevance treatment sphincter
morphine effect overcome able relevance treatment sphincter dyskinesia of
morphine effect overcome able relevance treatment sphincter dyskinesia Oddi
morphine effect overcome able relevance treatment sphincter dyskinesia
dobutamine stress spasm coronary
dobutamine stress spasm artery
dobutamine stress spasm
dobutamine induced ischemia due spasm coronary
dobutamine induced ischemia due spasm
dobutamine provoke patients angina coronary
dobutamine provoke patients angina spastic
dobutamine provoke patients angina
dobutamine provoke spasm coronary
dobutamine provoke spasm
Vasopressin hypotension
milrinone treatment Vasopressin hypotension
milrinone inhibitors use restricted cause vasodilation hypotension
vasopressin doses restored patients failure hypotension
milrinone treatment hypotension
milrinone effect inhibiting restored patients failure hypotension
metronidazole lesion colliculus inferior
metronidazole lesion colliculus
metronidazole lesion
metronidazole lesion encephalopathy
metronidazole lesions inferior
metronidazole lesions colliculus
metronidazole lesions
metronidazole lesions induced encephalopathy
metronidazole induced encephalopathy
metronidazole characteristic considered lesions inferior
metronidazole characteristic considered lesions colliculus
metronidazole characteristic considered lesions
metronidazole characteristic considered lesions CONCLUSIONS encephalopathy
PAN nephrosis
Puromycin nephrosis
aminonucleoside nephrosis
puromycin aminonucleoside injection induced nephrosis
aminonucleoside injection induced nephrosis
PAN BW injection induced nephrosis
PAN injection days as include phase proteinuria
PAN injection days as include phase proteinuria associated effacement phase proteinuria
gentamicin L induced loss hearing
gentamicin L induced loss
acetaminophen hepatotoxicity
acetaminophen hepatitis
acetaminophen suffering suggesting involves injury liver
acetaminophen suffering suggesting involves injury
AAP acetaminophen hepatitis
AAP acetaminophen suffering suggesting involves injury liver
AAP acetaminophen suffering suggesting involves injury
AAP injury involves suggesting suffering acetaminophen hepatitis
AAP injury liver
AAP injury
AAP hepatitis
ethanol consumption influence evaluates investigates effects diet substrate acts hepatitis
AAP presence measured inhibited damage liver
AAP presence measured inhibited damage
ethanol caused exacerbation inhibited damage liver
ethanol caused exacerbation inhibited damage
ethanol inhibited damage liver
ethanol inhibited damage
AAP mice given observed reduction hepatitis
ethanol mice given observed reduction hepatitis
AAP hepatitis
ethanol exacerbation AAP hepatitis
acetaminophen preparations use see avoid damage hepatic
acetaminophen preparations use see avoid damage
Cyclophosphamide induced cystitis
Cyclophosphamide used induce cystitis
CP Cyclophosphamide used induce cystitis
CP model induced model allowing understanding syndromes painful
CP model induced model allowing understanding syndromes
CP model induced model cystitis
methysergide woman ingestion secondary described case vasospasm
ergot history discussion includes caused ages role management headache migraine
ergot history discussion includes caused ages role management headache
ergot preparations continue play therapy migraine
steroid therapy term defect ventricular
steroid therapy term defect septal
steroid therapy term defect
steroid ventricular
steroid ventricular rupture septal
steroid ventricular rupture
steroid therapy rupture septal
steroid therapy rupture
Carmofur induced disorders organic
Carmofur induced disorders mental
Carmofur induced disorders
carmofur onset female year observed disorder Organic
carmofur onset female year observed disorder mental
carmofur onset female year observed disorder
carmofur onset female year induced leukoencephalopathy
carmofur leukoencephalopathy
raloxifene years associated risk thromboembolism venous
raloxifene years associated risk thromboembolism
Raloxifene associated risk thromboembolism venous
Raloxifene associated risk thromboembolism
Clarithromycin associated hallucinations visual
Clarithromycin associated hallucinations
clarithromycin antibiotic occurring hallucinations visual
clarithromycin antibiotic occurring hallucinations
cholesterol diffusion generation modulating hemorrhage ulcer
vitamin D coadministration induced atherosclerosis rats modulating hemorrhage ulcer
D coadministration induced atherosclerosis rats modulating hemorrhage ulcer
2 D coadministration induced atherosclerosis rats modulating hemorrhage ulcer
vitamin D coadministration induced atherosclerosis rats modulating hemorrhage gastric
vitamin D coadministration induced atherosclerosis rats modulating hemorrhage
D coadministration induced atherosclerosis rats modulating hemorrhage gastric
D coadministration induced atherosclerosis rats modulating hemorrhage
2 D coadministration induced atherosclerosis rats modulating hemorrhage gastric
2 D coadministration induced atherosclerosis rats modulating hemorrhage
cholesterol diffusion generation modulating rats atherosclerosis
vitamin D coadministration induced atherosclerosis
D coadministration induced atherosclerosis
2 D coadministration induced atherosclerosis
cholesterol diffusion generation modulating hemorrhage gastric
cholesterol diffusion generation modulating hemorrhage
cholesterol induce atherosclerosis
vitamin D containing oil kg cholesterol induce atherosclerosis
D containing oil kg cholesterol induce atherosclerosis
2 D containing oil kg cholesterol induce atherosclerosis
cholesterol calcium concentration parameters atherosclerotic
cholesterol calcium concentration parameters obtained rats atherosclerotic
paracetamol survivors Long induced failure acute
paracetamol survivors Long induced failure liver
paracetamol survivors Long induced failure
paracetamol survivors prognosis BACKGROUND induced remains failure acute
paracetamol survivors prognosis BACKGROUND induced remains failure liver
paracetamol survivors prognosis BACKGROUND induced remains failure
paracetamol induced increases acute
paracetamol induced increases liver
paracetamol induced increases failure
paracetamol caused ratio acute
paracetamol caused ratio liver
paracetamol caused ratio failure
paracetamol caused higher age age died survivors failure acute
paracetamol caused higher age age died survivors failure liver
paracetamol caused higher age age died survivors failure
Paracetamol CONCLUSIONS affect failure acute
Paracetamol CONCLUSIONS affect failure liver
Paracetamol CONCLUSIONS affect failure
heparin treatment ancrod Failure thrombosis
heparin associated remain thrombosis
heparin used prophylaxis development thrombosis
heparin used defined success patients developed syndrome thrombosis
heparin require aggregation induced heparin used prophylaxis development thrombosis
heparin require aggregation induced heparin used defined success patients developed syndrome thrombosis
heparin patient present thrombosis
Chlorpropamide induced neuropathy optic
Chlorpropamide induced neuropathy
chlorpropamide treated diabetes had neuropathy toxic
chlorpropamide treated diabetes had neuropathy optic
chlorpropamide treated diabetes had neuropathy
Diabenese diabetes had neuropathy toxic
Diabenese diabetes had neuropathy optic
Diabenese diabetes had neuropathy
chlorpropamide therapy discontinuation resolved neuropathy toxic
chlorpropamide therapy discontinuation resolved neuropathy optic
chlorpropamide therapy discontinuation resolved neuropathy
succinylcholine myalgia Postoperative
succinylcholine myalgia
succinylcholine associated effect myalgia postoperative
succinylcholine associated effect myalgia
succinylcholine incidence determined myalgia
succinylcholine pretreated patients determined myalgia
succinylcholine origin evidence myalgia
succinylcholine effective Administration IMPLICATIONS induced myalgia postoperative
succinylcholine effective Administration IMPLICATIONS induced myalgia
succinylcholine severity incidence decreasing effective Administration IMPLICATIONS induced myalgia postoperative
succinylcholine severity incidence decreasing effective Administration IMPLICATIONS induced myalgia
succinylcholine prevent myalgia postoperative
succinylcholine prevent myalgia
dexamethasone oxidase Role hypertension
dexamethasone hypertension
dexamethasone hypertension dex HT
dex hypertension
dex HT
Dex SBP increased
Dex SBP
Dex SBP thymus decreased
Dex SBP thymus
Dex SBP thymus 001 P
Dex SBP thymus 001 <
Dex SBP thymus 001 0
Dex SBP thymus 001
Dex SBP and
Dex SBP bodyweights
dex prevent HT
testosterone associated atherosclerosis
testosterone therapy estrogen women atherosclerosis
testosterone therapy affect atherosclerosis
pilocarpine model epilepsy temporal
pilocarpine model epilepsy lobe
pilocarpine model epilepsy
PILO model TLE
5 initiation
5 initiation induced
5 initiation induced carcinogens by
5 initiation induced carcinogens
azacytidine initiation
azacytidine initiation induced
azacytidine initiation induced carcinogens by
azacytidine initiation induced carcinogens
N pyrene -LSB- carcinogens induced synthesis phase given test plays role initiation
N pyrene -LSB- carcinogens induced synthesis phase given test plays role initiation process of
N pyrene -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
N pyrene -LSB- carcinogens induced synthesis phase given test plays role initiation process
methyl -LSB- carcinogens induced synthesis phase given test plays role initiation
methyl -LSB- carcinogens induced synthesis phase given test plays role initiation process of
methyl -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
methyl -LSB- carcinogens induced synthesis phase given test plays role initiation process
N methyl -LSB- carcinogens induced synthesis phase given test plays role initiation
N methyl -LSB- carcinogens induced synthesis phase given test plays role initiation process of
N methyl -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
N methyl -LSB- carcinogens induced synthesis phase given test plays role initiation process
nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation
nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation process of
nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation process
benzo -LSB- carcinogens induced synthesis phase given test plays role initiation
benzo -LSB- carcinogens induced synthesis phase given test plays role initiation process of
benzo -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
benzo -LSB- carcinogens induced synthesis phase given test plays role initiation process
-LSB- carcinogens induced synthesis phase given test plays role initiation
-LSB- carcinogens induced synthesis phase given test plays role initiation process of
-LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
-LSB- carcinogens induced synthesis phase given test plays role initiation process
a -RSB- -LSB- carcinogens induced synthesis phase given test plays role initiation
a -RSB- -LSB- carcinogens induced synthesis phase given test plays role initiation process of
a -RSB- -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
a -RSB- -LSB- carcinogens induced synthesis phase given test plays role initiation process
-RSB- -LSB- carcinogens induced synthesis phase given test plays role initiation
-RSB- -LSB- carcinogens induced synthesis phase given test plays role initiation process of
-RSB- -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
-RSB- -LSB- carcinogens induced synthesis phase given test plays role initiation process
pyrene -LSB- carcinogens induced synthesis phase given test plays role initiation
pyrene -LSB- carcinogens induced synthesis phase given test plays role initiation process of
pyrene -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
pyrene -LSB- carcinogens induced synthesis phase given test plays role initiation process
5 given test plays role initiation
5 given test plays role initiation process of
5 given test plays role initiation process carcinogenic
5 given test plays role initiation process
azacytidine 5 given test plays role initiation
azacytidine 5 given test plays role initiation process of
azacytidine 5 given test plays role initiation process carcinogenic
azacytidine 5 given test plays role initiation process
5 azacytidine 5 given test plays role initiation
5 azacytidine 5 given test plays role initiation process of
5 azacytidine 5 given test plays role initiation process carcinogenic
5 azacytidine 5 given test plays role initiation process
AzC 5 azacytidine 5 given test plays role initiation
AzC 5 azacytidine 5 given test plays role initiation process of
AzC 5 azacytidine 5 given test plays role initiation process carcinogenic
AzC 5 azacytidine 5 given test plays role initiation process
1 nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation
1 nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation process of
1 nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
1 nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation process
2 1 nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation
2 1 nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation process of
2 1 nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
2 1 nitrosourea -LSB- carcinogens induced synthesis phase given test plays role initiation process
dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation
dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process of
dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process
1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation
1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process of
1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process
2 1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation
2 1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process of
2 1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
2 1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process
DMH 1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation
DMH 1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process of
DMH 1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process carcinogenic
DMH 1 dimethylhydrazine -LSB- carcinogens induced synthesis phase given test plays role initiation process
risperidone Treatment hyperprolactinemia
Risperidone associated hyperprolactinemia
risperidone treatment report induced hyperprolactinemia
risperidone children review hyperprolactinemia
risperidone treatment hyperprolactinemia
penicillin potassium induced focus epileptic
G potassium induced focus epileptic
potassium induced focus epileptic
diclofenac etoricoxib lower rate due AEs GI
diclofenac etoricoxib lower rate due AEs
etoricoxib higher incidence discontinuations hypertension
etoricoxib % 0 001 hypertension
etoricoxib higher incidence discontinuations related oedema
etoricoxib % 0 001 01 oedema
diclofenac Discontinuations AEs GI
diclofenac Discontinuations AEs
diclofenac Discontinuations AEs higher common discontinuations AEs GI
diclofenac Discontinuations AEs higher common discontinuations AEs
metformin use associated jaundice Cholestatic
metformin use associated jaundice
metformin hydrochloride developed jaundice cholestatic
metformin hydrochloride developed jaundice
hydrochloride developed jaundice cholestatic
hydrochloride developed jaundice
methamphetamine abusing patients present hygiene caries
methamphetamine use reported experienced episodes carious
methamphetamine use reported experienced episodes
isoproterenol attenuation dose induced tachycardia
succinylcholine apnoea
succinylcholine hours apnoea
succinylcholine apnoea
doxorubicin + daunorubicin Sensitivity investigated toxicity hematologic
doxorubicin + daunorubicin Sensitivity investigated toxicity
daunorubicin Sensitivity investigated toxicity hematologic
daunorubicin Sensitivity investigated toxicity
etoposide daunorubicin Sensitivity investigated toxicity hematologic
etoposide daunorubicin Sensitivity investigated toxicity
etoposide daunorubicin reduced loss myelosuppression weight
etoposide daunorubicin reduced loss
etoposide daunorubicin reduced antagonized dexrazoxane myelosuppression loss weight
etoposide daunorubicin reduced antagonized dexrazoxane myelosuppression loss
doxorubicin cytotoxicity myelosuppression dexrazoxane antagonized reduced loss myelosuppression weight
doxorubicin cytotoxicity myelosuppression dexrazoxane antagonized reduced loss
doxorubicin cytotoxicity myelosuppression loss weight
doxorubicin cytotoxicity myelosuppression loss
daunorubicin reduced loss myelosuppression weight
daunorubicin reduced loss
daunorubicin reduced antagonized dexrazoxane myelosuppression loss weight
daunorubicin reduced antagonized dexrazoxane myelosuppression loss
etoposide doses combining metastases patients trials ongoing aim improving toxicity hematologic
etoposide doses combining metastases patients trials ongoing aim improving toxicity
dacarbazine therapy disease Veno
dacarbazine therapy disease occlusive
dacarbazine therapy disease liver
dacarbazine therapy disease
DTIC therapy disease Veno
DTIC therapy disease occlusive
DTIC therapy disease liver
DTIC therapy disease
dacarbazine therapy reported disease case veno
dacarbazine therapy reported disease occlusive
dacarbazine therapy reported disease
dacarbazine therapy reported disease liver of
dacarbazine therapy reported disease liver the
dacarbazine therapy reported disease liver
DTIC therapy reported disease case veno
DTIC therapy reported disease occlusive
DTIC therapy reported disease
DTIC therapy reported disease liver of
DTIC therapy reported disease liver the
DTIC therapy reported disease liver
phenacetin consumption associated cancer necrosis renal
phenacetin consumption associated cancer necrosis papillary
phenacetin consumption associated cancer necrosis
phenacetin consumption fold 20 increased risk necrosis renal
phenacetin consumption fold 20 increased risk necrosis papillary
phenacetin consumption fold 20 increased risk necrosis
isosorbide dinitrate administration infarction Myocardial
isosorbide dinitrate administration infarction
dinitrate administration infarction Myocardial
dinitrate administration infarction
isosorbide dinitrate administration wall infarction myocardial
isosorbide dinitrate administration wall infarction
dinitrate administration wall infarction myocardial
dinitrate administration wall infarction
tacrolimus Cyclosporine microangiopathy thrombotic
tacrolimus Cyclosporine microangiopathy
Cyclosporine microangiopathy thrombotic
Cyclosporine microangiopathy
cyclosporine use associated microangiopathy thrombotic
cyclosporine use associated microangiopathy
cyclosporine use associated microangiopathy TMA
tacrolimus switching reported option TMA
cyclosporine setting option TMA
tacrolimus application recognized TMA
tacrolimus application recognized TMA
tacrolimus cyclosporine exposed patients TMA
cyclosporine exposed patients TMA
cyclosporine developed recipient case TMA
cyclosporine withdrawal responded TMA
tacrolimus Introduction resulted recurrence TMA
tacrolimus switched Patients monitored signs TMA
cyclosporine switched Patients monitored signs TMA
amiodarone secondary hypothyroidism
amiodarone CHF Patients suffer hypothyroidism
simvastatin ezetimibe published events hepatotoxic
ezetimibe ezetimibe published events hepatotoxic
simvastatin 70 developed failure fulminant
simvastatin 70 developed failure hepatic
simvastatin 70 developed failure
10 mg simvastatin 70 developed failure fulminant
10 mg simvastatin 70 developed failure hepatic
10 mg simvastatin 70 developed failure
mg simvastatin 70 developed failure fulminant
mg simvastatin 70 developed failure hepatic
mg simvastatin 70 developed failure
ezetimibe mg mg simvastatin 70 developed failure fulminant
ezetimibe mg mg simvastatin 70 developed failure hepatic
ezetimibe mg mg simvastatin 70 developed failure
40 mg mg simvastatin 70 developed failure fulminant
40 mg mg simvastatin 70 developed failure hepatic
40 mg mg simvastatin 70 developed failure
mg mg simvastatin 70 developed failure fulminant
mg mg simvastatin 70 developed failure hepatic
mg mg simvastatin 70 developed failure
Simvastatinezetimibe discontinued excluded causes hepatotoxicity
simvastatinezetimibe induced hepatotoxicity
simvastatin hepatotoxicity
ezetimibe aware hepatotoxicity
Serotonergic antidepressants incontinence urinary
Serotonergic antidepressants incontinence
antidepressants incontinence urinary
antidepressants incontinence
venlafaxine taking experienced incontinence
sertraline paroxetine inhibitors incontinence
paroxetine inhibitors incontinence
venlafaxine developed third patients developed inhibitors incontinence
lithium carbonate blockers contributed incontinence
carbonate blockers contributed incontinence
serotonergic antidepressants incontinence
antidepressants incontinence
metoprolol administration Angioedema
lisinopril therapy angioedema
metoprolol given resulting angioedema
bupropion hydrochloride increasing Effect seizures
hydrochloride increasing Effect seizures
bupropion relationship seizures
bupropion HCl mg kg dose convulsive
HCl mg kg dose convulsive
bupropion HCl mg induced convulsions
HCl mg induced convulsions
bupropion severity kg dose convulsive
bupropion severity kg mg induced convulsions
bupropion mg administration kg induced convulsions
HCl mg administration kg induced convulsions
bupropion mg administration associated odds convulsions
HCl mg administration associated odds convulsions
bupropion mg time increasing revealed group induced convulsions
HCl mg time increasing revealed group induced convulsions
bupropion mg time increasing revealed group induced kg administration associated odds convulsions
HCl mg time increasing revealed group induced kg administration associated odds convulsions
bupropion dose fixed convulsive
bupropion dose risk convulsions
metoclopramide arrest Cardiac
metoclopramide arrest
metoclopramide arrest case injections metoclopramide causing episodes arrest cardiac
metoclopramide arrest case injections metoclopramide causing episodes arrest
metoclopramide injections case arrest Cardiac
metoclopramide injections case arrest
metoclopramide causing episodes arrest cardiac
metoclopramide causing episodes arrest
metoclopramide injection followed asystole
metoclopramide administration followed asystole
metoclopramide caused arrest cardiac
metoclopramide caused arrest
valproate added induced Encephalopathy
levetiracetam induced Encephalopathy
levetiracetam manifestation report encephalopathy
LEV levetiracetam manifestation report encephalopathy
folic acid activity induces SLE
acid activity induces SLE
folic acid SLE
acid SLE
folic acid dose barrier triggered disease drug lupus
acid dose barrier triggered disease drug lupus
folic acid dose barrier triggered cluster seizures
acid dose barrier triggered cluster seizures
nimesulide Tolerability urticaria angioedema
NSAID Tolerability urticaria angioedema
paracetamol nimesulide Tolerability urticaria angioedema
nimesulide angioedema
NSAID history number paracetamol nimesulide angioedema
paracetamol nimesulide angioedema
nimesulide procedure applied patients history angioedema
NSAID angioedema
paracetamol nimesulide procedure applied patients history angioedema
NSAID history subjects % induced angioedema
NSAID history subjects % induced angioedema angioedema
nimesulide tolerability confirm patients experienced angioedema
NSAIDs caused angioedema
paracetamol nimesulide tolerability confirm patients experienced angioedema
NSAID history angioedema
enflurane resulted seizures
enflurane delineated foci ablated seizure
MZ use caused hypoxia presented event hypoxia
MZ use caused hypoxia presented hypoxia
MZ use caused hypoxia
streptomycin sensitive indicating occurred occurred movements Abnormal
streptomycin sensitive indicating occurred occurred movements
streptomycin site responsible dyskinesias
streptomycin sensitive indicating occurred occurred movements deafness
fluphenazine enanthate induced parkinsonism
enanthate induced parkinsonism
benztropine treated had increase dyskinesia tardive
benztropine treated had increase dyskinesia
benztropine treated had condition anxiety depression
benztropine treated had condition anxiety
cimetidine was only dementia
cimetidine levels had disease liver was only dementia
cimetidine levels induce dementia
terbutaline treatment associated complications Cardiovascular
terbutaline treatment associated complications
terbutaline treated patients eight occurred complications cardiovascular
terbutaline treated patients eight occurred complications
Ticlopidine induced anemia aplastic
Ticlopidine induced anemia
ticlopidine induced anemia aplastic
ticlopidine induced anemia
ticlopidine initiation weeks recommended occurred Agranulocytosis
ticlopidine induced anemia aplastic
ticlopidine induced anemia
doxorubicin nephrosis
morphine administration induced learning impairment
morphine administration induced learning of
morphine administration induced learning
morphine administration learning
morphine administration learning impairment
puromycin aminonucleoside hypoxia syndrome nephrotic
puromycin aminonucleoside hypoxia syndrome
aminonucleoside hypoxia syndrome nephrotic
aminonucleoside hypoxia syndrome
puromycin aminonucleoside hypoxia
aminonucleoside hypoxia
puromycin aminonucleoside hypoxia hypoxia
aminonucleoside hypoxia hypoxia
puromycin model weeks fold reaching increased Expression hypoxia
aminonucleoside model weeks fold reaching increased Expression hypoxia
norfloxacin ciprofloxacin rats showed behaviour anxious
norfloxacin ciprofloxacin rats showed behaviour
ciprofloxacin rats showed behaviour anxious
ciprofloxacin rats showed behaviour
didanosine normal returned mild developed characteristic glucose
didanosine normal returned mild developed characteristic tolerance
didanosine normal returned mild developed characteristic curves
ACE inhibitors due Angioedema
inhibitors due Angioedema
angiotensin incidence angioedema
converting 1 incidence angioedema
enzyme treatment converting 1 incidence angioedema
ACE enzyme treatment converting 1 incidence angioedema
inhibitor treatment converting 1 incidence angioedema
ketamine combinations induced potentiation Catalepsy
morphine ketamine combinations induced potentiation Catalepsy
ketamine induced analgesia catalepsy
morphine ketamine induced analgesia catalepsy
ketamine treatment Pre tolerance ketamine augmented response cataleptic
ketamine augmented response cataleptic
morphine tolerance cross produced treatment Pre tolerance ketamine augmented response cataleptic
morphine pretreatment induce produced treatment Pre tolerance ketamine augmented response cataleptic
morphine attributed tolerance ketamine augmented response cataleptic
ribavirin prodrug liver has potential maintain decreasing risk anemia hemolytic
ribavirin prodrug liver has potential maintain decreasing risk anemia
ribavirin efficacy maintain decreasing risk anemia hemolytic
ribavirin efficacy maintain decreasing risk anemia
chlorhexidine factor digluconate associated cystitis
digluconate associated cystitis
kanamycin percentage iodine associated cystitis
povidone colistin percentage iodine associated cystitis
iodine associated cystitis
colistin percentage iodine associated cystitis
doxorubicin damage myocardial
doxorubicin damage
doxorubicin damage markers I Evaluation rats cardiomyopathy
doxorubicin model damage myocardial
doxorubicin model damage
doxorubicin model damage diagnosis investigated induced cardiomyopathy
DOX doxorubicin model damage myocardial
DOX doxorubicin model damage
DOX doxorubicin model damage diagnosis investigated induced cardiomyopathy
DOX injury markers showed detect damage myocardial
DOX injury markers showed detect damage
caffeine men hypertension
caffeine actions enhanced persons hypertensive
caffeine ingestion achieved levels hypertensive
caffeine were men hypertensive
caffeine were replicated protocols representative hypertensives
docetaxel cancer combination thromboembolism frequency venous
docetaxel cancer combination thromboembolism
thalidomide docetaxel cancer combination thromboembolism frequency venous
thalidomide docetaxel cancer combination thromboembolism
docetaxel treated cancer frequency thromboembolism venous
docetaxel treated cancer frequency thromboembolism
docetaxel treated cancer frequency thromboembolism VTE
thalidomide treated cancer frequency thromboembolism venous
thalidomide treated cancer frequency thromboembolism
thalidomide treated cancer frequency thromboembolism VTE
docetaxel developed VTE
docetaxel developed developed VTE
docetaxel thalidomide received patients 9 developed developed VTE
docetaxel thalidomide received patients 9 developed VTE
thalidomide received patients 9 developed developed VTE
thalidomide received patients 9 developed VTE
docetaxel addition CONCLUSION increases frequency VTE
thalidomide addition CONCLUSION increases frequency VTE
levomepromazine treatment induced Seizures
fluvoxamine treatment induced Seizures
levomepromazine induced seizures
fluvoxamine treatment levomepromazine induced seizures
tramadol intake Nightmares hallucinations
tramadol drugs hallucinations
telithromycin attack hepatitis
telithromycin usage occurred hepatitis
telithromycin cause hepatitis
telithromycin cause suggested drug induced hepatitis toxic
telithromycin cause suggested drug induced hepatitis
telithromycin prescribed physician communicated avoided Recurrence attack hepatitis
telithromycin administration associated hepatitis
metrizoate lower Frequencies fibrillation ventricular
metrizoate lower Frequencies fibrillation
paracetamol aspirin developed necrosis Renal
paracetamol aspirin developed necrosis papillary
paracetamol aspirin developed necrosis
paracetamol aspirin developed necrosis RPN
aspirin developed necrosis Renal
aspirin developed necrosis papillary
aspirin developed necrosis
aspirin developed necrosis RPN
methamphetamine hyperthermia
ropivacaine levobupivacaine seizures
levobupivacaine seizures
ropivacaine doses smaller doses levobupivacaine produced dysrhythmias
levobupivacaine produced dysrhythmias
levobupivacaine produced dysrhythmias asystole
ropivacaine doses smaller doses levobupivacaine produced dysrhythmias asystole
levobupivacaine toxicity intermediate conclude appears arrest cardiac
levobupivacaine toxicity intermediate conclude appears arrest
levobupivacaine bupivacaine induced that treatment susceptible appears arrest cardiac
levobupivacaine bupivacaine induced that treatment susceptible appears arrest
ropivacaine that intermediate conclude appears arrest cardiac
ropivacaine that intermediate conclude appears arrest
ropivacaine rate administered intermediate conclude appears arrest cardiac
ropivacaine rate administered intermediate conclude appears arrest
Triamterene nephrolithiasis
triamterene nephrolithiasis
triamterene nephrolithiasis
pimecrolimus tacrolimus immunomodulators use regarded cause dermatitis
SRL seems nephrotoxic
SRL seems act displaying effects nephrotoxic
SRL combined number described indications effect nephrotoxic
SRL CsA effect nephrotoxic
SRL 506 tolerated demonstrated effect nephrotoxic
FK 506 tolerated demonstrated effect nephrotoxic
506 tolerated demonstrated effect nephrotoxic
CsA effect nephrotoxic
metoprolol treatment SR block shock heart
metoprolol treatment SR block
verapamil SR block shock heart
verapamil SR block
metoprolol use verapamil seventy eight year woman presented block heart
metoprolol use verapamil seventy eight year woman presented block
verapamil seventy eight year woman presented block heart
verapamil seventy eight year woman presented block
verapamil seventy eight year woman presented block hypotension
metoprolol use verapamil seventy eight year woman presented block hypotension
FK A Nephrotoxicity
506 FK A Nephrotoxicity
cyclosporin A Nephrotoxicity
A Nephrotoxicity
FK CsA 506 effects nephrotoxic
506 effects nephrotoxic
CsA 506 effects nephrotoxic
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models Acute
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models experimental
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models damage of
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models damage renal
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models damage
aminonucleoside butadiene 3 bromoethylamine administration produced models Acute
aminonucleoside butadiene 3 bromoethylamine administration produced models experimental
aminonucleoside butadiene 3 bromoethylamine administration produced models
aminonucleoside butadiene 3 bromoethylamine administration produced models damage of
aminonucleoside butadiene 3 bromoethylamine administration produced models damage renal
aminonucleoside butadiene 3 bromoethylamine administration produced models damage
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models Acute
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models experimental
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models damage of
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models damage renal
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models damage
2 butadiene 3 bromoethylamine administration produced models Acute
2 butadiene 3 bromoethylamine administration produced models experimental
2 butadiene 3 bromoethylamine administration produced models
2 butadiene 3 bromoethylamine administration produced models damage of
2 butadiene 3 bromoethylamine administration produced models damage renal
2 butadiene 3 bromoethylamine administration produced models damage
bromoethylamine administration produced models Acute
bromoethylamine administration produced models experimental
bromoethylamine administration produced models
bromoethylamine administration produced models damage of
bromoethylamine administration produced models damage renal
bromoethylamine administration produced models damage
BEA bromoethylamine administration produced models Acute
BEA bromoethylamine administration produced models experimental
BEA bromoethylamine administration produced models
BEA bromoethylamine administration produced models damage of
BEA bromoethylamine administration produced models damage renal
BEA bromoethylamine administration produced models damage
hexachloro bromoethylamine administration produced models Acute
hexachloro bromoethylamine administration produced models experimental
hexachloro bromoethylamine administration produced models
hexachloro bromoethylamine administration produced models damage of
hexachloro bromoethylamine administration produced models damage renal
hexachloro bromoethylamine administration produced models damage
1 3 bromoethylamine administration produced models Acute
1 3 bromoethylamine administration produced models experimental
1 3 bromoethylamine administration produced models
1 3 bromoethylamine administration produced models damage of
1 3 bromoethylamine administration produced models damage renal
1 3 bromoethylamine administration produced models damage
3 bromoethylamine administration produced models Acute
3 bromoethylamine administration produced models experimental
3 bromoethylamine administration produced models
3 bromoethylamine administration produced models damage of
3 bromoethylamine administration produced models damage renal
3 bromoethylamine administration produced models damage
butadiene 3 bromoethylamine administration produced models Acute
butadiene 3 bromoethylamine administration produced models experimental
butadiene 3 bromoethylamine administration produced models
butadiene 3 bromoethylamine administration produced models damage of
butadiene 3 bromoethylamine administration produced models damage renal
butadiene 3 bromoethylamine administration produced models damage
HCBD butadiene 3 bromoethylamine administration produced models Acute
HCBD butadiene 3 bromoethylamine administration produced models experimental
HCBD butadiene 3 bromoethylamine administration produced models
HCBD butadiene 3 bromoethylamine administration produced models damage of
HCBD butadiene 3 bromoethylamine administration produced models damage renal
HCBD butadiene 3 bromoethylamine administration produced models damage
droperidol administration associated Angioedema
droperidol dose administration minutes developed protrusion year man allergies angioedema
ciprofloxacin associated thrombocytopenia anaemia haemolytic
ciprofloxacin associated thrombocytopenia anaemia
ciprofloxacin associated thrombocytopenia
ciprofloxacin administration 30 man reported pain abdominal
ciprofloxacin administration 30 man reported pain
ciprofloxacin administration 30 man reported pain jaundice
ciprofloxacin precipitate life thrombocytopenia anaemia haemolytic
ciprofloxacin precipitate life thrombocytopenia anaemia
ciprofloxacin precipitate life thrombocytopenia
ethambutol induced neuropathy optic
ethambutol induced neuropathy
ethambutol map induced neuropathy optic
ethambutol map induced neuropathy
ethambutol complication neuropathy optic
ethambutol complication neuropathy
ethambutol history subjects METHODS long administered deficits visual
ethambutol history subjects METHODS long administered deficits
EMB ethambutol history subjects METHODS long administered deficits visual
EMB ethambutol history subjects METHODS long administered deficits
ethambutol history subjects METHODS induced neuropathy optic
ethambutol history subjects METHODS induced neuropathy
EMB ethambutol history subjects METHODS induced neuropathy optic
EMB ethambutol history subjects METHODS induced neuropathy
EMB history subjects was loss A recovery patient B deficits visual
EMB history subjects was loss A recovery patient B deficits
EMB history subjects was loss A recovery deficits visual
EMB history subjects was loss A recovery deficits
EMB history neuropathy optic
EMB history neuropathy
EMB patients results CONCLUSIONS induced show neuropathy optic
EMB patients results CONCLUSIONS induced show neuropathy
EMB induced neuropathy optic
EMB induced neuropathy
ethambutol dosing manage important terms management EMB induced neuropathy optic
ethambutol dosing manage important terms management EMB induced neuropathy
norepinephrine caused bradycardia
norepinephrine had enhanced bradycardia
norepinephrine caused bradycardia
norepinephrine decreased bradycardia
prostaglandin E Epidural trimethaphan hypotension
E Epidural trimethaphan hypotension
1 E Epidural trimethaphan hypotension
trimethaphan hypotension
prostaglandin E trimethaphan induced hypotension
E trimethaphan induced hypotension
1 E trimethaphan induced hypotension
PGE 1 E trimethaphan induced hypotension
1 PGE 1 E trimethaphan induced hypotension
trimethaphan induced hypotension
TMP trimethaphan induced hypotension
PGE starting decreased remained degree hypotension
1 PGE starting decreased remained degree hypotension
PGE due hypotension
1 PGE due hypotension
TMP PGE starting decreased remained degree hypotension
PGE preferable TMP anaesthesia hypotensive
1 PGE preferable TMP anaesthesia hypotensive
TMP anaesthesia hypotensive
TMP decreased preferable TMP anaesthesia hypotensive
methylprednisolone cause was mention possibility myopathy
methylprednisolone offers protection recording recovers myopathy
methylprednisolone offers protection recording recovery myopathy
methylprednisolone cause myopathy
Simvastatin induced syndrome compartment
Simvastatin induced syndrome
simvastatin thyroxine presented syndrome compartment
simvastatin thyroxine presented syndrome
Fucoidan treated exhibited evidence blood impaired
Fucoidan treated exhibited evidence blood
Fucoidan treated exhibited evidence blood clotting
Fucoidan treated exhibited evidence blood hemodilution
Dexamethasone induced hypertension ocular
Dexamethasone induced hypertension
dexamethasone treated thickened eyes hypertensive
dexamethasone treated thickened eyes
Dexamethasone treatment eyes led generation hypertension ocular
Dexamethasone treatment eyes led generation hypertension
dexamethasone % led generation hypertension ocular
dexamethasone % led generation hypertension
acitretin dysphonia
acitretin treated complaining dysphonia
acitretin case dysphonia
puromycin aminonucleoside course induced nephropathy
aminonucleoside course induced nephropathy
puromycin aminonucleoside pathogenesis implicated induced antioxidants reducing proteinuria
aminonucleoside pathogenesis implicated induced antioxidants reducing proteinuria
PAN aminonucleoside pathogenesis implicated induced antioxidants reducing proteinuria
puromycin aminonucleoside pathogenesis implicated induced nephropathy
aminonucleoside pathogenesis implicated induced nephropathy
PAN aminonucleoside pathogenesis implicated induced nephropathy
PAN injury proteinuric
PAN injury
PAN injury mediating nephropathy
etomidate reduces myoclonus
etomidate induction compare incidence myoclonus
etomidate administration associated incidence myoclonus
etomidate induction reduced myoclonus
etomidate administration increased incidence myoclonus
paracetamol overdose survived failure fulminant
paracetamol overdose survived failure hepatic
paracetamol overdose survived failure
paracetamol overdose survived increased patients failure fulminant
paracetamol overdose survived increased patients failure hepatic
paracetamol overdose survived increased patients failure
Reserpine produced chewing mice signs dyskinesia tardive
Reserpine produced chewing mice signs dyskinesia
Reserpine produced tremor catalepsy
Reserpine produced tremor
reserpine induced catalepsy
reserpine produced increase tremor
reserpine induced increases tremor catalepsy
reserpine induced increases tremor
reserpine induced catalepsy
reserpine induced catalepsy tremor
reserpine protrusion increases tremor catalepsy
reserpine effects reversed Pretreatment protrusion increases tremor catalepsy
reserpine protrusion increases tremor
reserpine effects reversed Pretreatment protrusion increases tremor
reserpine produces movements different abnormal
reserpine produces movements
reserpine produces considered like tardive
reserpine produces considered like signs dsykinesia
magnesium blockade Neuromuscular
magnesium blockade
sulfate blockade Neuromuscular
sulfate blockade
nifedipine sulfate blockade Neuromuscular
nifedipine sulfate blockade
magnesium sulfate mg administered developed blockade neuromuscular
magnesium sulfate mg administered developed blockade
sulfate mg administered developed blockade neuromuscular
sulfate mg administered developed blockade
nifedipine received patient developed blockade neuromuscular
nifedipine received patient developed blockade
Selegiline hypotension postural
Selegiline hypotension
selegiline therapy associated hypotension systolic
selegiline therapy associated hypotension orthostatic
selegiline therapy associated hypotension
selegiline withdrawal abolished hypotension systolic
selegiline withdrawal abolished hypotension orthostatic
selegiline withdrawal abolished hypotension
selegiline stopping shed mechanisms causes hypotension orthostatic
selegiline stopping shed mechanisms causes hypotension
selegiline marked hypotension systolic
selegiline marked hypotension orthostatic
selegiline marked hypotension
selegiline withdrawal ameliorated hypotension Orthostatic
selegiline withdrawal ameliorated hypotension
selegiline Stopping reduced
selegiline Stopping reduced blood the
selegiline Stopping reduced blood supine
selegiline Stopping reduced blood systolic
selegiline Stopping reduced blood systolic and
selegiline Stopping reduced blood systolic diastolic
selegiline Stopping reduced blood
selegiline Stopping pressures
selegiline finding confirms associated hypotension orthostatic
selegiline finding confirms associated hypotension
levodopa Worsening dyskinesias
apomorphine dose administration dyskinesia study included patients had dyskinesia
apomorphine dose administration dyskinesia
levodopa stimulation dyskinesias
methamphetamine induced neurotoxicity
METH reverse dihydroxyphenylalanine show confounded neurotoxicity
METH neurotoxicity
METH effects preserved long METH neurotoxicity
METH development essential neurotoxicity
Cocaine induced disorder mood
Cocaine induced disorder
cocaine induced disorder mood
cocaine induced disorder
cocaine induced disorder mood
cocaine induced disorder
cocaine induced disorder disorders mood
cocaine induced disorder disorders
cocaine compared disorder mood
cocaine compared disorder
cocaine outpatients cocaine induced disorder mood
cocaine outpatients cocaine induced disorder
cocaine outpatients cocaine induced disorder disorders mood
cocaine outpatients cocaine induced disorder disorders
cocaine outpatients cocaine compared disorder mood
cocaine outpatients cocaine compared disorder
naproxen due necrosis Renal
naproxen due necrosis papillary
naproxen due necrosis
naproxen therapy institution developed necrosis renal
naproxen therapy institution developed necrosis papillary
naproxen therapy institution developed necrosis
naproxen therapy institution developed necrosis RPN
All induced nodosum erythema
All induced nodosum
trans All induced nodosum erythema
trans All induced nodosum
retinoic acid trans All induced nodosum erythema
retinoic acid trans All induced nodosum
acid trans All induced nodosum erythema
acid trans All induced nodosum
all acid associated nodosum Erythema
all acid associated nodosum
trans acid associated nodosum Erythema
trans acid associated nodosum
retinoic acid associated nodosum Erythema
retinoic acid associated nodosum
acid associated nodosum Erythema
acid associated nodosum
ATRA acid associated nodosum Erythema
ATRA acid associated nodosum
ATRA therapy developed nodosum erythema
ATRA therapy developed nodosum
ATRA therapy developed nodules erythematous
ATRA therapy developed nodules
ATRA therapy developed nodules Fever
ATRA seemed etiology nodosum erythema
ATRA seemed etiology nodosum
ATRA effective induced nodosum erythema
ATRA effective induced nodosum
ziprasidone induced syndrome Neuroleptic
ziprasidone induced syndrome malignant
ziprasidone induced syndrome
ziprasidone use associated syndrome neuroleptic
ziprasidone use associated syndrome malignant
ziprasidone use associated syndrome
ziprasidone use associated syndrome NMS
ziprasidone drugs cause associated NMS
ziprasidone dose developed signs NMS
ziprasidone due NMS
caffeine concentration containing consuming developed fibrillation ventricular
caffeine concentration containing consuming developed fibrillation
nicotine necessary induced seizures
nicotine Binding series behaviors go seizures
nicotine examined homozygous seizures
nicotine effects sensitive / induced seizures
nicotine measured doses sensitive sensitive / induced seizures
nicotine induced seizures
nicotine mediators induced seizures
GVG effects dopamine explored success risk defects visual
GVG effects dopamine explored success risk defects field
GVG effects dopamine explored success risk defects
GVG effects dopamine explored success risk defects VFD
lignocaine involving anaesthesia back Leg
lignocaine involving anaesthesia back Leg and
lignocaine involving anaesthesia back
lignocaine involving anaesthesia back pain
lignocaine use associated Leg
lignocaine use associated Leg and
lignocaine use associated Leg /
lignocaine use associated Leg or
lignocaine use associated Leg pain back
lignocaine use associated Leg pain
tamoxifen use association cancer endometrial
tamoxifen use association cancer
tamoxifen received Women likely have cancer endometrial
tamoxifen received Women likely have cancer
tamoxifen received had cancer endometrial
tamoxifen received had cancer
tamoxifen received had Women had those cancer endometrial
tamoxifen received had Women had those cancer
tamoxifen role suggest cancer endometrial
tamoxifen role suggest cancer
tamoxifen treated women diagnosed cancers Endometrial
tamoxifen treated women diagnosed cancers
Ro blocker induced alterations cardiovascular
Ro blocker induced alterations
40 Ro blocker induced alterations cardiovascular
40 Ro blocker induced alterations
5967 Ro blocker induced alterations cardiovascular
5967 Ro blocker induced alterations
verapamil significant observed incidence malformations cardiovascular
verapamil significant observed incidence malformations
nifedipine verapamil significant observed incidence malformations cardiovascular
nifedipine verapamil significant observed incidence malformations
cyclophosphamide mice mediators expression induced cystitis
CYP expression induced cystitis
cyclophosphamide cystitis
CYP cyclophosphamide cystitis
CYP VIP induced cystitis
Tac nephrotoxicity
Tac toxicity CsA CsA nephrotoxicity
CsA nephrotoxicity
CsA CsA nephrotoxicity
methadone treated patients prolongation Syncope
methadone treated patients prolongation Syncope QT
methadone treated patients prolongation
methadone effect caused attribute episodes syncope
methadone dose syncope
methadone treated subjects had interval prolonged
methadone treated subjects had interval QTc
methadone treated subjects had interval
methadone dose mg associated odds syncope
Methadone associated prolongation reporting syncope
Methadone associated prolongation QT
Methadone associated prolongation
Prednisolone induced caused dysfunction muscle
Prednisolone induced caused dysfunction
prednisolone dysfunction dose derives atrophy muscle
prednisolone dysfunction dose derives atrophy
bupivacaine triamcinolone injection caused syndrome cauda
bupivacaine triamcinolone injection caused syndrome equina
bupivacaine triamcinolone injection caused syndrome
suprofen associated development failure acute
suprofen associated development failure renal
suprofen associated development failure
suprofen causes declines acute
suprofen causes declines
suprofen causes declines function in
suprofen causes declines function renal
suprofen causes declines function
aminonucleoside existing captopril Effect proteinuria
puromycin aminonucleoside invoked proteinuria
aminonucleoside invoked proteinuria
haloperidol efficacy studies model catalepsy
risperidone reduction developed RS
risperidone profile related mechanism development RS
adriamycin mitochondria impairment Structural
adriamycin mitochondria impairment Structural and
adriamycin mitochondria impairment Structural functional
adriamycin mitochondria impairment
adriamycin mitochondria of
adriamycin mitochondria
ADR treatment caused arrhythmias characterized bradycardia
ADR effects involve impairment mitochondrial
ADR effects involve impairment structural
ADR effects involve impairment structural and
ADR effects involve impairment structural functional
ADR effects involve impairment
methamphetamine induced NRA hyperactivity
MAP methamphetamine induced NRA hyperactivity
NRA 0160 induced catalepsy
0160 induced catalepsy
clozapine 0160 induced catalepsy
Cefotetan induced anemia hemolytic
Cefotetan induced anemia
cocaine user man presented occasions history priapism
cocaine use presented occasions history priapism
Oxytocin uterotonic cause hypotension
Oxytocin attributed hypotension
oxytocin response Hypotension
Clotiazepam induced hepatitis
clotiazepam administration onset developed hepatitis
clotiazepam related administration interfere induce relapse hepatitis
clotiazepam induce hepatitis
clotiazepam induce shows suggests is hepatotoxicity
clotiazepam benzodiazepines hepatotoxicity is suggests shows induce hepatitis
clotiazepam benzodiazepines hepatotoxicity
Pentamidine isethionate associated pointes torsade
Pentamidine isethionate associated pointes de
Pentamidine isethionate associated pointes
isethionate associated pointes torsade
isethionate associated pointes de
isethionate associated pointes
Pentamidine induced related pointes torsade
Pentamidine induced related pointes de
Pentamidine induced related pointes
pentamidine occurred pointes Torsade
pentamidine occurred pointes de
pentamidine occurred pointes
pentamidine discontinuation recognized treated pointes Torsade
pentamidine discontinuation recognized treated pointes de
pentamidine discontinuation recognized treated pointes
Warfarin induced palsy femoral
Warfarin induced palsy nerve
Warfarin induced palsy
warfarin therapy man 28 case sustained tear muscle
warfarin therapy man 28 case sustained tear
warfarin form represents palsy femoral
warfarin form represents palsy nerve
warfarin form represents palsy
diltiazem threatening induced tetany
diltiazem infusion developed tetany
diltiazem administration accompany life tetany
haloperidol treatments change uptake dyskinesia orofacial
haloperidol treatments change uptake dyskinesia
reserpine treatments change uptake dyskinesia orofacial
reserpine treatments change uptake dyskinesia
haloperidol Reserpine dyskinesia orofacial
haloperidol Reserpine dyskinesia
haloperidol Reserpine dyskinesia models dyskinesia tardive
haloperidol Reserpine dyskinesia models dyskinesia
haloperidol Reserpine dyskinesia models TD
Reserpine dyskinesia orofacial
Reserpine dyskinesia
Reserpine dyskinesia models dyskinesia tardive
Reserpine dyskinesia models dyskinesia
Reserpine dyskinesia models TD
haloperidol administration reserpine induced dyskinesia orofacial
haloperidol administration reserpine induced dyskinesia
reserpine induced dyskinesia orofacial
reserpine induced dyskinesia
bupropion release associated Seizure
bupropion use describes seizure
bupropion use weeks experienced seizure
bupropion risk seizures
cyclosporine drug cause microangiopathy thrombotic
cyclosporine drug cause microangiopathy
Amiodarone induced block sinoatrial
Amiodarone induced block
amiodarone administration observed block sinoatrial
amiodarone administration observed block
amiodarone dosage Reduction resulted disappearance block sinoatrial
amiodarone dosage Reduction resulted disappearance block
phenobarbital therapy term Hepatonecrosis cholangitis
Phenobarbital has believed indicate development disease liver
Phenobarbital has believed indicate development disease
PB Phenobarbital has believed indicate development disease liver
PB Phenobarbital has believed indicate development disease
PB indicate development disease liver
PB indicate development disease
PB associated damage liver
PB associated damage
haloperidol models catalepsy
reserpine model catalepsy models akinesia
gentamicin died failure acute
gentamicin died failure renal
gentamicin died failure
carbamazepine induced block patient bradycardia
carbamazepine induced block patient bradycardia atrioventricular
carbamazepine induced block
carbamazepine overdose setting developed tachycardias sinus
carbamazepine overdose setting developed tachycardias
carbamazepine levels elevated developed threatening delay bradyarrhythmias
carbamazepine levels elevated developed threatening delay bradyarrhythmias atrioventricular
carbamazepine levels elevated developed threatening delay conduction
carbamazepine levels elevated developed threatening delay
tamoxifen induced erythrocytes Hemolysis
Tamoxifen induces changes shape erythrocytes anemia hemolytic
Tamoxifen induces changes shape erythrocytes anemia
TAM Tamoxifen induces changes shape erythrocytes anemia hemolytic
TAM Tamoxifen induces changes shape erythrocytes anemia
TAM effects evaluates erythrocytes induced anemia hemolytic
TAM effects evaluates erythrocytes induced anemia
TAM mechanisms identify attempting erythrocytes induced anemia hemolytic
TAM mechanisms identify attempting erythrocytes induced anemia
TAM induces hemolysis
TAM induces variable extension hemolysis
TAM induces hemolysis
TAM effect hemolytic
TAM effect prevented indicating related TAM hemolysis
TAM related indicating prevented effect hemolytic
TAM hemolysis
TAM determined consumption hemolysis
TAM caused Hemolysis
TAM caused Hemolysis preceded excluding colloid mechanism hemolysis
TAM incorporation related protection hemolysis
TAM results hemolysis
TAM promoted stability decreased resulting anemia hemolytic
TAM promoted stability decreased resulting anemia
vitamin C increase risk cardiovascular
vitamin C increase risk disease
C increase risk cardiovascular
C increase risk disease
vitamin intake relation examine disease cardiovascular
vitamin intake relation examine disease
C intake relation examine disease cardiovascular
C intake relation examine disease
vitamin intake relation mortality disease cardiovascular
vitamin intake relation mortality disease
C intake relation mortality disease cardiovascular
C intake relation mortality disease
vitamin intake quintiles 0 < trend P 1 adjustment factors cardiovascular
vitamin intake quintiles 0 < trend P 1 adjustment factors disease
C intake quintiles 0 < trend P 1 adjustment factors cardiovascular
C intake quintiles 0 < trend P 1 adjustment factors disease
vitamin intake quintiles 0 < trend P 1 type medication intakes carotene mortality adjusted risks disease cardiovascular
vitamin intake quintiles 0 < trend P 1 type medication intakes carotene mortality adjusted risks disease
C intake quintiles 0 < trend P 1 type medication intakes carotene mortality adjusted risks disease cardiovascular
C intake quintiles 0 < trend P 1 type medication intakes carotene mortality adjusted risks disease
Vitamin intake unrelated disease cardiovascular
Vitamin intake unrelated disease
C intake unrelated disease cardiovascular
C intake unrelated disease
vitamin intake associated risk mortality cardiovascular
vitamin intake associated risk mortality disease
C intake associated risk mortality cardiovascular
C intake associated risk mortality disease
pilocarpine rats seizures
trihexyphenidyl Bradycardia
hydrochloride Bradycardia
alcohol ingestion hour developed flushing face tachycardia
alcohol ingestion hour developed flushing face dyspnea
alcohol ingestion hour developed flushing
alcohol ingestion hour developed flushing face of
alcohol ingestion hour developed flushing face the
alcohol ingestion hour developed flushing face
troleandomycin cholestasis
troleandomycin induced hepatitis
troleandomycin case report followed cholestasis
troleandomycin case report followed hepatitis
troleandomycin administration occurred Jaundice
troleandomycin administration occurred associated hypereosinophilia
troleandomycin follow cholestasis
troleandomycin induced hepatitis
clozapine treatment Delirium
clozapine treatment delirium
clozapine treated reviewed incidence delirium
clozapine % found Delirium
flumazenil group nausea vomiting
flumazenil group nausea
flumazenil group nausea
azathioprine therapy injury cholestasis
azathioprine therapy injury bile
azathioprine therapy injury duct
azathioprine therapy injury
azathioprine therapy initiation developed features cholestasis
azathioprine case cholestasis
azathioprine case cholestasis associated evidence injury bile
azathioprine case cholestasis associated evidence injury duct
azathioprine case cholestasis associated evidence injury
cefotetan use associated anemia hemolytic
cefotetan use associated anemia
cefotetan cephalosporins associated anemia hemolytic
cefotetan cephalosporins associated anemia
cefotetan cases anemias hemolytic
cefotetan cases anemias
cefotetan prophylactically received patients 10 cases anemias hemolytic
cefotetan prophylactically received patients 10 cases anemias
pentobarbital caused Learning rats amnesia
pentobarbital produced amnesia
Acetaminophen induced hypotension
acetaminophen demonstrated produce symptoms anaphylaxis hypotension
acetaminophen administration developed episodes hypotension
acetaminophen consider patients hypotension
Methamphetamine causes alterations pathways display aggressiveness
methamphetamine abusers common suffer patients reported behaviors Aggressive
methamphetamine abusers common suffer patients reported behaviors
methamphetamine abusers common suffer disorders psychiatric
methamphetamine abusers common suffer disorders
METH abusers common suffer patients reported behaviors Aggressive
METH abusers common suffer patients reported behaviors
METH abusers common suffer disorders psychiatric
METH abusers common suffer disorders
METH injections increased aggressiveness
METH secondary increase aggressiveness
WR postinjection noted hemoglobinuria
242511 WR postinjection noted hemoglobinuria
contrast media Risk nephropathy
media Risk nephropathy
contrast media reports nephropathy
media reports nephropathy
contrast media reports nephropathy CIN
media reports nephropathy CIN
iohexol iopromide incidence CIN
contrast media CIN
media CIN
CM media CIN
CM type compared determined incidence CIN
iopromide incidence CIN
CM dosage received those 33 patients CIN
CM dosage received those increased those received difference incidence CIN
CM dosages related CIN incidence difference received those increased those 33 patients CIN
CM dosages related CIN
CM type depends depends needed reversible CIN
dipyridamole hyperemia
dipyridamole implications dipyridamole hyperemia
pentoxifylline derivative improve claudication intermittent
pentoxifylline derivative improve claudication
Trental pentoxifylline derivative improve claudication intermittent
Trental pentoxifylline derivative improve claudication
dipyridamole inhibits thallium induced hyperemia
dipyridamole stopped induced hyperemia
dipyridamole hyperemia
dipyridamole induced hyperemia
doxorubicin protects demonstrate apoptosis extent failure heart
doxorubicin protects demonstrate apoptosis extent failure
Risperidone disturbances visual
Risperidone disturbances
risperidone starting appeared disturbances visual
risperidone starting appeared disturbances
Risperidone administration continued wore disturbances visual
Risperidone administration continued wore disturbances
acetazolamide patients developed calculi renal
acetazolamide patients developed calculi
FK 506 Microangiopathic
FK 506 hemolytic
FK 506 anemia
506 Microangiopathic
506 hemolytic
506 anemia
tacrolimus 506 Microangiopathic
tacrolimus 506 hemolytic
tacrolimus 506 anemia
FK therapy recipients anemia microangiopathic
FK therapy recipients anemia hemolytic
FK therapy recipients anemia
506 therapy recipients anemia microangiopathic
506 therapy recipients anemia hemolytic
506 therapy recipients anemia
FK therapy recipients anemia MAHA
506 therapy recipients anemia MAHA
tacrolimus therapy recipients anemia microangiopathic
tacrolimus therapy recipients anemia hemolytic
tacrolimus therapy recipients anemia
tacrolimus therapy recipients anemia MAHA
FK discontinuation led resolution MAHA
506 FK discontinuation led resolution MAHA
FK reintroduction led recurrence MAHA
506 FK reintroduction led recurrence MAHA
FK associated rare MAHA
506 FK associated rare MAHA
FK 506 seem experience react A immuno drug known induce MAHA
506 seem experience react A immuno drug known induce MAHA
bupivacaine activity modified decreased time convulsions
bupivacaine obtain latency convulsions
diltiazem overdose arrest asystolic
diltiazem overdose arrest cardiac
diltiazem overdose arrest
diltiazem overdose
diltiazem nitrate g 8 overdose
diltiazem therapy overdose onset asystole
diltiazem therapy overdose
diltiazem overdose considered early cases arrest cardiac
diltiazem overdose considered early cases arrest
diltiazem overdose
paclitaxel stent implantation aneurysm Coronary
paclitaxel stent implantation aneurysm
paclitaxel receiving months developed aneurysm coronary
paclitaxel receiving months developed aneurysm
propofol obtund response hypotensive
propofol ephedrine addition appears method obtunding response hypotensive
propofol obtunding response hypotensive
propofol associated tachycardia
ephedrine use associated tachycardia
propofol use recommend risk tachycardia
ephedrine any patients use recommend risk tachycardia
epinephrine induced thrombosis
EP epinephrine induced thrombosis
cocaine actions stimulatory convulsive
cocaine SM convulsions
lindane toxic
lindane toxic system to
lindane toxic system the
lindane toxic system central
lindane toxic system nervous
lindane toxic system
lindane toxic accumulating associated anaemia aplastic
lindane toxic accumulating associated anaemia
Mitomycin C associated syndrome hemolytic
Mitomycin C associated syndrome uremic
Mitomycin C associated syndrome
C associated syndrome hemolytic
C associated syndrome uremic
C associated syndrome
Mitomycin C associated Syndrome Hemolytic
Mitomycin C associated Syndrome Uremic
Mitomycin C associated Syndrome
C associated Syndrome Hemolytic
C associated Syndrome Uremic
C associated Syndrome
Mitomycin C associated Syndrome HUS
C associated Syndrome HUS
mitomycin treatment associated failure renal
mitomycin treatment associated failure
C treatment associated failure renal
C treatment associated failure
mitomycin treatment start mth 8 develops failure renal
mitomycin treatment start mth 8 develops failure
C treatment start mth 8 develops failure renal
C treatment start mth 8 develops failure
mitomycin treatment start mth 8 develops % failure renal
mitomycin treatment start mth 8 develops % failure
C treatment start mth 8 develops % failure renal
C treatment start mth 8 develops % failure
mitomycin C developed failure renal
mitomycin C developed failure
C developed failure renal
C developed failure
Lithium associated deficits cognitive
Lithium associated deficits cognitive and
Lithium associated deficits cognitive functional
Lithium associated deficits
lithium effects management written remain effects deficits cognitive
lithium effects management written remain effects deficits
lithium effects management written remain effects deficits loss
lithium effects management written remain effects deficits loss creativity of
lithium effects management written remain effects deficits loss creativity
lithium effects management written remain effects deficits impairments functional
lithium effects management written remain effects deficits impairments
lithium effects deficits cognitive
lithium effects deficits
lithium effects deficits loss
lithium effects deficits loss creativity of
lithium effects deficits loss creativity
lithium effects deficits impairments functional
lithium effects deficits impairments
lithium switching divalproex alleviate impairments cognitive
lithium switching divalproex alleviate impairments cognitive and
lithium switching divalproex alleviate impairments cognitive functional
lithium switching divalproex alleviate impairments
lithium substitution helpful reducing cognitive
lithium substitution helpful reducing cognitive motivational
lithium substitution helpful reducing cognitive or
lithium substitution helpful reducing cognitive deficits creative
lithium substitution helpful reducing cognitive deficits
lithium attributed deficits cognitive
lithium attributed deficits cognitive motivational
lithium attributed deficits cognitive or
lithium attributed deficits creative
lithium attributed deficits
lithium patients experiencing deficits cognitive
lithium patients experiencing deficits
lithium patients experiencing deficits loss
lithium patients experiencing deficits loss creativity of
lithium patients experiencing deficits loss creativity
lithium patients experiencing deficits impairments functional
lithium patients experiencing deficits impairments
Doxorubicin agent known cause cardiomyopathy
angiotensin introduction converting reported cases hypotension
converting reported cases hypotension
enzyme inhibitors converting reported cases hypotension
ACE inhibitors converting reported cases hypotension
inhibitors converting reported cases hypotension
prazosin multicenter trial designed compared incidence hypotension
ACE enalapril safety assess designed compared incidence hypotension
inhibitor enalapril safety assess designed compared incidence hypotension
prazosin received patients enalapril hypotension
ciprofloxacin treatment described followed failure acute
ciprofloxacin treatment described followed failure renal
ciprofloxacin treatment described followed failure
ciprofloxacin diagnosis supports followed improvement induced failure acute
ciprofloxacin diagnosis supports followed improvement induced failure renal
ciprofloxacin diagnosis supports followed improvement induced failure
methamphetamine antagonist action associated decrease hyperthermia
methamphetamine hyperthermia
methamphetamine reduction associated induced induced decrease hyperthermia
Diazepam facilitates bradycardia
adrenaline infusion produced bradycardia
diazepam rats pretreatment enhance adrenaline induced bradycardia
adrenaline change effect causing pretreatment enhance adrenaline induced bradycardia
adrenaline induced bradycardia
diazepam enhancement adrenaline induced bradycardia
adrenaline induced bradycardia
diazepam acts facilitate bradycardia
trazodone dose block heart
trazodone dose block
trazodone dose receiving minutes developed block heart
trazodone dose receiving minutes developed block
Methimazole induced jaundice cholestatic
Methimazole induced jaundice
methimazole had jaundice itching
DES adenocarcinoma clear
DES adenocarcinoma cell
DES adenocarcinoma
Levodopa induced dyskinesia
Levodopa alleviated dyskinesia
levodopa induced dyskinesias
Phenylephrine reduces
Phenylephrine reduces oxygenation frontal
Phenylephrine reduces oxygenation lobe
Phenylephrine reduces oxygenation
acetaminophen associated deaths apoptotic necrotic
acetaminophen associated induced nephrotoxicity
doxorubicin toxicity amiodarone associated deaths apoptotic necrotic
doxorubicin toxicity amiodarone induced cardiotoxicity
amiodarone associated deaths apoptotic necrotic
amiodarone toxicity lung
amiodarone toxicity
acetaminophen prevent extract proanthocyanidin induced nephrotoxicity
AAP acetaminophen prevent extract proanthocyanidin induced nephrotoxicity
doxorubicin toxicity induced proanthocyanidin induced cardiotoxicity
DOX doxorubicin toxicity induced proanthocyanidin induced cardiotoxicity
amiodarone nephrotoxicity induced proanthocyanidin induced toxicity lung
amiodarone nephrotoxicity induced proanthocyanidin induced toxicity
AMI nephrotoxicity induced proanthocyanidin induced toxicity lung
AMI nephrotoxicity induced proanthocyanidin induced toxicity
AAP induced drugs necrosis
DOX AAP induced drugs necrosis
AMI AAP induced drugs necrosis
levodopa dyskinesias
propofol sedation underwent dementia delirium
amikacin nephrotoxicity
amikacin associated nephrotoxicity
amikacin efficacy increase means nephrotoxicity
amphetamine diagnosis service patients relationship catecholamines symptoms psychotic
amphetamine diagnosis service patients relationship catecholamines symptoms
amphetamine diagnosis service patients relationship examine interviewed psychosis
cocaine relationship catecholamines symptoms psychotic
cocaine relationship catecholamines symptoms
cocaine relationship examine interviewed psychosis
Methamphetamine levels related scores rating hyperkinesia
amphetamine Methamphetamine levels related scores rating hyperkinesia
Valproic acid induced encephalopathy
acid induced encephalopathy
VPA associated effect acid induced encephalopathy
VPA suppression induced encephalopathy
VPA hepatotoxicity induced suppression induced encephalopathy
VPA suppression induced hepatotoxicity
VPA hepatotoxicity
VPA suppression bone
VPA suppression marrow
VPA suppression
VPA hepatotoxicity induced suppression bone
VPA hepatotoxicity induced suppression marrow
VPA hepatotoxicity induced suppression
VPA suppression pancreatitis
VPA hepatotoxicity induced suppression pancreatitis
VPA induced encephalopathy
VPA signs consciousness impaired
VPA signs consciousness
VPA effect proof is patients encephalopathy
VPA patients associated encephalopathy
cimetidine taking impotence
cimetidine replaced disappeared developed impotence
hydroxychloroquine chloroquine used found case drugs attributable chorioretinopathy
nicotine mechanisms induced hyperactivity locomotor
nicotine mechanisms induced hyperactivity
nicotine hyperactivity locomotor
nicotine hyperactivity
nicotine treated develop hyperactivity locomotor
nicotine treated develop hyperactivity
nicotine develop hyperactivity locomotor
nicotine develop hyperactivity
Prostaglandin D had action hyperalgesic
D had action hyperalgesic
2 had action hyperalgesic
prostaglandin D that lasted showed effect hyperalgesic
D that lasted showed effect hyperalgesic
2 D that lasted showed effect hyperalgesic
Prostaglandin E showed effect hyperalgesic
E showed effect hyperalgesic
2 E showed effect hyperalgesic
prostaglandin D effect hyperalgesic
D effect hyperalgesic
2 D effect hyperalgesic
prostaglandin induced blocked hyperalgesia
E 2 prostaglandin induced blocked hyperalgesia
2 prostaglandin induced blocked hyperalgesia
prostaglandin D hyperalgesia
D hyperalgesia
2 hyperalgesia
prostaglandin 2 hyperalgesia
E hyperalgesia
2 hyperalgesia
Valproic I course biomarkers toxicity liver
Valproic I course biomarkers toxicity
acid I course biomarkers toxicity liver
acid I course biomarkers toxicity
valproic levels biomarkers toxicity liver
valproic levels biomarkers toxicity
acid levels biomarkers toxicity liver
acid levels biomarkers toxicity
VPA relationship was determine stress hepatotoxicity
VPA treated Sprague stress hepatotoxicity
VPA results steatosis
VPA results measured IsoP precedes onset necrosis
indomethacin due anemia aplastic
indomethacin due anemia
indomethacin implicated cause anemia aplastic
indomethacin implicated cause anemia
indomethacin allopurinol other given described case anemia aplastic
indomethacin allopurinol other given described case anemia
indomethacin test substantiates role drug causing anemia aplastic
indomethacin test substantiates role drug causing anemia
midazolam arrest cardiorespiratory
midazolam arrest
midazolam administration associated arrest cardiorespiratory
midazolam administration associated arrest
reserpine induced dyskinesia
reserpine role dyskinesia
alfentanil induced rigidity muscle
alfentanil induced rigidity
alfentanil acting attenuated produced rigidity muscle
alfentanil acting attenuated produced rigidity
alfentanil produced rigidity
alfentanil followed ketanserin received animals motionless absence rigidity
alfentanil receiving animals motionless absence rigidity
epinephrine induced ischemia myocardial
epinephrine induced ischemia
epinephrine eliciting ischemia myocardial
epinephrine eliciting ischemia
epinephrine produced ischemia myocardial
epinephrine produced ischemia
epinephrine induced ischemia myocardial
epinephrine induced ischemia
epinephrine volume product rate Exercise marked ischemia myocardial
epinephrine volume product rate Exercise marked ischemia
Nimodipine Trial BACKGROUND reduction
Nimodipine Trial BACKGROUND reduction pressure in
Nimodipine Trial BACKGROUND reduction pressure blood
Nimodipine Trial BACKGROUND reduction pressure
nimodipine correlation found Trial BACKGROUND reduction
nimodipine correlation found Trial BACKGROUND reduction pressure in
nimodipine correlation found Trial BACKGROUND reduction pressure blood
nimodipine correlation found Trial BACKGROUND reduction pressure
Nimodipine treatment resulted reduction
Nimodipine treatment resulted reduction BP in
Nimodipine treatment resulted reduction BP systolic
Nimodipine treatment resulted reduction BP
phenylpropanolamine associated hemorrhage Cerebral
phenylpropanolamine associated hemorrhage
caffeine associated hemorrhage Cerebral
caffeine associated hemorrhage
Phenylpropanolamine drug associated effects stroke
PPA Phenylpropanolamine drug associated effects stroke
PPA caffeine lead stroke
caffeine lead stroke normotensive rats hypertensive
PPA caffeine lead stroke normotensive rats hypertensive
caffeine administration lead hypertension
caffeine administration lead hypertension normotensive animals hypertensive
PPA administration lead hypertension
PPA administration lead hypertension normotensive animals hypertensive
PPA caffeine lead hemorrhage cerebral
PPA caffeine lead hemorrhage
caffeine lead hemorrhage cerebral
caffeine lead hemorrhage
caffeine lead hemorrhage animals hypertensive
PPA caffeine lead hemorrhage animals hypertensive
amoxicillin patient case hepatitis
clavulanic acid case hepatitis
acid case hepatitis
amoxicillin patient case hepatitis granulomas
clavulanic acid case hepatitis granulomas
acid case hepatitis granulomas
cimetidine patients studies confusion
cimetidine cases reported confusion
DNR failure heart
DNR failure
5 infusion confusion
fluorouracil confusion
folinic acid fluorouracil confusion
acid fluorouracil confusion
5 lasting coma
fluorouracil infusion lasting coma
5 lasting coma lapsed developed symptoms confusion
fluorouracil infusion lasting coma lapsed developed symptoms confusion
5 lasting coma lapsed developed symptoms confusion disorientation
fluorouracil infusion lasting coma lapsed developed symptoms confusion disorientation
folinic fluorouracil infusion lasting coma
acid infusion lasting coma
folinic fluorouracil infusion lasting coma lapsed developed symptoms confusion
acid infusion lasting coma lapsed developed symptoms confusion
folinic fluorouracil infusion lasting coma lapsed developed symptoms confusion disorientation
acid infusion lasting coma lapsed developed symptoms confusion disorientation
scopolamine prevention rats sublethal short amnesia
scopolamine prevention rats sublethal exposed rats response protection amnesia
Fluconazole induced pointes torsade
Fluconazole induced pointes de
Fluconazole induced pointes
fluconazole case torsade
fluconazole case torsade pointes de
fluconazole case torsade pointes
fluconazole case torsade pointes TDP
fluconazole case present discuss causing TDP
fluconazole role discuss present case torsade
fluconazole role discuss present case torsade pointes de
fluconazole role discuss present case torsade pointes
fluconazole role discuss present case torsade pointes TDP
fluconazole role discuss causing TDP
fluconazole commencing days developed TDP
fluconazole had TDP
fluconazole commencing days developed abscess isolated glabrata woman abnormalities was association initiation fluconazole TDP
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed TDP
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed days commencing fluconazole had TDP
fluconazole TDP
fluconazole discontinued resolved TDP
fluconazole discontinued resolved indicates relationship use development TDP
fluconazole use relationship indicates resolved TDP
fluconazole use development TDP
fluconazole suggests was etiology explain TDP
fluconazole cause leading TDP
olanzapine induced syndrome Hypomania
olanzapine treatment introduction developed hypomania
lindane convulsions
lindane convulsions incidence produce pretreatment increased incidence convulsions
lindane convulsions incidence increased pretreatment produce incidence convulsions
lindane convulsions
lindane blocked incidence convulsions
lindane treated animals increased P metabolism lindane blocked incidence convulsions
lindane se indicating lindane treated animals increased P metabolism lindane blocked incidence convulsions
PTU associated vasculitis
propylthiouracil vasculitis
PTU propylthiouracil vasculitis
PTU withdrawal symptoms resolution observation made diagnosis propylthiouracil vasculitis
lidocaine cocaine kindled seizures
cocaine kindled seizures
lidocaine seizures
lidocaine seizures development inhibited had effect seizures
cocaine lidocaine seizures
cocaine lidocaine seizures development inhibited had effect seizures
cocaine mortality incidence seizure
lidocaine induced seizures
cocaine kindled lidocaine induced seizures
lidocaine seizures
cocaine lidocaine seizures
cocaine induced seizures
cocaine injection induced seizures
cocaine influences seizures
heparin patients thrombosis
heparin patients thrombosis thrombocytopenia
heparin two antigen thrombosis
heparin concentration characteristics two antigen thrombosis
heparin two antigen thrombocytopenia
heparin two antigen HIT
heparin concentration characteristics two antigen thrombocytopenia
heparin concentration characteristics two antigen HIT
heparin exposure decrease count thrombocytopenia
heparin -RSB- concentration inhibition antigen two had heparin exposure decrease count thrombocytopenia
captopril treatment function deterioration sudden
captopril treatment function deterioration
captopril treatment function of
captopril treatment function renal
captopril treatment function
Levodopa induced dyskinesias
levodopa dyskinesias
levodopa pathophysiology systems preclinical induced dyskinesias
streptozotocin rats membrane associated Reduction induced nephropathy diabetic
streptozotocin rats membrane associated Reduction induced nephropathy
carbimazole therapy bupropion Acute
carbimazole therapy bupropion Acute failure liver
carbimazole therapy bupropion Acute failure
bupropion Acute
bupropion Acute failure liver
bupropion Acute failure
bupropion induced hepatotoxicity
carbimazole treatment receiving resulted case is increasing evidence hepatotoxicity
carbimazole treatment receiving resulted failure acute
carbimazole treatment receiving resulted failure liver
carbimazole treatment receiving resulted failure
bupropion induced hepatotoxicity
bupropion while receiving resulted case is increasing evidence hepatotoxicity
bupropion induced hepatotoxicity evidence increasing is case resulted failure acute
bupropion induced hepatotoxicity evidence increasing is case resulted failure liver
bupropion induced hepatotoxicity evidence increasing is case resulted failure
bupropion while receiving resulted failure acute
bupropion while receiving resulted failure liver
bupropion while receiving resulted failure
bupropion given drugs hepatotoxic
bupropion induced insult acute
bupropion induced insult liver
bupropion induced insult
azelastine placebo significantly group increased Drowsiness perception altered
azelastine placebo significantly group increased Drowsiness perception taste
azelastine placebo significantly group increased Drowsiness perception
azelastine placebo significantly group increased Drowsiness
cyclophosphamide granulomatosis cancer Urinary
cyclophosphamide granulomatosis cancer bladder
cyclophosphamide granulomatosis cancer
cyclophosphamide relation cancer bladder
cyclophosphamide relation cancer
cyclophosphamide bladder
cyclophosphamide cancer
cyclophosphamide = doubled risk cancer bladder
cyclophosphamide = doubled risk cancer
cyclophosphamide relationship dose risk cancer bladder
cyclophosphamide relationship dose risk cancer
morphine treated Hyperalgesia myoclonus
morphine treated Hyperalgesia
morphine doses treated disease stages patients developed hyperalgesia
morphine doses relationship myoclonus
morphine plays indicates available descriptions relationship myoclonus
morphine doses relationship myoclonus hyperalgesia
morphine plays indicates available descriptions relationship myoclonus hyperalgesia
chlorthalidone administration loss hypokalaemia
lidocaine system role convulsion
lidocaine convulsions
lidocaine convulsions
lidocaine incidence increased treatment L induced convulsions
lidocaine mediator convulsions
tamoxifen women events vascular
tamoxifen women events
tamoxifen women events hypertriglyceridaemia
L patients overactivation dose dyskinesia
dopa overactivation dose dyskinesia
L patients groups supplementary task execution dopa dyskinesia
dopa medication execution dopa dyskinesia
L patients groups supplementary task execution other dyskinesia
dopa medication execution other dyskinesia
L one medication execution dopa dyskinesia
dopa dyskinesia
L one medication execution other dyskinesia
dopa execution other dyskinesia
L movement abnormal
L movement involuntary
L movement
dopa L movement abnormal
dopa L movement involuntary
dopa L movement
L induced dyskinesia
dopa L induced dyskinesia
cinacalcet reported nausea headache
cinacalcet desipramine treated patients reported nausea headache
desipramine treatment alone receiving cinacalcet reported nausea
desipramine receiving cinacalcet reported nausea
desipramine treated patients reported nausea
cinacalcet reported nausea
cinacalcet desipramine treated patients reported nausea
desipramine treatment alone receiving cinacalcet reported nausea headache
desipramine receiving cinacalcet reported nausea headache
desipramine treated patients reported nausea headache
cisplatin injection induced injury acute
cisplatin injection induced injury renal
cisplatin injection induced injury
paracetamol developed bladder epithelium Papillomas bore carcinomas bladder
paracetamol developed bladder epithelium Papillomas bore carcinomas
paracetamol % treated developed hyperplasia
paracetamol livers study treated revealed hepatocytes resemble those result variety hepatocarcinogens
paclitaxel received suffered edema moderate brain
paclitaxel received suffered edema
paclitaxel total received edema moderate brain
paclitaxel total received edema
capsaicin administration induced hyperalgesia
haloperidol induced hyperprolactinemia
haloperidol induced hyperprolactinemia
HAL haloperidol induced hyperprolactinemia
tranylcypromine interaction syndrome Serotonin
tranylcypromine interaction syndrome
venlafaxine syndrome Serotonin
venlafaxine syndrome
tranylcypromine taking male y venlafaxine interaction resulted syndrome serotonin
tranylcypromine taking male y venlafaxine interaction resulted syndrome
venlafaxine interaction resulted syndrome serotonin
venlafaxine interaction resulted syndrome
Ciprofloxacin induced nephritis interstitial
Ciprofloxacin induced nephritis
Ciprofloxacin associated effects nephritis anemia hemolytic
Ciprofloxacin associated effects nephritis anemia
Ciprofloxacin associated effects nephritis interstitial
Ciprofloxacin associated effects nephritis
ciprofloxacin case nephritis interstitial
ciprofloxacin case nephritis
puromycin aminonucleoside induced Plasma lipids development syndrome nephrotic
puromycin aminonucleoside induced Plasma lipids development syndrome
aminonucleoside induced Plasma lipids development syndrome nephrotic
aminonucleoside induced Plasma lipids development syndrome
puromycin aminonucleoside induced syndrome nephrotic
puromycin aminonucleoside induced syndrome
aminonucleoside induced syndrome nephrotic
aminonucleoside induced syndrome
puromycin aminonucleoside induced syndrome found lipoproteins alterations due syndrome nephrotic
puromycin aminonucleoside induced syndrome found lipoproteins alterations due syndrome
aminonucleoside induced syndrome found lipoproteins alterations due syndrome nephrotic
aminonucleoside induced syndrome found lipoproteins alterations due syndrome
aminonucleoside or syndrome due alterations lipoproteins found syndrome nephrotic
aminonucleoside or syndrome due alterations lipoproteins found syndrome
aminonucleoside or syndrome nephrotic
aminonucleoside or syndrome
puromycin aminonucleoside administration development syndrome nephrotic
puromycin aminonucleoside administration development syndrome
aminonucleoside administration development syndrome nephrotic
aminonucleoside administration development syndrome
oral therapy complications pretreatment levels factors blood
oral therapy complications pretreatment levels factors coagulation
contraceptive therapy complications pretreatment levels factors blood
contraceptive therapy complications pretreatment levels factors coagulation
diltiazem interaction cisapride related Prolongation
diltiazem interaction cisapride related Prolongation interval of
diltiazem interaction cisapride related Prolongation interval the
diltiazem interaction cisapride related Prolongation interval QT
diltiazem interaction cisapride related Prolongation interval
cisapride related Prolongation
cisapride related Prolongation interval of
cisapride related Prolongation interval the
cisapride related Prolongation interval QT
cisapride related Prolongation interval
azole erythromycin agents reported Prolongation interval death sudden
azole erythromycin agents reported Prolongation interval death cardiac
azole erythromycin agents reported Prolongation interval death
azole erythromycin agents reported Prolongation interval pointes torsades
azole erythromycin agents reported Prolongation interval pointes de
azole erythromycin agents reported Prolongation interval pointes
erythromycin agents reported Prolongation interval pointes torsades
erythromycin agents reported Prolongation interval pointes de
erythromycin agents reported Prolongation interval pointes
azole erythromycin agents reported Prolongation
azole erythromycin agents reported Prolongation interval of
azole erythromycin agents reported Prolongation interval QT
azole erythromycin agents reported Prolongation interval
erythromycin agents reported Prolongation interval death sudden
erythromycin agents reported Prolongation interval death cardiac
erythromycin agents reported Prolongation interval death
erythromycin agents reported Prolongation
erythromycin agents reported Prolongation interval of
erythromycin agents reported Prolongation interval QT
erythromycin agents reported Prolongation interval
MMC m developed failure cardiac
MMC m developed failure
doxorubicin m developed failure cardiac
doxorubicin m developed failure
lithium treatment hypothyroidism
lithium taking developed Hypothyroidism
gentamicin resistance responsible suggested failure acute
gentamicin resistance responsible suggested failure renal
gentamicin resistance responsible suggested failure
gentamicin resistance responsible suggested failure ARF
streptozotocin mellitus diabetes
streptozotocin mellitus
streptozotocin DM
gentamicin ARF
ethambutol due neuropathy Bilateral
ethambutol due neuropathy optic
ethambutol due neuropathy
isoniazid treatment ethambutol due neuropathy Bilateral
isoniazid treatment ethambutol due neuropathy optic
isoniazid treatment ethambutol due neuropathy
doxorubicin kinase inducible induced syndrome nephrotic
doxorubicin kinase inducible induced syndrome
Doxorubicin treatment resulted 44 mice leading ascites
Doxorubicin treatment resulted proteinuria
Doxorubicin treatment resulted 44 mice leading ascites hypoalbuminemia
Doxorubicin treatment resulted 44 mice leading syndrome nephrotic
Doxorubicin treatment resulted 44 mice leading syndrome
Doxorubicin treatment resulted 44 mice leading ascites lipidemia
atazanavir simvastatin use secondary failure rhabdomyolysis
atazanavir simvastatin use secondary failure rhabdomyolysis acute
atazanavir simvastatin use secondary failure renal
atazanavir simvastatin use secondary failure
amiodarone simvastatin use secondary failure rhabdomyolysis
simvastatin use secondary failure rhabdomyolysis acute
simvastatin use secondary failure renal
simvastatin use secondary failure
simvastatin use secondary failure rhabdomyolysis
amiodarone simvastatin use secondary failure rhabdomyolysis acute
amiodarone simvastatin use secondary failure renal
amiodarone simvastatin use secondary failure
atazanavir simvastatin resulting failure rhabdomyolysis
atazanavir simvastatin resulting failure rhabdomyolysis acute
atazanavir simvastatin resulting failure renal
atazanavir simvastatin resulting failure
amiodarone simvastatin resulting failure rhabdomyolysis
simvastatin resulting failure rhabdomyolysis acute
simvastatin resulting failure renal
simvastatin resulting failure
simvastatin resulting failure rhabdomyolysis
amiodarone simvastatin resulting failure rhabdomyolysis acute
amiodarone simvastatin resulting failure renal
amiodarone simvastatin resulting failure
simvastatin metabolism inhibit presence increased risk rhabdomyolysis
coniine failed produce arthrogryposis
nicotine sulfate occurred hemorrhage cranial
nicotine sulfate occurred hemorrhage
coniine model arthrogryposis
N aspirin administration co carcinomas induction tumors forestomach
N aspirin administration co carcinomas induction tumors
-LSB- administration co carcinomas induction tumors forestomach
-LSB- administration co carcinomas induction tumors
4 -LSB- administration co carcinomas induction tumors forestomach
4 -LSB- administration co carcinomas induction tumors
5 -LSB- administration co carcinomas induction tumors forestomach
5 -LSB- administration co carcinomas induction tumors
nitro 5 -LSB- administration co carcinomas induction tumors forestomach
nitro 5 -LSB- administration co carcinomas induction tumors
2 nitro 5 -LSB- administration co carcinomas induction tumors forestomach
2 nitro 5 -LSB- administration co carcinomas induction tumors
furyl 2 nitro 5 -LSB- administration co carcinomas induction tumors forestomach
furyl 2 nitro 5 -LSB- administration co carcinomas induction tumors
2 administration co carcinomas induction tumors forestomach
2 administration co carcinomas induction tumors
thiazolyl -RSB- 2 administration co carcinomas induction tumors forestomach
thiazolyl -RSB- 2 administration co carcinomas induction tumors
-RSB- 2 administration co carcinomas induction tumors forestomach
-RSB- 2 administration co carcinomas induction tumors
formamide administration co carcinomas induction tumors forestomach
formamide administration co carcinomas induction tumors
FANFT formamide administration co carcinomas induction tumors forestomach
FANFT formamide administration co carcinomas induction tumors
FANFT incidence resulted administration co carcinomas induction tumors forestomach
FANFT incidence resulted administration co carcinomas induction tumors
N aspirin administration co carcinomas bladder
N aspirin administration co carcinomas
-LSB- administration co carcinomas bladder
-LSB- administration co carcinomas
4 -LSB- administration co carcinomas bladder
4 -LSB- administration co carcinomas
5 -LSB- administration co carcinomas bladder
5 -LSB- administration co carcinomas
nitro 5 -LSB- administration co carcinomas bladder
nitro 5 -LSB- administration co carcinomas
2 nitro 5 -LSB- administration co carcinomas bladder
2 nitro 5 -LSB- administration co carcinomas
furyl 2 nitro 5 -LSB- administration co carcinomas bladder
furyl 2 nitro 5 -LSB- administration co carcinomas
2 administration co carcinomas bladder
2 administration co carcinomas
thiazolyl -RSB- 2 administration co carcinomas bladder
thiazolyl -RSB- 2 administration co carcinomas
-RSB- 2 administration co carcinomas bladder
-RSB- 2 administration co carcinomas
formamide administration co carcinomas bladder
formamide administration co carcinomas
FANFT formamide administration co carcinomas bladder
FANFT formamide administration co carcinomas
FANFT incidence resulted administration co carcinomas bladder
FANFT incidence resulted administration co carcinomas
amphotericin nephrotoxicity
B nephrotoxicity
amphotericin B potential nephrotoxic
B potential nephrotoxic
sulphasalazine treatment restarting developed eyes effusion pleural
sulphasalazine treatment restarting developed eyes effusion
sulphasalazine treatment cessation resulted fever effusions pleural
sulphasalazine treatment cessation resulted fever effusions
sulphasalazine treatment cessation resulted initiated remained effusion pleural
sulphasalazine treatment cessation resulted initiated remained effusion
sulphasalazine treatment cessation resulted fever
Methylphenidate induced obsessive
Methylphenidate induced obsessive symptoms compulsive
Methylphenidate induced obsessive symptoms
methylphenidate replaced diminished ensued obsessive
methylphenidate replaced diminished ensued behavior compulsive
methylphenidate replaced diminished ensued behavior
nicotine mg caused locomotor significantly lesions operated induced hyperactivity
nicotine enhanced operated induced hyperactivity
morphine antinociception constipation
morphine combination effects constipating
morphine inhibited suggesting develop effects constipating
morphine produced constipation
morphine potentiate suggesting produced constipation
adriamycin -LSB- induced proteinuria
adriamycin elicited proteinuria
adriamycin correlated rise proteinuria
LiCl administration 2 mice led polyuria
pravastatin use associated myopathy inflammatory
pravastatin use associated myopathy
Clonidine bradycardia
1 exposure had workers investigated epidemic disease liver
1 exposure had workers investigated epidemic disease
chloro - 1 exposure had workers investigated epidemic disease liver
chloro - 1 exposure had workers investigated epidemic disease
- 1 exposure had workers investigated epidemic disease liver
- 1 exposure had workers investigated epidemic disease
1 - 1 exposure had workers investigated epidemic disease liver
1 - 1 exposure had workers investigated epidemic disease
2 - 1 exposure had workers investigated epidemic disease liver
2 - 1 exposure had workers investigated epidemic disease
2 - 1 exposure had workers investigated epidemic disease liver
2 - 1 exposure had workers investigated epidemic disease
2 - 1 exposure had workers investigated epidemic disease liver
2 - 1 exposure had workers investigated epidemic disease
tetrafluoroethane - 1 exposure had workers investigated epidemic disease liver
tetrafluoroethane - 1 exposure had workers investigated epidemic disease
HCFC tetrafluoroethane - 1 exposure had workers investigated epidemic disease liver
HCFC tetrafluoroethane - 1 exposure had workers investigated epidemic disease
124 HCFC tetrafluoroethane - 1 exposure had workers investigated epidemic disease liver
124 HCFC tetrafluoroethane - 1 exposure had workers investigated epidemic disease
1 mixture exposure had workers investigated epidemic disease liver
1 mixture exposure had workers investigated epidemic disease
1 exposure had workers investigated epidemic disease liver
1 exposure had workers investigated epidemic disease
dichloro - 1 exposure had workers investigated epidemic disease liver
dichloro - 1 exposure had workers investigated epidemic disease
- 1 exposure had workers investigated epidemic disease liver
- 1 exposure had workers investigated epidemic disease
2 - 1 exposure had workers investigated epidemic disease liver
2 - 1 exposure had workers investigated epidemic disease
2 - 1 exposure had workers investigated epidemic disease liver
2 - 1 exposure had workers investigated epidemic disease
2 - 1 exposure had workers investigated epidemic disease liver
2 - 1 exposure had workers investigated epidemic disease
trifluoroethane exposure had workers investigated epidemic disease liver
trifluoroethane exposure had workers investigated epidemic disease
HCFC 123 trifluoroethane exposure had workers investigated epidemic disease liver
HCFC 123 trifluoroethane exposure had workers investigated epidemic disease
123 trifluoroethane exposure had workers investigated epidemic disease liver
123 trifluoroethane exposure had workers investigated epidemic disease
scopolamine cholinesterase 247 Effects induced amnesia
NIK Effects induced amnesia
247 Effects induced amnesia
scopolamine 247 induced examined amnesia
tacrine 247 induced examined amnesia
E tacrine 247 induced examined amnesia
2020 effects 247 induced examined amnesia
NIK effects 247 induced examined amnesia
247 induced examined amnesia
scopolamine induced amnesia
scopolamine induced amnesia
NIK 247 improves scopolamine induced amnesia
- 247 improves scopolamine induced amnesia
247 improves scopolamine induced amnesia
levodopa administration caused epilepsy
/ administration caused epilepsy
carbidopa administration caused epilepsy
dexamethasone treatment years age dysfunction neurological
dexamethasone treatment years age dysfunction
dexamethasone therapy assess dysfunction neurological
dexamethasone therapy assess dysfunction
dexamethasone treatment showed rate dysfunctions neurological
dexamethasone treatment showed rate dysfunctions
sodium anticoagulant resulting hypocalcemia
citrate anticoagulant resulting hypocalcemia
citrate due prevent help recommended screening medications conditions predisposing hypocalcemia
2 injection chloroprocaine CE limb paralysis
chloroprocaine CE limb paralysis
CE limb paralysis
2 received animals cords showed necrosis subpial
2 received animals cords showed necrosis
chloroprocaine showed necrosis subpial
chloroprocaine showed necrosis
CE showed necrosis subpial
CE showed necrosis
methotrexate accident leukoencephalopathy
methotrexate treated patients identified reports leukoencephalopathy
5 methotrexate treated patients identified reports leukoencephalopathy
fluorouracil 5 methotrexate treated patients identified reports leukoencephalopathy
carmofur fluorouracil 5 methotrexate treated patients identified reports leukoencephalopathy
capecitabine methotrexate treated patients identified reports leukoencephalopathy
scopolamine MEASURES impairment
scopolamine MEASURES impairment recall in
scopolamine MEASURES impairment recall word
scopolamine MEASURES impairment recall
scopolamine induced impairment
scopolamine induced impairment recall in
scopolamine induced impairment recall word
scopolamine induced impairment recall
amiodarone treatment occurring block presented intra
amiodarone treatment occurring block Hisian
amiodarone treatment occurring block
cocaine users sleepiness daytime
cocaine users sleepiness
cocaine users decreases sleepiness daytime
cocaine users decreases sleepiness
cocaine use related incidence increasing indicate exceeds that infarction cerebral
cocaine use related incidence increasing indicate exceeds that infarction
cocaine - indicate exceeds that infarction cerebral
cocaine - indicate exceeds that infarction
cocaine administration route follow indicate exceeds that infarction cerebral
cocaine administration route follow indicate exceeds that infarction
cocaine use associated indicate exceeds that infarction cerebral
cocaine use associated indicate exceeds that infarction
cocaine 5 stroke exceeds that infarction cerebral
cocaine 5 stroke exceeds that infarction
isoproterenol detection mTc induced infarction myocardial
isoproterenol detection mTc induced infarction
isoproterenol rats study used easy mTc induced infarction myocardial
isoproterenol rats study used easy mTc induced infarction
estrogen microscopic prolactinomas
estrogen applied clarify cells prolactinoma
estrogen applied induced h cells prolactinoma
Calcium toxicity milk
Calcium toxicity alkali
Calcium toxicity alkali syndrome
carbonate toxicity milk
carbonate toxicity alkali
carbonate toxicity alkali syndrome
calcium carbonate describe induced insights hypercalcemia
carbonate describe induced insights hypercalcemia
calcium carbonate describe induced cause milk
calcium carbonate describe alkali
calcium carbonate describe alkali syndrome
carbonate describe induced cause milk
carbonate describe alkali
carbonate describe alkali syndrome
pamidronate intravenously caused hypocalcemia
calcium carbonate amounts precipitated cause CONCLUSION Milk
calcium carbonate amounts precipitated cause syndrome alkali
calcium carbonate amounts precipitated cause syndrome
carbonate amounts precipitated cause CONCLUSION Milk
carbonate amounts precipitated cause syndrome alkali
carbonate amounts precipitated cause syndrome
calcium carbonate amounts precipitated cause hypercalcemia
carbonate amounts precipitated cause hypercalcemia
Pamidronate treatment associated risk hypocalcemia
sirolimus administration association syndrome capillary
sirolimus administration association syndrome leak
sirolimus administration association syndrome
rapamycin sirolimus administration association syndrome capillary
rapamycin sirolimus administration association syndrome leak
rapamycin sirolimus administration association syndrome
sirolimus treatment syndrome capillary
sirolimus treatment syndrome leak
sirolimus treatment syndrome
sirolimus specimen OBSERVATIONS induced leak capillary
sirolimus specimen OBSERVATIONS induced leak
sirolimus specimen OBSERVATIONS induced leak syndrome
sirolimus fold 3 syndrome leak capillary
sirolimus fold 3 syndrome leak
sirolimus fold 3 syndrome
sirolimus effects include fever syndrome capillary
sirolimus effects include fever syndrome leak
sirolimus effects include fever syndrome
diazepam complications Venous
diazepam complications
midazolam complications Venous
midazolam complications
diazepam associated venous
diazepam associated complications
midazolam associated venous
midazolam associated complications
diazepam injection evaluated incidence complications venous
diazepam injection evaluated incidence complications
midazolam diazepam injection evaluated incidence complications venous
midazolam diazepam injection evaluated incidence complications
diazepam frequent complications venous
diazepam frequent complications
midazolam frequent complications venous
midazolam frequent complications
streptozotocin role nephropathy diabetic
streptozotocin role nephropathy
streptozotocin tissues using nephropathy diabetic
streptozotocin tissues using nephropathy
streptozotocin tissues patients diabetic
streptozotocin tissues patients nephropathy
streptozotocin tissues model diabetic
streptozotocin tissues model nephropathy
prednisolone administration occurred enlargement wastage muscle
prednisolone administration occurred enlargement wastage
prednisolone administration occurred enlargement Liver
prednisolone administration occurred enlargement
streptozocin crocin L constituents Effects model disease Alzheimer
streptozocin crocin L constituents Effects model disease Alzheimer '
streptozocin crocin L constituents Effects model disease s
streptozocin crocin L constituents Effects model disease
streptozocin induced disease Alzheimer
streptozocin induced disease Alzheimer '
streptozocin induced disease s
streptozocin induced disease
STZ streptozocin induced disease Alzheimer
STZ streptozocin induced disease Alzheimer '
STZ streptozocin induced disease s
STZ streptozocin induced disease
STZ injected groups Alzheimer
STZ injected groups Alzheimer '
STZ injected groups s
STZ injected groups disease
STZ repeated injected groups Alzheimer
STZ repeated injected groups Alzheimer '
STZ repeated injected groups s
STZ repeated injected groups disease
STZ caused deficits cognitive
STZ caused deficits
STZ caused deficits antagonizing demonstrate disease potential treatment diseases Alzheimer
STZ caused deficits antagonizing demonstrate disease potential treatment diseases Alzheimer '
STZ caused deficits antagonizing demonstrate disease s
STZ caused deficits antagonizing demonstrate disease
aminophylline threshold initiating fibrillation ventricular
aminophylline threshold initiating fibrillation
aminophylline threshold ventricular
aminophylline threshold fibrillation
aminophylline infusion reduced threshold ventricular
aminophylline infusion reduced threshold fibrillation
aminophylline infusion resulted decrease threshold ventricular
aminophylline infusion resulted decrease threshold fibrillation
octreotide analog function formation gallstone
octreotide treatment had gallstones
octreotide treatment had developed cholecystitis acute
octreotide treatment had developed cholecystitis
octreotide patients gallstones
octreotide therapy cholecystitis sludge gallstones
timolol 0 treated % h diagnosed suffering depression
timolol treatment patients presented values depression
timolol inducer less depression
ACTH stimulation dystonia
MSH ACTH stimulation dystonia
suxamethonium doses Comparison bradycardia
suxamethonium doses arrhythmia bradycardia
corticosteroid therapy resolved pressure elevated
corticosteroid therapy resolved pressure intraocular
corticosteroid therapy resolved pressure
amphotericin related dilated
amphotericin related cardiomyopathy
B therapy amphotericin related dilated
B therapy amphotericin related cardiomyopathy
amphotericin B developed cardiomyopathy failure heart
amphotericin B developed cardiomyopathy failure
B developed cardiomyopathy failure heart
B developed cardiomyopathy failure
AmB B developed cardiomyopathy failure heart
AmB B developed cardiomyopathy failure
amphotericin B developed cardiomyopathy dilated
amphotericin B developed cardiomyopathy
B developed cardiomyopathy dilated
B developed cardiomyopathy
AmB B developed cardiomyopathy dilated
AmB B developed cardiomyopathy
AmB substituted abnormalities failure heart
AmB substituted abnormalities failure
cidofovir Use associated failure progressive
cidofovir Use associated failure renal
cidofovir Use associated failure
cidofovir Use associated failure neutropenia
Cocaine induced infarction myocardial
Cocaine induced infarction
cocaine result infarction acute
cocaine result infarction myocardial
cocaine result infarction
cocaine associated demand result infarction acute
cocaine associated demand result infarction myocardial
cocaine associated demand result infarction
Verapamil induced neurotoxicity
carbamazepine induced neurotoxicity
verapamil treatment neurotoxicity
carbamazepine neurotoxicity
methylphenidate intake vasculitis Cerebral
methylphenidate intake vasculitis
methylphenidate intake reported documented vasculitis Cerebral
methylphenidate intake reported documented vasculitis
sulphasalazine course day developed constellation dermatitis hepatitis
sulphasalazine course day developed constellation dermatitis lymphadenopathy
sulphasalazine course day developed constellation dermatitis
sulphasalazine course day developed constellation dermatitis fever
levodopa dyskinesias
fenoldopam induced hypotension
fenoldopam used induce hypotension
fenoldopam induced + hypotension
fenoldopam increased flow hypotension
nitroprusside cent 8 flow increased fenoldopam induced + hypotension
nitroprusside cent 8 flow hypotension
nitroprusside non arteriolar produce kidney hypotension
riboflavin thiamine deficiency common neuropathy Peripheral
riboflavin thiamine deficiency common neuropathy
riboflavin thiamine deficiency common neuropathy presented neuropathy sensory sensori
riboflavin thiamine deficiency common neuropathy presented neuropathy motor
riboflavin thiamine deficiency common neuropathy presented neuropathy
thiamine deficiency common neuropathy Peripheral
thiamine deficiency common neuropathy
thiamine deficiency common neuropathy presented neuropathy sensory sensori
thiamine deficiency common neuropathy presented neuropathy motor
thiamine deficiency common neuropathy presented neuropathy
vitamin doses D 5 x associated hypercalcemia hyperphosphatemia
D 5 x associated hypercalcemia hyperphosphatemia
3 D 5 x associated hypercalcemia hyperphosphatemia
vitamin D 10 associated hypercalcemia hyperphosphatemia
D 10 associated hypercalcemia hyperphosphatemia
3 D 10 associated hypercalcemia hyperphosphatemia
vitamin 3 increases hypercalcemia hyperphosphatemia
D 3 increases hypercalcemia hyperphosphatemia
3 increases hypercalcemia hyperphosphatemia
vitamin doses D 5 x associated hypercalcemia
D 5 x associated hypercalcemia
3 D 5 x associated hypercalcemia
vitamin D 10 associated hypercalcemia
D 10 associated hypercalcemia
3 D 10 associated hypercalcemia
vitamin 3 increases hypercalcemia
D 3 increases hypercalcemia
3 increases hypercalcemia
adriamycin cardiotoxicity
adriamycin effects cardiotoxic
cyclooxygenase inhibitors treatment failure infarction stroke
inhibitors treatment failure infarction stroke
cyclooxygenase inhibitors treatment failure myocardial
cyclooxygenase inhibitors treatment failure infarction
inhibitors treatment failure myocardial
inhibitors treatment failure infarction
cyclooxygenase inhibitors treatment failure infarction hypertension
inhibitors treatment failure infarction hypertension
cyclooxygenase inhibitors treatment failure infarction heart
cyclooxygenase inhibitors treatment failure
inhibitors treatment failure infarction heart
inhibitors treatment failure
pilocarpine neurons containing induced seizures
pilocarpine injected studied 1 seizures
pilocarpine intervals 1 seizures
phenylephrine labeled quantitated induced hypertension
Nitroglycerin shown reduce ST induced hypotension
nitroglycerin reverse agents potentiated elevation ST induced hypotension
levodopa dyskinesias
mannitol lower elevated
mannitol lower elevated ICP
zidovudine suppression bone
zidovudine suppression marrow
zidovudine suppression
ZDV zidovudine suppression bone
ZDV zidovudine suppression marrow
ZDV zidovudine suppression
ZDV therapy supplementation 12 seem B induced myelotoxicity
ZDV induced myelotoxicity
phenytoin patients cerebellum volumetry overdosages
phenytoin overdosage
phenytoin medication cause unlikely conclude result overdosage
sirolimus switch proteinuria
sirolmus lacks reported proteinuria
Srl sirolmus lacks reported proteinuria
Srl associated proteinuria
Srl associated proteinuria
Srl develop proteinuria
Srl used monitored proteinuria
haloperidol induced catalepsy
haloperidol induced catalepsy
Haloperidol challenged catalepsy
haloperidol injections previous attenuated catalepsy
haloperidol mechanisms glutamate induced catalepsy
Acetazolamide induced syndrome Gerstmann
Acetazolamide induced syndrome
acetazolamide case report induced syndrome Gerstmann
acetazolamide case report induced syndrome
oral contraception associated Chorea
contraception associated Chorea
oral contraceptives receiving developed chorea
contraceptives receiving developed chorea
amphetamine induced chorea
oral contraception induced chorea
contraception induced chorea
co exams formation cases patients developed cholestasis intrahepatic
co exams formation cases patients developed cholestasis
trimoxazole treatment formation cases patients developed cholestasis intrahepatic
trimoxazole treatment formation cases patients developed cholestasis
haloperidol induced rigidity Muscle
haloperidol induced rigidity
haloperidol rigidity muscle
haloperidol rigidity
CLZ ingestion accompanying flush nausea
CLZ ingestion accompanying duration headache
CLZ ingestion accompanying flush facial
CLZ ingestion accompanying flush
clonidine induces withdrawal bradycardia
clonidine effects hypothesized exhibits given induces withdrawal bradycardia
clonidine rate induced bradycardia
ribavirin has managed anemia
iohexol study comparing effects nephrotoxic
neostigmine nicotine induced endpoints convulsion
carbachol nicotine induced endpoints convulsion
nicotine induced endpoints convulsion
fluocinolone implant treated uveitis patients report incidence pressure elevated
fluocinolone implant treated uveitis patients report incidence pressure intraocular
fluocinolone implant treated uveitis patients report incidence pressure
acetonide implant treated uveitis patients report incidence pressure elevated
acetonide implant treated uveitis patients report incidence pressure intraocular
acetonide implant treated uveitis patients report incidence pressure
FA implant treated uveitis patients report incidence pressure elevated
FA implant treated uveitis patients report incidence pressure intraocular
FA implant treated uveitis patients report incidence pressure
haloperidol antagonist beta induced catalepsy
haloperidol induced catalepsy
haloperidol induced catalepsy
DFP TOTP given chickens exacerbated induced neuropathy
TOTP effects had corticosterone concentrations induced neuropathy
TOTP given chickens exacerbated induced neuropathy
DFP TOTP evident fibers Degenerating
DFP TOTP evident fibers myelinated
DFP TOTP evident fibers
TOTP evident fibers Degenerating
TOTP evident fibers myelinated
TOTP evident fibers
carbon tetrachloride effects hepatotoxic
tetrachloride effects hepatotoxic
CCl tetrachloride effects hepatotoxic
4 CCl tetrachloride effects hepatotoxic
acetaminophen CHCl CCl effects hepatotoxic
CCl effects hepatotoxic
4 CCl effects hepatotoxic
CHCl CCl effects hepatotoxic
3 CHCl CCl effects hepatotoxic
galactosamine CCl effects hepatotoxic
adriamycin administration effect cardiotoxic
galactosamine hepatotoxicity
streptomycin edaravone effect vestibulotoxicity
streptomycin induced vestibulotoxicity
streptomycin induced vestibulotoxicity
indomethacin misoprostol effect induced dysfunction renal
indomethacin misoprostol effect induced dysfunction
indomethacin dysfunction renal
indomethacin dysfunction
paclitaxel neurotoxicity peripheral
paclitaxel neurotoxicity
paclitaxel chemotherapy factor neuropathy peripheral
paclitaxel chemotherapy factor neuropathy
PAC paclitaxel chemotherapy factor neuropathy peripheral
PAC paclitaxel chemotherapy factor neuropathy
PAC ameliorate claimed factor neuropathy peripheral
PAC ameliorate claimed factor neuropathy
PAC preventing evaluate aimed induced neuropathy peripheral
PAC preventing evaluate aimed induced neuropathy
PAC neurotoxicity peripheral
PAC neurotoxicity
cyclosporine nephrotoxicity
cyclosporine role role combination chemotherapeutics development toxicity renal
cyclosporine role role combination chemotherapeutics development toxicity
CSA cyclosporine role role combination chemotherapeutics development toxicity renal
CSA cyclosporine role role combination chemotherapeutics development toxicity
CSA administration potential nephrotoxic
CSA toxicity aggravate administration potential nephrotoxic
CSA increased nephrotoxicity
CSA induced nephrotoxicity
smoking influence estimated associated loss hearing
smoking influence estimated associated loss
smoking associated loss hearing
smoking associated loss
haloperidol doses higher incidence parkinsonism
CaCl induced aneurysm thoracic
CaCl induced aneurysm aortic
CaCl induced aneurysm
2 CaCl induced aneurysm thoracic
2 CaCl induced aneurysm aortic
2 CaCl induced aneurysm
calcium chloride establish model aneurysm thoracic
calcium chloride establish model aneurysm aortic
calcium chloride establish model aneurysm
chloride establish model aneurysm thoracic
chloride establish model aneurysm aortic
chloride establish model aneurysm
calcium chloride establish model aneurysm TAA
chloride establish model aneurysm TAA
calcium chloride establish designed explore formation TAA
chloride establish designed explore formation TAA
CaCl chloride establish model aneurysm thoracic
CaCl chloride establish model aneurysm aortic
CaCl chloride establish model aneurysm
2 NNS chloride establish model aneurysm thoracic
2 NNS chloride establish model aneurysm aortic
2 NNS chloride establish model aneurysm
CaCl chloride establish model aneurysm TAA
2 NNS chloride establish model aneurysm TAA
CaCl chloride establish designed explore formation TAA
2 NNS chloride establish designed explore formation TAA
CaCl establishes model TAA
2 exposure CaCl establishes model TAA
suprofen epidemiology syndrome flank
suprofen epidemiology syndrome pain
CGS agonist manner induced responses cataleptic
21680 CGS agonist manner induced responses cataleptic
reserpine induced induced catalepsy
haloperidol induced catalepsy
capsaicin components memory pain
capsaicin doses injections received address long memory pain
capsaicin doses able magnitude pain
penicillamine therapy caused gravis Myasthenia
penicillamine therapy caused gravis
chloroquine penicillamine therapy caused gravis Myasthenia
chloroquine penicillamine therapy caused gravis
penicillamine therapy had gravis myasthenia
penicillamine therapy had gravis
chloroquine penicillamine therapy had gravis myasthenia
chloroquine penicillamine therapy had gravis
ketamine induced tachycardia
sulpiride induced catalepsy
fluphenazine sulpiride induced catalepsy
SCH 23390 fluphenazine sulpiride induced catalepsy
23390 fluphenazine sulpiride induced catalepsy
sulpiride Combination induce potentiation catalepsy
SCH Combination induce potentiation catalepsy
23390 SCH Combination induce potentiation catalepsy
sulpiride fluphenazine induced catalepsy
fluphenazine induced catalepsy
SCH fluphenazine induced catalepsy
23390 SCH fluphenazine induced catalepsy
delta induced involvement catalepsy
9 delta induced involvement catalepsy
tetrahydrocannabinol delta induced involvement catalepsy
haloperidol induced catalepsy important have role manifestation catalepsy
haloperidol induced catalepsy
THC induced catalepsy
THC induced catalepsy manifestation role have important catalepsy
Lithium seems polyuria
dobutamine glucagon induced ischemia myocardial
dobutamine glucagon induced ischemia
dobutamine testing attenuates evidence ischemia myocardial
dobutamine testing attenuates evidence ischemia
oral contraceptives use thromboembolism venous
oral contraceptives use thromboembolism
contraceptives use thromboembolism venous
contraceptives use thromboembolism
oral contraceptives associated thromboembolism venous
oral contraceptives associated thromboembolism
contraceptives associated thromboembolism venous
contraceptives associated thromboembolism
oral contraceptives associated thromboembolism VTE
contraceptives associated thromboembolism VTE
OC contraceptives associated thromboembolism venous
OC contraceptives associated thromboembolism
OC contraceptives associated thromboembolism VTE
OC use patterns distinguish risk thromboembolism venous
OC use patterns distinguish risk thromboembolism
OC use patterns distinguish risk thromboembolism VTE
OC users VTE
mepivacaine seen addition damage muscle
mepivacaine seen addition damage
lidocaine mepivacaine seen addition damage muscle
lidocaine mepivacaine seen addition damage
amphetamine Protection induced neurotoxicity
amphetamine compounds effect neurotoxic
cyclophosphamide responses characterization cystitis
cyclophosphamide cystitis
aspirin users users higher risk Thrombotic
aspirin nonusers higher risk Thrombotic
Capsaicin injected induce pain
nitric oxide levels gene headache
oxide levels gene headache
nitric oxide induced headache
oxide induced headache
NO oxide induced headache
glyceryl trinitrate induced headache
trinitrate induced headache
GTN trinitrate induced headache
NO donor glyceryl trinitrate induced headache
GTN headache
GTN day developed headache
GTN day developed pronounced headache
NO headache
Levodopa induced dystonia
phenylpropanolamine infarction Cerebral
phenylpropanolamine infarction
PPA dose taking suffered infarction cerebral
PPA dose taking suffered infarction
sodium Contribution valproate syndrome
sodium Contribution valproate syndrome secretion of
sodium Contribution valproate syndrome secretion inappropriate
sodium Contribution valproate syndrome secretion
sodium Contribution valproate syndrome secretion hormone of
sodium Contribution valproate syndrome secretion hormone antidiuretic
sodium Contribution valproate syndrome secretion hormone
valproate syndrome
valproate syndrome secretion of
valproate syndrome secretion inappropriate
valproate syndrome secretion
valproate syndrome secretion hormone of
valproate syndrome secretion hormone antidiuretic
valproate syndrome secretion hormone
sodium valproate administered developed syndrome
sodium valproate administered developed syndrome secretion of
sodium valproate administered developed syndrome secretion inappropriate
sodium valproate administered developed syndrome secretion
sodium valproate administered developed syndrome secretion hormone of
sodium valproate administered developed syndrome secretion hormone antidiuretic
sodium valproate administered developed syndrome secretion hormone
valproate administered developed syndrome
valproate administered developed syndrome secretion of
valproate administered developed syndrome secretion inappropriate
valproate administered developed syndrome secretion
valproate administered developed syndrome secretion hormone of
valproate administered developed syndrome secretion hormone antidiuretic
valproate administered developed syndrome secretion hormone
sodium valproate administered developed syndrome secretion hormone SIADH
valproate administered developed syndrome secretion hormone SIADH
VPA valproate administered developed syndrome
VPA valproate administered developed syndrome secretion of
VPA valproate administered developed syndrome secretion inappropriate
VPA valproate administered developed syndrome secretion
VPA valproate administered developed syndrome secretion hormone of
VPA valproate administered developed syndrome secretion hormone antidiuretic
VPA valproate administered developed syndrome secretion hormone
VPA valproate administered developed syndrome secretion hormone SIADH
VPA administration consider episode SIADH
furosemide pretreated function Renal
furosemide pretreated function
furosemide pretreated function deteriorated significantly
furosemide pretreated function deteriorated
valproate features encephalopathy
sodium application valproate revealed valproate encephalopathy
valproate revealed valproate encephalopathy
valproate encephalopathy
valproate encephalopathy
levodopa exhibit primed induced dyskinesias
levodopa exhibit primed induced evaluate locomotor effects dyskinetic
levodopa induced MPTP alleviating efficacious induced dyskinesias
levodopa reproduce likely efficacious induced dyskinesias
levodopa challenge 171555 86929 efficacious induced dyskinesias
MPTP induced parkinsonism
fluoxetine prenatally increases prevalence syndrome pulmonary
fluoxetine prenatally increases prevalence syndrome hypertension
fluoxetine prenatally increases prevalence syndrome
fluoxetine effect pulmonary
fluoxetine effect hypertension
fluoxetine exposure induces hypertension pulmonary
fluoxetine exposure induces hypertension
sulpiride induced hyperprolactinemia
molindone administration rhabdomyolysis
molindone administration failure acute
molindone administration failure renal
molindone administration failure
molindone administration failure rhabdomyolysis
epinephrine developed stunning myocardial
epinephrine developed stunning
lidocaine sevoflurane effects convulsions
lidocaine influence studied convulsions
lidocaine / was threshold convulsive
lidocaine toxicity effect convulsive
salbutamol triggered tachyarrhythmia atrial
salbutamol triggered tachyarrhythmia
Salbutamol presented trigger SIAT
alcohol impairment growth
alcohol impairment
alcohol recognition resulted growth reduced
alcohol recognition resulted growth cerebellar
alcohol recognition resulted growth
alcohol recognition resulted growth cranial decreased
alcohol recognition resulted growth cranial
alcohol recognition resulted growth cranial growth to
alcohol recognition resulted growth cranial growth body
alcohol recognition resulted growth cranial growth
imipenem cilastatin doses receiving developed seizures
/ cilastatin doses receiving developed seizures
cilastatin doses receiving developed seizures
oral contraceptives associated factors pathogenesis tumors liver
oral contraceptives associated factors pathogenesis tumors
contraceptives associated factors pathogenesis tumors liver
contraceptives associated factors pathogenesis tumors
oral steroids using seen tumors liver
oral steroids using seen tumors
contraceptive steroids using seen tumors liver
contraceptive steroids using seen tumors
Oral Contraceptives Associated Liver
Oral Contraceptives Associated Tumors
Contraceptives Associated Liver
Contraceptives Associated Tumors
digoxin administration assessment dysfunction sexual
digoxin administration assessment dysfunction
lithium therapy secondary block atrioventricular
lithium therapy secondary block
lithium effects reported dysfunction Sinus
lithium effects reported dysfunction node
lithium effects reported dysfunction
lithium therapy secondary developed attacks block atrioventricular
lithium therapy secondary developed attacks block atrioventricular AV
lithium therapy secondary developed attacks block
diazepam greater impaired
diazepam greater impaired recall immediate
diazepam greater impaired recall free
diazepam greater impaired recall
propranolol greater impaired
propranolol greater impaired recall immediate
propranolol greater impaired recall free
propranolol greater impaired recall
6 caused disease veno Hepatic
6 caused disease veno
6 caused disease occlusive
6 caused disease
thioguanine veno Hepatic
thioguanine veno
thioguanine veno disease occlusive
thioguanine veno disease
6 man year developed liver disease veno
6 man year developed liver disease occlusive
6 man year developed liver disease
6 man year developed liver of
6 man year developed liver the
6 man year developed liver
thioguanine year developed liver disease veno
thioguanine year developed liver disease occlusive
thioguanine year developed liver disease
thioguanine year developed liver of
thioguanine year developed liver the
thioguanine year developed liver
6 related occlusive case presented observe features veno hepatic
6 related occlusive case presented observe features veno
6 related occlusive case presented observe features veno disease occlusive
6 related occlusive case presented observe features veno disease
thioguanine case presented observe features veno hepatic
thioguanine case presented observe features veno
thioguanine case presented observe features veno disease occlusive
thioguanine case presented observe features veno disease
Heparin induced thrombocytopenia
Heparin thrombocytopenia
Heparin thrombocytopenia HIT
heparin reaction Heparin thrombocytopenia
heparin reaction Heparin thrombocytopenia HIT
heparin transplantation HIT
heparin antibody antibody HIT
UFH developed related HIT
alpha mg methyldopa effect hypotensive
methyldopa effect hypotensive
hepatitis reactivation hepatitis
hepatitis reactivation B
B antigen Lamivudine prevention reactivation hepatitis
B antigen Lamivudine prevention reactivation B
surface antigen Lamivudine prevention reactivation hepatitis
surface antigen Lamivudine prevention reactivation B
antigen Lamivudine prevention reactivation hepatitis
antigen Lamivudine prevention reactivation B
HBSAG antigen Lamivudine prevention reactivation hepatitis
HBSAG antigen Lamivudine prevention reactivation B
butylated hydroxyanisole induced rats carcinogenesis forestomach
butylated hydroxyanisole induced rats carcinogenesis
hydroxyanisole induced rats carcinogenesis forestomach
hydroxyanisole induced rats carcinogenesis
butylated hydroxyanisole tumorigenesis forestomach
butylated hydroxyanisole tumorigenesis
hydroxyanisole tumorigenesis forestomach
hydroxyanisole tumorigenesis
BHA hydroxyanisole tumorigenesis forestomach
BHA hydroxyanisole tumorigenesis
BHA given groups increased incidence tumors forestomach
BHA given groups increased incidence tumors
BHA carcinogen forestomach
BHA carcinogen forestomach carcinogenesis
cocaine marker oscillation pupillary
cocaine marker oscillation
cocaine marker oscillation measure paranoia
Cocaine induced remains paranoia
Cocaine induced remains paranoia CIP
Cocaine induced remains drug model paranoia
Propylthiouracil induced staining pericarditis
propylthiouracil case describe induced vasculitis manifesting pericarditis
propylthiouracil developed syndrome pericarditis fever
propylthiouracil developed syndrome pericarditis
propylthiouracil developed syndrome pericarditis glomerulonephritis
propylthio associated vasculitis pANCA uracil revealed reports pericarditis
uracil revealed reports pericarditis
propylthio attributable induced manifestation Pericarditis
uracil therapy manifestation Pericarditis
Adriamycin induced plays role model failure heart
Adriamycin induced plays role model failure
adriamycin induced failure heart
adriamycin induced failure
adriamycin induced failure heart
adriamycin induced failure
adriamycin induced failure progression involved develop failure heart
adriamycin induced failure progression involved develop failure
adriamycin induced rats model heart
adriamycin induced rats model failure
adriamycin induced rats plays role pathogenesis failure heart
adriamycin induced rats plays role pathogenesis failure
adriamycin caused failure heart
adriamycin caused failure
ADR induced alterations cardiac
ADR induced alterations morphological
ADR induced alterations
Cocaine pain chest
Cocaine pain
cocaine produce pain chest
cocaine produce pain
cocaine tendency ought mind faced victim pain chest
cocaine tendency ought mind faced victim pain
cocaine use related pain chest
cocaine use related pain
aspirin ingestion salicylates association lack disappearing syndrome Reye
aspirin ingestion salicylates association lack disappearing syndrome
nitroglycerin caused impairment hypotension
nitroglycerin caused impairment memory
nitroglycerin caused impairment
nitroglycerin onset administered tested preserve hypotension
NTG nitroglycerin onset administered tested preserve hypotension
NTG NIMO saline injected those showed Mice subjected hypotensive
NTG delayed injected those showed Mice subjected hypotensive
NTG injection produced impairment memory mice had hypotension
NTG caused improve absence hypotension
Ammonia higher patients complained drowsiness
NH 3 Ammonia higher patients complained drowsiness
3 Ammonia higher patients complained drowsiness
VPA levels similar higher patients complained drowsiness
lithium therapy years hypothyroidism
lithium therapy onset years hypothyroidism
lithium therapy factor hypothyroidism
epinephrine bolus provoked crisis hypertensive
Doxorubicin cardiomyopathy
DOX cardiomyopathy
DOX cardiomyopathy development elucidate studied B induced cardiomyopathy
DOX induction investigating mice B studied elucidate development cardiomyopathy
DOX induction investigating mice B induced cardiomyopathy
DOX cardiomyopathy
DOX treatment antagonists utilizing cardiomyopathy
Diazepam served amnesia
scopolamine amnesia
diazepam scopolamine induced amnesia
scopolamine induced amnesia
indomethacin therapy pulmonale patient cirrhosis ascites
indomethacin therapy pulmonale reported hyperkalemia
indomethacin therapy pulmonale patient cirrhosis cor
indomethacin therapy pulmonale
indomethacin therapy pulmonale patient cirrhosis
indomethacin dose exposure caused recurrence oliguria
pilocarpine injection rats Similar causes epilepticus status
pilocarpine injection rats Similar causes epilepticus
pilocarpine injection rats Similar causes epilepticus SE
pilocarpine injection rats Similar causes epilepticus development seizures
pilocarpine treated mice experience SE
levodopa hypotension disorders gastrointestinal
levodopa hypotension disorders
levodopa hypotension orthostatic
levodopa hypotension
levodopa psychosis parasomnias
Pilocarpine age impairment
Pilocarpine age impairment discrimination in
Pilocarpine age impairment discrimination auditory
Pilocarpine age impairment discrimination location
Pilocarpine age impairment discrimination
Pilocarpine induced epilepticus status
Pilocarpine induced epilepticus
Pilocarpine induced resulted epilepticus status
Pilocarpine induced resulted epilepticus
muscimol drugs jerks myoclonic
muscimol drugs jerks
muscimol produced jerks myoclonic
muscimol produced jerks
muscimol myoclonus
muscimol myoclonus management beneficial found seems myoclonus
nitroglycerin Provocation hypotension
phenytoin administration developed bradycardia
haloperidol potentiation induced catalepsy
apomorphine prevention catalepsy induced potentiation induced hyperactivity
pilocarpine acid seizures
kainic pilocarpine acid seizures
acid seizures
pilocarpine acid seizures epilepticus status
pilocarpine acid seizures epilepticus
kainic pilocarpine acid seizures epilepticus status
kainic pilocarpine acid seizures epilepticus
acid seizures epilepticus status
acid seizures epilepticus
pilocarpine activity evaluated beta metabolites seizures
kainic acid beta metabolites seizures
acid beta metabolites seizures
pilocarpine protecting effective Steroids induced seizures
pilocarpine protecting effective Steroids induced seizures epilepticus status
pilocarpine protecting effective Steroids induced seizures epilepticus
pilocarpine seizures
pilocarpine seizures protecting potent had values TD divided protection seizure
kainic acid induced seizures
acid induced seizures
kainic acid induced seizures onset produced protect seizures
acid induced seizures onset produced protect seizures
kainic acid administered However obtained seizures
acid administered However obtained seizures
kainic acid administered However obtained seizures epilepticus status
kainic acid administered However obtained seizures epilepticus
acid administered However obtained seizures epilepticus status
acid administered However obtained seizures epilepticus
pilocarpine acid seizures
kainic pilocarpine acid seizures
acid seizures
pilocarpine acid seizures epilepticus status
pilocarpine acid seizures epilepticus
pilocarpine acid protecting effective utility treatment forms epilepticus status
pilocarpine acid protecting effective utility treatment forms epilepticus
kainic pilocarpine acid seizures epilepticus status
kainic pilocarpine acid seizures epilepticus
acid seizures epilepticus status
acid seizures epilepticus
kainic pilocarpine acid protecting effective utility treatment forms epilepticus status
kainic pilocarpine acid protecting effective utility treatment forms epilepticus
acid protecting effective utility treatment forms epilepticus status
acid protecting effective utility treatment forms epilepticus
morphine analgesia hypothermia
morphine analgesia catalepsy
morphine bradycardia
morphine induced bradycardia
morphine bradycardia induced hypotension
morphine induced hypotension
methylprednisolone Hypotension
methylprednisolone Hypotension bradycardia
methylprednisolone Hypotension asystole
methylprednisolone year administration hypotension
methylprednisolone year administration hypotension bradycardia
methylprednisolone year administration hypotension asystole
Mipafox dosages produced degree damage cord
Mipafox dosages produced degree damage
amiodarone Hepatotoxicity
amiodarone treatment due hepatitis presented given review hepatotoxicity
amiodarone hepatotoxicity
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis cirrhosis
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis liver of
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis liver the
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis liver
amiodarone treatment due injury steatosis
amiodarone treatment due injury hepatic
amiodarone treatment due injury
isoflurane metabolism flow induced hypotension
isoflurane hypotension
isoflurane dose increasing induced MAP hypotension
Spironolactone induced insufficiency renal
Spironolactone induced insufficiency
Spironolactone induced insufficiency hyperkalemia
spironolactone use evaluating patients reported risk hyperkalemia insufficiency renal
spironolactone use evaluating patients reported risk hyperkalemia insufficiency
spironolactone use evaluating patients reported risk hyperkalemia
spironolactone treated patients determine prevalence associations insufficiency hyperkalemia renal
spironolactone treated patients determine prevalence associations insufficiency
spironolactone treated patients determine prevalence associations insufficiency hyperkalemia
spironolactone failure renal
spironolactone failure
spironolactone hyperkalemia
Spironolactone CONCLUSIONS common hyperkalemia insufficiency renal
Spironolactone CONCLUSIONS common hyperkalemia insufficiency
Spironolactone CONCLUSIONS common hyperkalemia
MDMA users show process impairments coupled processes social impaired
MDMA users show process impairments coupled processes social
MDMA users show process impairments coupled processes social and
MDMA users show process impairments coupled processes social emotional
MDMA users show process impairments coupled processes judgement
MDMA users show process impairments coupled processes
melatonin effects narcosis
Melatonin affects clear influence drug narcosis
Melatonin pre affected narcosis
melatonin dose caused produced reduction duration narcosis
ketamine narcosis
diazepam ketamine narcosis
Melatonin 0 5 kg influenced duration latency narcosis
melatonin narcosis
diclofenac induced recorded abnormalities
diclofenac induced recorded abnormalities function of
diclofenac induced recorded abnormalities function liver
diclofenac induced recorded abnormalities function
diclofenac induced hepatitis
MDMA users observed evidence impairment memory
MDMA users observed evidence impairment
MDMA use associated functioning impaired
MDMA use associated functioning memory
MDMA use associated functioning
MDMA use associated lead impairments memory
MDMA use associated lead impairments
MDMA use use lead associated functioning impaired
MDMA use use lead associated functioning memory
MDMA use use lead associated functioning
MDMA use use lead impairments memory
MDMA use use lead impairments
haloperidol Effects catalepsy parkinsonian
haloperidol Effects catalepsy
haloperidol pallidus infusions RESULTS catalepsy parkinsonian
haloperidol pallidus infusions RESULTS catalepsy
testosterone implanted rats developed incidence cancer prostate
testosterone implanted rats developed incidence cancer
testosterone developed cancer prostate
testosterone developed cancer
testosterone prostatitis
citalopram adolescent twitching Palpebral
citalopram adolescent twitching
citalopram boy treatment report depression exhibited twitching palpebral
citalopram boy treatment report depression exhibited twitching
Quinidine hepatitis
quinidine had hepatotoxicity
scopolamine produced Amnesia
cycloheximide scopolamine produced Amnesia
scopolamine reversed cycloheximide induced amnesia
scopolamine pre failed reverse amnesia
scopolamine cycloheximide induced amnesia
scopolamine cycloheximide reversed scopolamine pre failed reverse amnesia
cycloheximide induced amnesia
cycloheximide reversed scopolamine pre failed reverse amnesia
cycloheximide amnesia reverse failed pre scopolamine reversed cycloheximide induced amnesia
cycloheximide amnesia
penicillamine therapy complications recorded rashes polymyositis
penicillamine therapy complications recorded rashes erythematosus systemic
penicillamine therapy complications recorded rashes erythematosus lupus
penicillamine therapy complications recorded rashes erythematosus
penicillamine therapy complications recorded rashes Skin
penicillamine therapy complications recorded rashes
penicillamine therapy complications recorded rashes proteinuria
penicillamine therapy complications recorded rashes gravis myasthenia
penicillamine therapy complications recorded rashes gravis
morphine group incidence tachyarrhythmias beats ventricular
morphine group incidence tachyarrhythmias beats ectopic
morphine group incidence tachyarrhythmias beats
choline diet fed rats developed nodules carcinomas hepatocellular
choline diet fed rats developed nodules carcinomas
choline diet fed developed nodule carcinoma hepatocellular
choline diet fed developed nodule carcinoma
choline fed rats % carcinomas incidence hepatocellular
choline fed rats % carcinomas
choline containing diet fed rats fed rats % carcinomas incidence hepatocellular
choline containing diet fed rats fed rats % carcinomas
ketamine catatonia
ketamine idolamines catatonia
ketamine increased duration catatonia
dopamine pretreatment increased duration catatonia
ketamine catatonia
dopamine appeared act induction catatonia
vigabatrin carbamazepine administration epilepsy absence
vigabatrin carbamazepine administration epilepsy
carbamazepine administration epilepsy absence
carbamazepine administration epilepsy
sodium nitroprusside anesthesia pressure maintenance system hypotension
nitroprusside anesthesia pressure maintenance system hypotension
SNP anesthesia pressure maintenance system hypotension
halothane anesthesia pressure maintenance system hypotension
SNP halothane effects hypotensive
halothane effects hypotensive
Amphetamine similar locomotor
Amphetamine similar hyperactivity
heparin injection duration effect study bruising pain
heparin injection duration effect study bruising
heparin injection administration bruising pain
heparin injection administration bruising
heparin injection pain
heparin injection pain bruising prevent methods studied documented effect duration occurrence bruising pain
heparin injection pain bruising
heparin injection pain bruising prevent methods studied documented effect duration occurrence bruising
heparin bruising
heparin administration had effect bruising pain
heparin administration had effect bruising
iopamidol patients administration different nephropathy
iodixanol high iopamidol patients administration different nephropathy
Cyclophosphamide cancer bladder
Cyclophosphamide cancer
cyclophosphamide associated cancer bladder
cyclophosphamide associated cancer
Cyclophosphamide associated disease tumor bladder
Cyclophosphamide associated disease tumor
Amisulpride tic
Amisulpride symptoms like
Amisulpride symptoms
amisulpride dose reduced resolved symptoms tic
amisulpride dose reduced resolved symptoms like
amisulpride dose reduced resolved symptoms
amisulpride quetiapine occur suggests tic
amisulpride quetiapine occur symptoms like
amisulpride quetiapine occur symptoms
5 infusion occurred reaction consisting edema angioneurotic
5 infusion occurred reaction consisting edema
fluorouracil occurred reaction consisting edema angioneurotic
fluorouracil occurred reaction consisting edema
ouabain rat induced designed models arrhythmia
aconitine using designed models arrhythmia
ouabain aconitine induced rat arrhythmic
aconitine induced rat arrhythmic
Prazosin induced incontinence stress
Prazosin induced incontinence
prazosin due incontinence stress
prazosin due incontinence
prazosin taking change incontinence Patients present stress
prazosin taking change incontinence
warfarin model hemorrhage associated hemorrhage intracerebral
warfarin model hemorrhage associated hemorrhage
Warfarin associated type hemorrhage intracerebral
Warfarin associated type hemorrhage
Warfarin associated type hemorrhage W ICH
Desipramine induced delirium
Desipramine treated patient developed delirium
Rizatriptan superior ergotamine proportions patients nausea
rizatriptan caffeine events dizziness 6 nausea
rizatriptan caffeine events dizziness
rifampin therapy associated glomerulonephritis
rifampin treated patient glomerulonephritis
rifampin regimen 10 underwent discovered developed signs failure renal
rifampin regimen 10 underwent discovered developed signs failure
rifampin treated patient documents occurrence glomerulonephritis
rifampin treated patient documents occurrence glomerulonephritis crescents glomerulonephritis
haloperidol induced catalepsy
haloperidol duration induced catalepsy
phenylephrine indicate instituted hypertension
suxamethonium dose spasm masseter
suxamethonium dose spasm
piroxicam dose treated rats found toxicity retardation intrauterine
piroxicam dose treated rats found toxicity retardation growth
piroxicam dose treated rats found toxicity retardation
piroxicam dose treated rats found toxicity increase
piroxicam dose treated rats found toxicity increase variations of
piroxicam dose treated rats found toxicity increase variations external
piroxicam dose treated rats found toxicity increase variations external and
piroxicam dose treated rats found toxicity increase variations external skeletal
piroxicam dose treated rats found toxicity increase variations
gentamicin therapy sodium combination receiving necrosis acute
gentamicin therapy sodium combination receiving necrosis tubular
gentamicin therapy sodium combination receiving necrosis
sulfate therapy sodium combination receiving necrosis acute
sulfate therapy sodium combination receiving necrosis tubular
sulfate therapy sodium combination receiving necrosis
cephalothin sodium combination receiving necrosis acute
cephalothin sodium combination receiving necrosis tubular
cephalothin sodium combination receiving necrosis
sodium combination receiving necrosis acute
sodium combination receiving necrosis tubular
sodium combination receiving necrosis
morphine cord changes 801 MK induced paraparesis spastic
morphine cord changes 801 MK induced paraparesis
morphine reduced paraparesis spastic
morphine reduced paraparesis
morphine induces paraparesis spastic
morphine induces paraparesis
propofol pain
propofol pain
propofol pain
amantadine Readministration increased occurred suppression
amantadine Readministration increased occurred suppression motility of
amantadine Readministration increased occurred suppression motility
amantadine mice caused depression behavioral
amantadine mice caused depression
epinephrine overflow stimulus induced mediated rats hypertensive
morphine produced rigidity muscular
morphine produced rigidity
morphine produced rigidity muscular
morphine produced rigidity
morphine dose given controls Saline showed rigidity
morphine days treated showed differences half animals showed rigidity
morphine dose showed rigidity
morphine days treated showed differences half animals showed akinetic
morphine dose showed akinetic
haloperidol mg used block estimate rigidity
Haloperidol enhanced rigidity
morphine action due assumed rigidity
Amphotericin B induced seizures
B induced seizures
amphotericin infusion patent report case episodes activity seizure
B infusion patent report case episodes activity seizure
amphotericin B infusion experienced stopped seizures
B infusion experienced stopped seizures
amphotercin administration occurred persisted seizures
B administration occurred persisted seizures
amphotericin B cause seizures
B cause seizures
Amphotericin B seems cause seizures
B seems cause seizures
amphotericin B associated seizures
B associated seizures
scopolamine amnesia
scopolamine ritanserin effect amnesia
scopolamine amnesia
scopolamine induced impairment memory
scopolamine induced impairment
scopolamine induced attention impairment
scopolamine induced attention of
scopolamine induced attention
scopolamine induced attention and
scopolamine induced attention memory
amoxicillin allergic
amoxicillin allergic reactions
amoxicillin responses had allergic
amoxicillin responses allergic
AX amoxicillin responses had allergic
AX amoxicillin responses allergic
AX allergy
AX tests performed establish diagnosis reaction allergic
AX tests performed establish diagnosis reaction
AX establish diagnosis reaction allergic
AX establish diagnosis reaction
AX test negative performed establish diagnosis reaction allergic
AX test negative performed establish diagnosis reaction
AX group patients allergic
alkylating agents treated Patients have risk development leukemia acute
alkylating agents treated Patients have risk development leukemia nonlymphocytic
alkylating agents treated Patients have risk development leukemia
agents treated Patients have risk development leukemia acute
agents treated Patients have risk development leukemia nonlymphocytic
agents treated Patients have risk development leukemia
alkylating agents associated have risk development leukemia acute
alkylating agents associated have risk development leukemia nonlymphocytic
alkylating agents associated have risk development leukemia
agents associated have risk development leukemia acute
agents associated have risk development leukemia nonlymphocytic
agents associated have risk development leukemia
alkylating agents treated Patients have associated development non
alkylating agents treated Patients have lymphoma Hodgkin
alkylating agents treated Patients have lymphoma Hodgkin '
alkylating agents treated Patients have lymphoma s
alkylating agents treated Patients have lymphoma
agents treated Patients have associated development non
agents treated Patients have lymphoma Hodgkin
agents treated Patients have lymphoma Hodgkin '
agents treated Patients have lymphoma s
agents treated Patients have lymphoma
alkylating agents associated development non
alkylating agents associated have lymphoma Hodgkin
alkylating agents associated have lymphoma Hodgkin '
alkylating agents associated have lymphoma s
alkylating agents associated have lymphoma
agents associated development non
agents associated have lymphoma Hodgkin
agents associated have lymphoma Hodgkin '
agents associated have lymphoma s
agents associated have lymphoma
azathioprine agents associated development non
azathioprine agents associated have lymphoma Hodgkin
azathioprine agents associated have lymphoma Hodgkin '
azathioprine agents associated have lymphoma s
azathioprine agents associated have lymphoma
Ethambutol associated neuropathy optic
Ethambutol associated neuropathy
Ethambutol used treatment prevalent associated loss visual
Ethambutol used treatment prevalent associated loss
ethambutol patients PICTURE associated neuropathy optic
ethambutol patients PICTURE associated neuropathy
Ethambutol usage associated loss visual
Ethambutol usage associated loss
Ifosfamide encephalopathy
ifosfamide infusion developed myoclonus
ifosfamide findings infusion asterixis presence suggest associated myoclonus
IFX use associated myoclonus
MPTP mediator receptor Cardona neurodegeneration
MPTP METH caused damage CNS
MPTP METH caused damage
METH caused damage CNS
METH caused damage
METH role plays hypothesized selective damage CNS
METH role plays hypothesized selective damage
lidocaine incidence symptoms Transient
lidocaine incidence symptoms neurologic
lidocaine incidence symptoms
prilocaine incidence symptoms Transient
prilocaine incidence symptoms neurologic
prilocaine incidence symptoms
lidocaine anesthesia follow symptoms transient
lidocaine anesthesia follow symptoms neurologic
lidocaine anesthesia follow symptoms
lidocaine anesthesia follow symptoms TNSs
lidocaine prilocaine compares duration risk TNSs
prilocaine compares duration risk TNSs
lidocaine TNSs
lidocaine TNSs receiving patients Nine RESULTS had TNSs
prilocaine had receiving patients 1 Nine patients receiving TNSs
prilocaine had receiving patients 1 Nine RESULTS had TNSs
lidocaine preferable has duration incidence TNSs
Prilocaine preferable has duration incidence TNSs
propofol Assessment onset amnesia
amphetamine reflects rotation contralateral
amphetamine reflects rotation
amphetamine examined clarify nature rotation contralateral
amphetamine examined clarify nature rotation
amphetamine induced behavior rotational
amphetamine induced behavior
amphetamine administered days lesioning involvement cells rotation contralateral
amphetamine administered days lesioning involvement cells rotation
amphetamine dose volume recovery duration regardless tended rotation
amphetamine duration regardless tended rotation
amphetamine injections circled tended rotation
amphetamine has suggest pool contributing rotation contralateral
amphetamine has suggest pool contributing rotation
Clarithromycin induced tachycardia ventricular
Clarithromycin induced tachycardia
erythromycin profile established gastroenteritis
Phenobarbital dyskinesia
phenobarbital therapy starting soon dyskinesia
phenobarbital challenge recurred dyskinesia
salbutamol effects Tremor
salbutamol effects tremor
salbutamol doses administration assessed tremor
Salbutamol increased severity tremor
pilocarpine latency indicated increased seizures
pilocarpine latency indicated increased seizures
carbamazepine presenting reaction erythroderma
carbamazepine presenting reaction leukemoid
carbamazepine presenting reaction
carbamazepine Hypersensitivity
carbamazepine presenting reaction failure renal
carbamazepine presenting reaction failure
carbamazepine presented erythroderma
carbamazepine presented erythroderma reaction leukemoid
carbamazepine presented erythroderma reaction
carbamazepine hypersensitivity
carbamazepine presented erythroderma failure renal
carbamazepine presented erythroderma failure
carbamazepine presented erythroderma hyponatremia
amphetamine ie challenge models hyperactivity
MK ie challenge models hyperactivity
801 ie challenge models hyperactivity
MK antagonist hyperactivity
801 hyperactivity
MK antagonist hyperactivity 801 hyperactivity
801 hyperactivity
amphetamine induced hyperactivity
Valproate induced encephalopathy
Valproate syndrome encephalopathy
valproate induced encephalopathy
cimetidine infusion arrest Sinus
cimetidine infusion arrest
cimetidine infusions administration associated development bradyarrhythmias
cimetidine mg continuous hour receiving developed episodes arrest sinus
cimetidine mg continuous hour receiving developed episodes arrest
cimetidine case arrest sinus
cimetidine case arrest
methyl dopa occurring depressions
dopa occurring depressions
haloperidol induced catalepsy
haloperidol induced reverse catalepsy
gemfibrozil cyclosporin treated patients lovastatin reported Myopathy
lovastatin reported associated myoglobinuria
lovastatin reported associated failure renal
lovastatin reported associated failure
niacin cyclosporin treated patients lovastatin reported Myopathy
cyclosporin treated patients lovastatin reported Myopathy
adriamycin activity Detection induced cardiomyopathy
adriamycin induced cardiomyopathy
adriamycin model Using tested hypothesis appear exacerbated cardiomyopathy
adriamycin cardiomyopathy exacerbated appear hypothesis tested Using model adriamycin induced cardiomyopathy
adriamycin cardiomyopathy
adriamycin detection method indicates appearance presence impairment myocardial
adriamycin detection method indicates appearance presence impairment
adriamycin induced cardiomyopathy
sodium nitroprusside than greater induced hypotension
nitroprusside than greater induced hypotension
SNP group that lower hypotension
SNP group Hg / Hg mm was SPV hypotension
SNP HEM groups Hg 20 hypotension
bendrofluazide treatment impotence
bendrofluazide treatment association show occurred impotence
propranolol taking patients occurred show association treatment impotence
propranolol taking patients occurred impotence
propranolol taking phenomenon Raynaud
propranolol taking phenomenon Raynaud '
propranolol taking phenomenon s
propranolol taking phenomenon
bendrofluazide treatment associated men gout
bendrofluazide treatment associated men gout tolerance impaired
bendrofluazide treatment associated men gout tolerance glucose
bendrofluazide treatment associated men gout tolerance
propranolol taking phenomenon dyspnoea
scopolamine impaired memory
scopolamine impaired
scopolamine impaired memory improve showed associative s relieved deficit
scopolamine impaired memory improve showed associative s relieved deficit memory of
scopolamine impaired memory improve showed associative s relieved deficit memory associative
scopolamine impaired memory improve showed associative s relieved deficit memory
lidocaine buffered Reduction pain
lidocaine injection associated pain
lidocaine pH adjust solution addition reduce pain
lidocaine receiving quantify severity pain
lidocaine area receiving quantify severity pain
lidocaine score pain
lidocaine score lower score pain
lidocaine adjustment accomplished reduction pain
cyclosporine levels reduction led relief pain
tacrolimus cyclosporine levels reduction led relief pain
cyclosporine effect Syndrome Pain
tacrolimus cyclosporine effect Syndrome Pain
warfarin discontinued available patients lesions LV
warfarin discontinued available patients lesions Cutaneous
warfarin discontinued available patients lesions
tranexamic thrombin acid injection fibrinolysis coagulation intravascular
tranexamic thrombin acid injection fibrinolysis coagulation
acid injection fibrinolysis coagulation intravascular
acid injection fibrinolysis coagulation
AMCA acid injection fibrinolysis coagulation intravascular
AMCA acid injection fibrinolysis coagulation
Sulfonamides associated anencephaly
Sulfonamides associated anencephaly adjusted AOR syndrome CI atresia AOR 0 % = transverse
Sulfonamides associated anencephaly adjusted AOR syndrome CI atresia AOR 0 % = limb
Sulfonamides associated anencephaly adjusted AOR syndrome CI atresia AOR 0 % = deficiency
Sulfonamides associated anencephaly adjusted AOR syndrome hernia diaphragmatic
Sulfonamides associated anencephaly adjusted AOR syndrome hernia
Sulfonamides associated anencephaly adjusted AOR syndrome CI coarctation
Sulfonamides associated anencephaly adjusted AOR syndrome CI coarctation aorta of
Sulfonamides associated anencephaly adjusted AOR syndrome CI coarctation aorta the
Sulfonamides associated anencephaly adjusted AOR syndrome CI coarctation aorta
Sulfonamides associated anencephaly adjusted AOR syndrome CI atresia choanal
Sulfonamides associated anencephaly adjusted AOR syndrome CI atresia
Sulfonamides associated anencephaly adjusted AOR syndrome hypoplastic
Sulfonamides associated anencephaly adjusted AOR syndrome left
Sulfonamides associated anencephaly adjusted AOR syndrome heart
Sulfonamides associated anencephaly adjusted AOR syndrome
Nitrofurantoins associated anophthalmia microphthalmos
Nitrofurantoins associated anophthalmia microphthalmos lip cleft
Nitrofurantoins associated anophthalmia microphthalmos lip
Nitrofurantoins associated anophthalmia
Nitrofurantoins associated anophthalmia microphthalmos CI syndrome hypoplastic
Nitrofurantoins associated anophthalmia microphthalmos CI syndrome left
Nitrofurantoins associated anophthalmia microphthalmos CI syndrome heart
Nitrofurantoins associated anophthalmia microphthalmos CI syndrome
Nitrofurantoins associated anophthalmia microphthalmos CI syndrome AOR 2 % defects atrial
Nitrofurantoins associated anophthalmia microphthalmos CI syndrome AOR 2 % defects septal
Nitrofurantoins associated anophthalmia microphthalmos CI syndrome AOR 2 % defects
Nitrofurantoins associated anophthalmia microphthalmos lip = cleft
Nitrofurantoins associated anophthalmia microphthalmos lip = palate
nitrofurantoins Sulfonamides associated defects birth
nitrofurantoins Sulfonamides associated defects
Sulfonamides associated defects birth
Sulfonamides associated defects
estrogens treatment implicated development cancer endometrial
estrogens treatment implicated development cancer
estrogens women have risk carcinoma endometrial
estrogens women have risk carcinoma
haloperidol induced Catalepsy
thioperamide methylhistamine R cause catalepsy
THP thioperamide methylhistamine R cause catalepsy
THP Administration increase times catalepsy
haloperidol mg THP Administration increase times catalepsy
amphetamine induced hyperactivity
THP exhibited antipsychotic like induced catalepsy
amphetamine reducing like induced hyperactivity
haloperidol potentiating like induced catalepsy
tranexamic Acid associated seizures
Acid associated seizures
TXA usage seizures
TXA doses received patients seizures
TXA high surgery use associated seizures
paracetamol overdose due ALF
paracetamol overdose due defect ALF
LiCl pre administered Tacrine induces seizures
LiCl pre administered Tacrine induces seizures damage hippocampal
LiCl pre administered Tacrine induces seizures damage
Tacrine induces seizures damage hippocampal
Tacrine induces seizures damage
Tacrine induces seizures
tacrine administration induced damage
tacrine administration induced damage cells of
tacrine administration induced damage cells neuronal
tacrine administration induced damage cells
tacrine solution treated tacrine administration induced damage
tacrine solution treated tacrine administration induced damage cells of
tacrine solution treated tacrine administration induced damage cells neuronal
tacrine solution treated tacrine administration induced damage cells
Nicotine induced correlates nystagmus
nicotine pathomechanism nystagmus
nicotine pathomechanism nystagmus NIN
hexafluorodiethyl ether induced Seizures
ether induced Seizures
hexafluorodiethyl ether induced Seizures found seizures
ether induced Seizures found seizures
HFDE Seizures
HFDE Seizures found seizures
HFDE protective induced seizures
amphetamine antagonism localization induced hyperactivity
ritonavir treatment increases formation atherosclerotic
ritonavir treatment increases formation lesion
pilocarpine model status
pilocarpine model epilepticus
pilocarpine model evaluated effect PDTC epilepticus status
pilocarpine model evaluated effect PDTC epilepticus
Amiodarone agent effects pneumonitis
isoproterenol tea Effect induced infarction myocardial
isoproterenol tea Effect induced infarction
isoproterenol ATPases infarction myocardial
isoproterenol ATPases infarction
ISO isoproterenol ATPases infarction myocardial
ISO isoproterenol ATPases infarction
ISO induced infarction myocardial
ISO induced infarction
furosemide Tetany
furosemide Tetany rhabdomyolysis
ribavirin strategies anemia hemolytic
ribavirin strategies anemia
ribavirin anemia hemolytic
ribavirin anemia
ribavirin anemia RIHA
ribavirin dosage reduction standard care management RIHA
ribavirin dose incidence RIHA
cyclophosphamide high regimen failure congestive
cyclophosphamide high regimen failure heart
cyclophosphamide high regimen failure
cyclophosphamide high regimen failure CHF
cyclophosphamide CHF
cyclophosphamide monitoring EKG predict development CHF
Octreotide induced hypertension hypoxemia pulmonary
Octreotide induced hypertension
octreotide developed hypertension Pulmonary
octreotide developed hypertension
DEN given reduced number size foci preneoplastic
DEN given reduced number size foci
androgen administration sleep Induction obstructive
androgen administration sleep
androgen administration sleep syndrome apnea
androgen administration sleep syndrome
androgens exogenous developed changes syndrome
androgens exogenous developed changes syndrome apnea of
androgens exogenous developed changes syndrome apnea obstructive
androgens exogenous developed changes syndrome apnea sleep
androgens exogenous developed changes syndrome apnea
androgen rechallenge produced symptoms apnea obstructive
androgen rechallenge produced symptoms apnea sleep
androgen rechallenge produced symptoms apnea
androgen therapy effect considered Development syndrome obstructive
androgen therapy effect considered Development syndrome sleep
androgen therapy effect considered Development syndrome apnea
androgen therapy effect considered Development syndrome
labetalol comparison hypotension
nitroprusside labetalol comparison hypotension
labetalol hypotension hypotension
labetalol hypotension
nitroprusside hypotension
nitroprusside hypotension hypotension
nitroprusside discontinuation observed associated increase
nitroprusside discontinuation observed associated increase rate in
nitroprusside discontinuation observed associated increase rate heart
nitroprusside discontinuation observed associated increase rate
nitroprusside discontinuation observed associated increase rate and
nitroprusside discontinuation observed associated increase rate output cardiac
nitroprusside discontinuation observed associated increase rate output
cyproterone acetate prescribed women thromboembolism venous
cyproterone acetate prescribed women thromboembolism
acetate prescribed women thromboembolism venous
acetate prescribed women thromboembolism
ethinyl estradiol prescribed women thromboembolism venous
ethinyl estradiol prescribed women thromboembolism
estradiol prescribed women thromboembolism venous
estradiol prescribed women thromboembolism
CPA EE associated thromboembolism venous
CPA EE associated thromboembolism
CPA EE associated thromboembolism VTE
EE associated thromboembolism venous
EE associated thromboembolism
EE associated thromboembolism VTE
CPA EE associated VTE
EE associated VTE
CPA EE use associated VTE
EE use associated VTE
5 patients supervision discontinued observed pain chest
5 patients supervision discontinued observed pain
FU treatment supervision discontinued observed pain chest
FU treatment supervision discontinued observed pain
levodopa patients selected dyskinesias
fentanyl infusion result urine retention
fentanyl infusion result urine of
fentanyl infusion result urine
fentanyl administration effects include rigidity hypotension
fentanyl administration effects include rigidity depression respiratory
fentanyl administration effects include rigidity depression
fentanyl administration effects include rigidity bradycardia
fentanyl infusion result mimicking leading retention urinary
fentanyl infusion result mimicking leading retention bladder
fentanyl infusion result mimicking leading retention
clomipramine effects sexual
clomipramine effects side
clomipramine effects
ifosfamide toxicity renal
ifosfamide toxicity
epsilon induce myopathy
aminocaproic acid epsilon induce myopathy
acid epsilon induce myopathy
EACA epsilon induce myopathy
Valproate induced chorea encephalopathy
Valproate induced chorea
valproate therapy initiation have hyperglycinemia presentation encephalopathy
valproate therapy initiation have hyperglycinemia presentation encephalopathy chorea
carboplatin chemotherapy Acute
carboplatin chemotherapy Acute failure renal
carboplatin chemotherapy Acute failure
Carboplatin reported cause failure acute
Carboplatin reported cause failure renal
Carboplatin reported cause failure
amphotericin B prevention drug it hypokalemia
B prevention drug it hypokalemia
AmB treatment patients prevent hypokalemia
AmB treatment patients reducing prevent hypokalemia
methyldopa induced Patterns injury hepatic
methyldopa induced Patterns injury
methyldopa episode recommenced hepatitis
methyldopa dysfunction relationship proved recurrence hepatitis
sulfasalazine associated Hepatotoxicity
sulfasalazine hepatotoxicity
sulfasalazine hepatotoxicity
sulfasalazine hepatotoxicity
sulfasalazine associated hepatotoxicity
noradrenaline infusion caused hypertension
noradrenaline infusion hypertension
noradrenaline circulating levels produced hypertension
caffeine administration onset convulsions
caffeine administration interval increased acetaminophen pretreatment pretreatment acetaminophen reduced incidence seizures
caffeine presence produced incidence reduced acetaminophen pretreatment pretreatment acetaminophen increased interval administration onset convulsions
caffeine presence produced incidence seizures
caffeine 5 seizures
pentylenetetrezol dose alter modify seizures
caffeine absence modify seizures
PTZ suppressed increased amplitude startle
PTZ suppressed increased suppressed startle
PTZ suppressed startle
yohimbine increased amplitude startle
yohimbine increased suppressed startle
yohimbine increased suppressed startle
mCPP suppressed increased amplitude startle
mCPP suppressed startle
mCPP suppressed increased suppressed startle
sodium powders ate reported case two nephrolithiasis
bicarbonate powders ate reported case two nephrolithiasis
calcium carbon amounts consumed patients reported case hypercalcaemia
carbon amounts consumed patients reported case hypercalcaemia
ate reported case hypercalcaemia
calcium carbon amounts consumed patients reported case two nephrolithiasis
carbon amounts consumed patients reported case two nephrolithiasis
ate reported case two nephrolithiasis
sodium powders ate reported case hypercalcaemia
bicarbonate powders ate reported case hypercalcaemia
terbutaline relationship induced hypokalemia
terbutaline concentrations spite antagonized hypokalemia
isoniazid therapy due convulsions
isoniazid mg infant day 17 kg admitted days fits clonic
isoniazid mg infant day 17 kg admitted days fits
isoniazid medication suggesting ceased fits
warfarin juice haemopericardium haemorrhage gastrointestinal
warfarin juice haemopericardium haemorrhage
vancomycin course receiving Acute
vancomycin course receiving Acute failure renal
vancomycin course receiving Acute failure
clomiphene citrate associated infarction Myocardial
clomiphene citrate associated infarction
citrate associated infarction Myocardial
citrate associated infarction
CC reported complication rare Thromboembolism
CC infarction myocardial
CC infarction
Mellaril appeared responsible cases tachycardia ventricular
Mellaril appeared responsible cases tachycardia
thioridazine Mellaril appeared responsible cases tachycardia ventricular
thioridazine Mellaril appeared responsible cases tachycardia
Aventyl produced block left
Aventyl produced block bundle
Aventyl produced block branch
Aventyl produced block
nortriptyline Aventyl produced block left
nortriptyline Aventyl produced block bundle
nortriptyline Aventyl produced block branch
nortriptyline Aventyl produced block
Elavil Aventyl produced block left
Elavil Aventyl produced block bundle
Elavil Aventyl produced block branch
Elavil Aventyl produced block
amitriptyline Elavil Aventyl produced block left
amitriptyline Elavil Aventyl produced block bundle
amitriptyline Elavil Aventyl produced block branch
amitriptyline Elavil Aventyl produced block
cocaine abusers Eleven had evidence injury defined infarction block bundle
cocaine abusers Eleven had evidence injury defined infarction block branch
cocaine abusers Eleven had evidence injury defined infarction block
cocaine abusers Eleven had evidence injury defined infarction myocardial
cocaine abusers Eleven had evidence injury defined infarction
doxorubicin heart derivative induced cardiomyopathy
doxorubicin courses received Animals demonstrated changes decrease cardiomyopathy
doxorubicin cardiomyopathy
terbutaline metoprolol antagonism hypokalemia
diphenylhydantoin toxicity manifestation hemiparesis
diphenylhydantoin overdose effects encountered those dysfunction cerebellar
diphenylhydantoin overdose effects encountered those dysfunction
DPH overdose effects encountered those dysfunction cerebellar
DPH overdose effects encountered those dysfunction
diphenylhydantoin overdose
DPH overdose
DPH overdose
DPH overdose due hemiparesis
dexamethasone programs injury hypertension
dexamethasone programs injury hypertension renal
dexamethasone programs injury
dexamethasone programmed increase
dexamethasone programmed pressure in
dexamethasone programmed pressure blood
dexamethasone programmed pressure
dexamethasone programmed pressure injury renal
dexamethasone programmed pressure injury
dexamethasone gestation administered rats Offspring had reduction
dexamethasone gestation administered rats Offspring had reduction number in
dexamethasone gestation administered rats Offspring had reduction number glomerular
dexamethasone gestation administered rats Offspring had reduction number
dexamethasone received rats had pressures elevated
dexamethasone received rats had pressures blood
dexamethasone received rats had pressures
dexamethasone received rats had have reduction
dexamethasone received rats had have reduction number in
dexamethasone received rats had have reduction number glomerular
dexamethasone received rats had have reduction number
dexamethasone shows results reduction number hypertension
dexamethasone shows results reduction
dexamethasone shows results reduction number in
dexamethasone shows results reduction number glomerular
dexamethasone shows results reduction number
gentamicin induced failure acute
gentamicin induced failure renal
gentamicin induced failure
Heparin induced thrombocytopenia hemorrhage
Heparin induced thrombocytopenia
heparin patients Sixty induced reported thrombocytopenia
heparin receiving hemorrhage
heparin receiving hemorrhage events thromboembolic
carbamazepine phenobarbitone rats dysfunction cognitive
carbamazepine phenobarbitone rats dysfunction
phenobarbitone rats dysfunction cognitive
phenobarbitone rats dysfunction
carbamazepine drugs known cause impairment cognitive
carbamazepine drugs known cause impairment
phenobarbitone drugs known cause impairment cognitive
phenobarbitone drugs known cause impairment
carbamazepine phenobarbitone impairment cognitive
carbamazepine phenobarbitone impairment
phenobarbitone impairment cognitive
phenobarbitone impairment
carbamazepine phenobarbitone administration caused impairment
carbamazepine phenobarbitone administration caused impairment learning of
carbamazepine phenobarbitone administration caused impairment learning
carbamazepine phenobarbitone administration caused impairment learning and
carbamazepine phenobarbitone administration caused impairment learning memory
phenobarbitone administration caused impairment
phenobarbitone administration caused impairment learning of
phenobarbitone administration caused impairment learning
phenobarbitone administration caused impairment learning and
phenobarbitone administration caused impairment learning memory
carbamazepine phenobarbitone treated rats mitigating deterioration
carbamazepine phenobarbitone treated rats mitigating deterioration functions of
carbamazepine phenobarbitone treated rats mitigating deterioration functions cognitive
carbamazepine phenobarbitone treated rats mitigating deterioration functions
phenobarbitone treated rats mitigating deterioration
phenobarbitone treated rats mitigating deterioration functions of
phenobarbitone treated rats mitigating deterioration functions cognitive
phenobarbitone treated rats mitigating deterioration functions
carbamazepine phenobarbitone preventing impairment cognitive
carbamazepine phenobarbitone preventing impairment
phenobarbitone preventing impairment cognitive
phenobarbitone preventing impairment
carbachol produced mydriasis
carbachol produced mydriasis tremor
eserine carbachol produced mydriasis clonic
eserine carbachol produced convulsions tonic
eserine carbachol produced convulsions
eserine carbachol produced mydriasis
carbachol produced mydriasis clonic
carbachol produced convulsions tonic
carbachol produced convulsions
eserine carbachol produced mydriasis tremor
carbachol evoked convulsions changed hand mydriasis
carbachol evoked convulsions changed hand tremor
eserine carbachol evoked convulsions changed hand clonic
eserine carbachol evoked convulsions tonic
eserine carbachol evoked convulsions
eserine carbachol evoked convulsions changed hand mydriasis
carbachol evoked convulsions changed hand clonic
carbachol evoked convulsions tonic
carbachol evoked convulsions
eserine carbachol evoked convulsions changed hand tremor
carbachol caused convulsions phenomena mydriasis
carbachol caused convulsions phenomena mydriasis tremor
eserine carbachol caused convulsions phenomena mydriasis clonic
eserine carbachol caused convulsions tonic
eserine carbachol caused convulsions
eserine carbachol caused convulsions phenomena mydriasis
carbachol caused convulsions phenomena mydriasis clonic
carbachol caused convulsions tonic
carbachol caused convulsions
eserine carbachol caused convulsions phenomena mydriasis tremor
dextromethorphan abuse deterioration Cognitive
dextromethorphan abuse deterioration
DM use resulting deterioration cognitive
DM use resulting deterioration
ritodrine therapy section tachyarrhythmias Ventricular
ritodrine therapy section tachyarrhythmias
scopolamine depletion induced deficits memory
scopolamine depletion induced deficits
pilocarpine SE
lithium subjected rats estradiol effects pilocarpine SE
Clomipramine induced disturbance sleep
Clomipramine induced disturbance
clomipramine administration induced disturbance sleep
clomipramine administration induced disturbance
tobramycin sulfate sulfate day followed failure renal
tobramycin sulfate sulfate day followed failure
sulfate sulfate day followed failure renal
sulfate sulfate day followed failure
gentamicin sulfate day followed failure renal
gentamicin sulfate day followed failure
sulfate day followed failure renal
sulfate day followed failure
tobramycin 33 Five treated had failure renal
tobramycin 33 Five treated had failure
gentamicin 29 16 patients treated Five treated had failure renal
gentamicin 29 16 patients treated Five treated had failure
tobramycin times failure renal
tobramycin times failure
gentamicin associated failure renal
gentamicin associated failure
PTZ pentylenetrazol decrease threshold seizure
PTZ pentylenetrazol h seizures
PTZ threshold h pentylenetrazol decrease threshold seizure
PTZ threshold h seizures
methyl acid 3 due activity different decreased activity Seizure
6 methyl acid 3 due activity different decreased activity Seizure
7 methyl acid 3 due activity different decreased activity Seizure
dimethoxy 3 due activity different decreased activity Seizure
4 3 due activity different decreased activity Seizure
ethyl 3 due activity different decreased activity Seizure
B 3 due activity different decreased activity Seizure
carboline 3 due activity different decreased activity Seizure
3 3 due activity different decreased activity Seizure
carboxylate 3 due activity different decreased activity Seizure
methyl acid 3 due activity seizure
6 methyl acid 3 due activity seizure
7 methyl acid 3 due activity seizure
dimethoxy 3 due activity seizure
4 3 due activity seizure
ethyl 3 due activity seizure
B 3 due activity seizure
carboline 3 due activity seizure
3 3 due activity seizure
carboxylate 3 due activity seizure
DMCM carboxylate 3 due activity different decreased activity Seizure
DMCM carboxylate 3 due activity seizure
strychnine 3 due activity different decreased activity Seizure
strychnine 3 due activity seizure
STR activity different decreased activity Seizure
STR activity seizure
picrotoxin activity Seizure
picrotoxin activity decreased different activity seizure
PTX picrotoxin activity Seizure
PTX picrotoxin activity decreased different activity seizure
PTZ due activity Seizure
PTZ due activity decreased different activity seizure
3 due activity different decreased activity Seizure
mercaptopropionic acid 3 due activity different decreased activity Seizure
acid 3 due activity different decreased activity Seizure
3 due activity seizure
mercaptopropionic acid 3 due activity seizure
acid 3 due activity seizure
MPA acid 3 due activity different decreased activity Seizure
MPA acid 3 due activity seizure
bicuculline acid 3 due activity different decreased activity Seizure
bicuculline acid 3 due activity seizure
BCC bicuculline acid 3 due activity different decreased activity Seizure
BCC bicuculline acid 3 due activity seizure
PTX occur activity seizure
PTX occur suggest decreased HCH response seizure
PTZ induced activity seizure
PTZ induced activity occur suggest decreased HCH response seizure
gentamicin failure acute
gentamicin failure renal
gentamicin failure
ifosfamide Treatment toxicity urothelial
ifosfamide Treatment toxicity
ifosfamide induced toxicity urothelial
ifosfamide induced toxicity
IF effect sodium sulphonate toxicity urothelial
IF effect sodium sulphonate toxicity
IF treatment tested effect sodium sulphonate toxicity urothelial
IF treatment tested effect sodium sulphonate toxicity
cisplatin paclitaxel drugs neurons cultures exposing mimic neuropathy peripheral
cisplatin paclitaxel drugs neurons cultures exposing mimic neuropathy
paclitaxel drugs neurons cultures exposing mimic neuropathy peripheral
paclitaxel drugs neurons cultures exposing mimic neuropathy
prostaglandin E effects hypotension
E effects hypotension
1 E effects hypotension
prostaglandin E hypotension
E hypotension
1 E hypotension
PGE 1 E hypotension
1 PGE 1 E hypotension
PGE induced hypotension
1 PGE induced hypotension
PGE min combination cause impairment
PGE min combination cause impairment function of
PGE min combination cause impairment function hepatic
PGE min combination cause impairment function
1 PGE min combination cause impairment
1 PGE min combination cause impairment function of
1 PGE min combination cause impairment function hepatic
1 PGE min combination cause impairment function
PGE min hypotension
1 PGE min hypotension
tamoxifen use associated tumor Granulosa
tamoxifen use associated tumor cell
tamoxifen use associated tumor
tamoxifen use associated tumor ovary of
tamoxifen use associated tumor ovary the
tamoxifen use associated tumor ovary
tamoxifen Patients CONCLUSION induced risk dysfunction liver
tamoxifen Patients CONCLUSION induced risk dysfunction
tamoxifen metabolism alterations tumors risk dysfunction liver
tamoxifen metabolism alterations tumors risk dysfunction
Li events DVP EPS
Li DVP different DVP EPS
haloperidol treated events related EPS
haloperidol treated experienced events related EPS
lithium treated patients 26 experienced treated events related EPS
lithium treated patients 26 experienced events related EPS
Lithium associated incidence tremor
Lithium associated contributed tremor
Lithium associated contributed rate tremor
lithium effect tremor contributed associated incidence tremor
lithium effect tremor
lithium effect tremor contributed rate tremor
lithium therapy receiving patients contributed associated incidence tremor
lithium therapy receiving patients contributed tremor
lithium therapy receiving patients contributed rate tremor
Haloperidol induced incidence akathisia syndrome extrapyramidal
Haloperidol induced incidence akathisia syndrome
Haloperidol induced incidence akathisia tremor
Haloperidol induced incidence akathisia
haloperidol indicated developed moderate signs extrapyramidal
haloperidol indicated developed moderate signs
adriamycin injection induced syndrome nephrotic
adriamycin injection induced syndrome
ADR adriamycin injection induced syndrome nephrotic
ADR adriamycin injection induced syndrome
Dexatrim cause infarction myocardial
Dexatrim cause infarction
Phenylpropanolamine Dexatrim cause infarction myocardial
Phenylpropanolamine Dexatrim cause infarction
scopolamine non induced amnesia
S non induced amnesia
- non induced amnesia
ET non induced amnesia
126 non induced amnesia
mexiletine group frequent effects tremor problems gastrointestinal
mexiletine group frequent effects tremor problems
mexiletine group frequent effects tremor
terodiline terfenadine g market led effect side TDP
terfenadine g market led effect side TDP
terodiline terfenadine compounds known increase cause investigated TDP
cisapride terfenadine compounds known increase cause investigated TDP
terfenadine compounds known increase cause investigated TDP
terodiline cisapride clinic TDP
cisapride clinic TDP
terfenadine cisapride clinic TDP
doxorubicin development failure heart
doxorubicin development failure
cefazedone beagle cefonicid dogs administration caused dose incidence anemia neutropenia
cefonicid dogs administration caused dose incidence anemia neutropenia
cefazedone beagle cefonicid dogs administration caused dose incidence anemia thrombocytopenia
cefonicid dogs administration caused dose incidence anemia
cefazedone beagle cefonicid dogs administration caused dose incidence anemia
cefonicid dogs administration caused dose incidence anemia thrombocytopenia
cefonicid mg receiving dogs % occurred compromising anemia
cefazedone kg mg receiving dogs % occurred compromising anemia
isoproterenol Crataegus tincture effect infarction myocardial
isoproterenol Crataegus tincture effect infarction
ethinyl treatment used models cholestasis intrahepatic
ethinyl treatment used models cholestasis
estradiol treatment used models cholestasis intrahepatic
estradiol treatment used models cholestasis
EE treatment used models cholestasis intrahepatic
EE treatment used models cholestasis
isoniazid unmasked disorder behavioral
isoniazid unmasked disorder
isoniazid administration difficulties hyperkinesis had deterioration behavioral
isoniazid administration difficulties hyperkinesis had deterioration
isoniazid administration difficulties hyperkinesis
fentanyl administration rigidity
fentanyl dose received period case rigidity
oxytocin administration associated intoxication Water
oxytocin administration associated intoxication
oxytocin administration intoxication cases water
oxytocin administration intoxication
Oxytocin administration advocated carried aware symptoms intoxication water
Oxytocin administration advocated carried aware symptoms intoxication
clioquinol dose ingestion related encephalopathy
tiazofurin usage associated lesions cerebral
tiazofurin usage associated lesions
octreotide associated stones gall
octreotide associated stones bladder
octreotide associated stones
Octreotide induces stones gall
Octreotide induces stones bladder
Octreotide induces stones
octreotide treated stones gall
octreotide treated stones
octreotide stones gall
octreotide stones
octreotide stones small have common disease gall
octreotide stones small have common disease stone
octreotide stones small have common disease
octreotide stones small have duct stones gall
octreotide stones small have duct stones
metoclopramide caused case dyskinesia tardive
metoclopramide caused case dyskinesia
metoclopramide took patient appeared movements Abnormal
metoclopramide took patient appeared movements involuntary
metoclopramide took patient appeared movements
metoclopramide administration discontinued improved movements abnormal
metoclopramide administration discontinued improved movements
ammonium Pretreatment doubled increased incoordination
acetate approximately doubled increased incoordination
NH 4 Ac acetate approximately doubled increased incoordination
4 Ac acetate approximately doubled increased incoordination
Ac acetate approximately doubled increased incoordination
NH 4 treatment had doubled increased incoordination
4 treatment had doubled increased incoordination
Ac treatment had doubled increased incoordination
diazepam increased incoordination
NH 4 activity analgesia diazepam incoordination
4 activity analgesia diazepam incoordination
Ac activity analgesia diazepam incoordination
NH verapamil mg activity analgesia diazepam incoordination
4 Ac verapamil mg activity analgesia diazepam incoordination
Ac verapamil mg activity analgesia diazepam incoordination
diazepam incoordination
Hydrocortisone hypertension
hydrocortisone rise
hydrocortisone rise pressure in
hydrocortisone rise pressure resting
hydrocortisone rise pressure blood
hydrocortisone rise pressure
lead course expression hypertension
lead rats increased reduced hypertension
lead NOx hypertension
lead hypertension
lead inactivation actions stress associated hypertension
Procainamide induced tachycardia ventricular
Procainamide induced tachycardia
procainamide cases polymorphous presented tachycardia ventricular
procainamide cases polymorphous presented tachycardia
procainamide mg administration appeared tachycardia ventricular
procainamide mg administration appeared tachycardia
procainamide mg administration appeared treatment tachycardia ventricular
procainamide mg administration appeared treatment tachycardia
procainamide therapy continuation inserted polymorphous reoccur tachycardia ventricular
procainamide therapy continuation inserted polymorphous reoccur tachycardia
procainamide produce Q syndrome tachycardia ventricular
procainamide produce Q syndrome tachycardia
Apomorphine selected effects ability induce hypothermia
apomorphine induced hyperactivity
apomorphine drug hypothermia
dexamethasone induced hypertension
dexamethasone assess hypertension
dex dexamethasone assess hypertension
dex hypertension
dex 392 + superoxide hypertension
dex < 0001 392 + superoxide hypertension
dexamethasone induced hypertension
Glyceryl trinitrate induces attacks migraine
Glyceryl trinitrate induces aura without
Glyceryl trinitrate induces aura
trinitrate induces attacks migraine
trinitrate induces aura without
trinitrate induces aura
nitric oxide involved mechanisms migraine
nitric oxide involved aura without
nitric oxide involved aura
oxide involved mechanisms migraine
oxide involved aura without
oxide involved aura
NO oxide involved mechanisms migraine
NO oxide involved aura without
NO oxide involved aura
bendrofluazide Amelioration hypokalemia
bendrofluazide treatment hypokalemia
alpha induced mice Changes liver hepatoma
benzene Changes liver hepatoma
hexachloride benzene Changes liver hepatoma
alpha induced Peroxisomes lesions hepatomas
benzene hexachloride examined induced Peroxisomes lesions hepatomas
hexachloride examined induced Peroxisomes lesions hepatomas
succinylcholine apnea
succinylcholine action duration patients eleven had indicating reason period apnea
prostaglandin E inhibition dose induced hyperalgesia
E inhibition dose induced hyperalgesia
2 E inhibition dose induced hyperalgesia
8 induced hyperalgesia
bromo monophosphate hyperalgesia
cyclic monophosphate hyperalgesia
adenosine monophosphate hyperalgesia
monophosphate hyperalgesia
haloperidol sensitization impairment cognitive
haloperidol sensitization impairment
haloperidol administration observed Impairment
haloperidol administration observed Impairment function of
haloperidol administration observed Impairment function cognitive
haloperidol administration observed Impairment function
Haloperidol produced profile impairment cognitive
Haloperidol produced profile impairment
methadone associated movements Choreoathetoid
methadone associated movements
methadone report movements euphoria choreoathetoid
methadone report movements
cocaine heroine abusing methadone report movements euphoria choreoathetoid
cocaine heroine abusing methadone report movements
metoclopramide induced pointes de Torsade
metoclopramide induced pointes de
metoclopramide induced pointes
metoclopramide administration developed pointes torsade
metoclopramide administration developed pointes de
metoclopramide administration developed pointes
erythromycin cisapride given pointes de torsade
erythromycin cisapride given pointes de
erythromycin cisapride given pointes
cisapride given pointes de torsade
cisapride given pointes de
cisapride given pointes
metoclopramide provokes torsade
metoclopramide provokes torsade clinically de
metoclopramide provokes torsade clinically pointes
Metoclopramide used patients risk pointes torsade
Metoclopramide used patients risk pointes de
Metoclopramide used patients risk pointes
benzoylecgonine induced Seizures
cocaine benzoylecgonine induced Seizures
cocaine life short occur some seizures
benzoylecgonine cocaine metabolite potential evaluated cause seizures
BE benzoylecgonine cocaine metabolite potential evaluated cause seizures
cocaine metabolite potential evaluated cause seizures
BE occurred seizures
cocaine amounts induced those latencies had occurred seizures
BE induced those prolonged characterized cocaine seizures
cocaine seizures
BE rats have had seizures
BE injected seizures
cocaine had seizures
cocaine had have rats BE injected seizures
BE cocaine seizures
BE cocaine seizures differ finding suggests mechanism seizures
BE metabolite importance emphasizes suggests finding differ seizures
BE metabolite importance emphasizes suggests mechanism seizures
cocaine seizures
cocaine seizures differ finding suggests mechanism seizures
cocaine mechanism suggests finding differ seizures
cocaine mechanism seizures
cocaine metabolite importance emphasizes suggests finding differ seizures
cocaine metabolite importance emphasizes suggests mechanism seizures
mazindol effects included appetite symptoms gastrointestinal
mazindol effects included appetite symptoms
mazindol dosage reduced included appetite symptoms gastrointestinal
mazindol dosage reduced included appetite symptoms
mazindol effects included appetite decreased
mazindol effects included appetite
mazindol dosage reduced included appetite decreased
mazindol dosage reduced included appetite
mazindol effects included appetite mouth dry
mazindol effects included appetite mouth
mazindol dosage reduced included appetite mouth dry
mazindol dosage reduced included appetite mouth
ifosfamide function impaired
ifosfamide function renal
ifosfamide function
ifosfamide anuria
ifosfamide sixty developed anuria
Ifosfamide drug nephrotoxic
Ifosfamide drug tubulopathies
ifosfamide due anuria
ifosfamide use recommend patients pretreated chemotherapy nephrotoxic
lithium Attenuation diabetes
lithium Attenuation diabetes insipidus
lithium Attenuation syndrome like
lithium Attenuation syndrome
lithium attenuation diabetes
lithium attenuation insipidus
lithium attenuation syndrome like
lithium attenuation syndrome
lithium concentration ratio reduction accompanied attenuation diabetes
lithium concentration ratio reduction accompanied attenuation insipidus
lithium concentration ratio reduction accompanied attenuation syndrome like
lithium concentration ratio reduction accompanied attenuation syndrome
edrophonium min stability provided kg induced bradycardias
edrophonium induced bradycardias
pilocarpine neurotransmitters urea effects seizure
pilocarpine rats seizure
pilocarpine protect finding seizure
pilocarpine reduce finding induced seizure
pilocarpine observed partly account induced finding induced seizure
desipramine toxicity tachycardia ventricular
desipramine toxicity tachycardia
desipramine toxicity induced tachycardia ventricular
desipramine toxicity induced tachycardia
quinine containing products produce complications confusion
quinine containing products produce complications confusion seizures
quinine containing products produce complications confusion coma
desipramine IP produce hypotension
desipramine IP produce hypotension bradycardia
CaCl group incidence arrhythmias ventricular
CaCl group incidence arrhythmias
2 group incidence arrhythmias ventricular
2 group incidence arrhythmias
lithium case pathology insipidus diabetes
lithium case pathology insipidus
lithium case reported insipidus diabetes
lithium case reported insipidus
ouabain administration falls conclude disease failure left
ouabain administration falls conclude disease failure left end ventricular
ouabain administration falls conclude disease failure left end
ouabain administration falls volume diastolic
ouabain administration falls volume
ouabain administration falls
statin therapy associated myopathy
Statins cause myopathy
statins induce myopathy
statins initiate immune myopathy
statins involve uncertain mechanism myopathy
propofol controlled Reduction pain
propofol injection Pain
propofol pain
propofol infusion starting infusing prevented pain
propofol caused pain
propofol infusion scale four using evaluated pain
propofol TCI anaesthesia induction achieved reduction pain
propofol pain
cyclophosphamide used damage heart
cyclophosphamide used damage
mitoxantrone cyclophosphamide used damage heart
mitoxantrone cyclophosphamide used damage
warfarin induced haemorrhage Cerebral
warfarin induced haemorrhage
warfarin frequency evaluate induced due haemorrhages cerebral
warfarin frequency evaluate induced due haemorrhages
warfarin due haemorrhages cerebral
warfarin due haemorrhages
warfarin warfarin due haemorrhages cerebral
warfarin warfarin due haemorrhages
warfarin evaluate studied caused haemorrhage cerebral
warfarin evaluate studied caused haemorrhage
warfarin warfarin evaluate studied caused haemorrhage cerebral
warfarin warfarin evaluate studied caused haemorrhage
warfarin related treatment assessed patients haemorrhage cerebral
warfarin related treatment assessed patients haemorrhage
Warfarin CONCLUSIONS problem haemorrhages cerebral
Warfarin CONCLUSIONS problem haemorrhages
warfarin proportion prevented haemorrhages cerebral
warfarin proportion prevented haemorrhages
warfarin interact known taken prevented haemorrhages cerebral
warfarin interact known taken prevented haemorrhages
scopolamine induced amnesia
scopolamine amnesia
cocaine microinjected HT hyperactivity locomotor
cocaine microinjected HT hyperactivity
cocaine induced locomotor
cocaine induced hyperactivity
cocaine prior induced hyperactivity locomotor
cocaine prior induced hyperactivity
CP antagonist effects consisting modification core shell microinjected indicate modified hyperlocomotion
93129 CP antagonist effects consisting modification core shell microinjected indicate modified hyperlocomotion
cocaine hyperlocomotion
ampicillin caused multiforme myocarditis hypersensitivity
ampicillin caused multiforme myocarditis
ampicillin caused multiforme Erythema
ampicillin caused multiforme
ampicillin caused multiforme myocarditis hypersensitivity
ampicillin caused multiforme myocarditis
ampicillin caused multiforme erythema
ampicillin caused multiforme
caffeine pretreatment related case tachycardia ventricular
caffeine pretreatment related case tachycardia
caffeine used improve duration seizure
caffeine used tolerated reports ectopy ventricular
caffeine used tolerated reports ectopy
caffeine administration developed bigeminy runs tachycardia ventricular
caffeine administration developed bigeminy runs tachycardia
heparin therapy receiving patients thromboembolism induced thrombocytopenia
heparin associated complication thromboembolism induced thrombocytopenia
heparin therapy initiation days occurring ischemia thrombi occlusion arterial
heparin therapy initiation days occurring ischemia thrombi occlusion
heparin therapy initiation days preceded thrombocytopenia
heparin factor relating thromboembolism thrombocytopenia
Prostaglandin E hyperactivity bladder
Prostaglandin E hyperactivity
E hyperactivity bladder
E hyperactivity
2 E hyperactivity bladder
2 E hyperactivity
azithromycin induced nephritis interstitial
azithromycin induced nephritis
azithromycin recurrent reported nephritis interstitial
azithromycin recurrent reported nephritis
L model analysis DOPA dyskinesia
DOPA dyskinesia
L complications dyskinesia
DOPA L complications dyskinesia
L complications dyskinesia LID
DOPA L complications dyskinesia LID
L treatment arise complications dyskinesia
DOPA arise complications dyskinesia
L treatment arise complications dyskinesia LID
DOPA arise complications dyskinesia LID
L treated allocated groups based presence LID
DOPA allocated groups based presence LID
clozapine threshold agranulocytosis
clozapine agranulocytosis
MA induced hyperthermia
MA ameliorate induced damage neuronal
MA ameliorate induced damage
haloperidol catalepsy
clonidine treated subjects bradycardia
clonidine treated those treated subjects bradycardia
clonidine monitor bradycardia
methotrexate taking co associated found common Impotence
Chloroquine block blindness
chloroquine ingestion presented deterioration dizziness
chloroquine ingestion presented deterioration fatiguability
chloroquine ingestion presented deterioration dizziness progressing attacks syncopal
chloroquine ingestion presented deterioration dizziness progressing attacks
chloroquine ingestion presented deterioration dyspnoea
chloroquine retinopathy features revealed revealed features failure heart
chloroquine retinopathy features revealed revealed features failure
chloroquine retinopathy features revealed revealed pattern right
chloroquine retinopathy features revealed revealed pattern bundle
chloroquine retinopathy features revealed revealed pattern branch
chloroquine retinopathy features revealed revealed pattern block
chloroquine retinopathy
chloroquine discontinuation resolved failure heart
chloroquine discontinuation resolved failure
Oral contraceptives risk infarction myocardial
Oral contraceptives risk infarction
contraceptives risk infarction myocardial
contraceptives risk infarction
oral contraceptives use risk infarction myocardial
oral contraceptives use risk infarction
contraceptives use risk infarction myocardial
contraceptives use risk infarction
oral contraceptives levonorgestrel dose presence identified years had infarction myocardial
oral contraceptives levonorgestrel dose presence identified years had infarction
contraceptives levonorgestrel dose presence identified years had infarction myocardial
contraceptives levonorgestrel dose presence identified years had infarction
oral contraceptives levonorgestrel 925 women had infarction myocardial
oral contraceptives levonorgestrel 925 women had infarction
contraceptives levonorgestrel 925 women had infarction myocardial
contraceptives levonorgestrel 925 women had infarction
oral contraceptive type used women infarction myocardial
oral contraceptive type used women infarction
contraceptive type used women infarction myocardial
contraceptive type used women infarction
oral contraceptives generation women increased risk infarction myocardial
oral contraceptives generation women increased risk infarction
contraceptives generation women increased risk infarction myocardial
contraceptives generation women increased risk infarction
oral contraceptives used women similar risk infarction myocardial
oral contraceptives used women similar risk infarction
contraceptives used women similar risk infarction myocardial
contraceptives used women similar risk infarction
hepatitis antigen born infants done following screening B hepatitis
hepatitis antigen born infants done following screening B
B antigen born infants done following screening B hepatitis
B antigen born infants done following screening B
surface antigen born infants done following screening B hepatitis
surface antigen born infants done following screening B
antigen born infants done following screening B hepatitis
antigen born infants done following screening B
hepatitis antigen born infants done following administration dose hepatitis
hepatitis antigen born infants done following administration dose B
B antigen born infants done following administration dose hepatitis
B antigen born infants done following administration dose B
surface antigen born infants done following administration dose hepatitis
surface antigen born infants done following administration dose B
antigen born infants done following administration dose hepatitis
antigen born infants done following administration dose B
hepatitis antigen born infants done following administration globulin hepatitis
hepatitis antigen born infants done following administration globulin B
B antigen born infants done following administration globulin hepatitis
B antigen born infants done following administration globulin B
surface antigen born infants done following administration globulin hepatitis
surface antigen born infants done following administration globulin B
antigen born infants done following administration globulin hepatitis
antigen born infants done following administration globulin B
hepatitis antigen born infants received globulin hepatitis
hepatitis antigen born infants received globulin B
B antigen born infants received globulin hepatitis
B antigen born infants received globulin B
surface antigen born infants received globulin hepatitis
surface antigen born infants received globulin B
antigen born infants received globulin hepatitis
antigen born infants received globulin B
atracurium use Persistent paralysis
vecuronium bromide NMBAs aminosteroid involved Reports paralysis
bromide NMBAs aminosteroid involved Reports paralysis
Atracurium besylate associated paralysis
besylate associated paralysis
atracurium case paralysis
enflurane anesthetics associated allergic injury hepatic
enflurane anesthetics associated allergic injury
halothane exposure both injury hepatic
halothane exposure both injury
isoflurane enflurane anesthetics associated allergic injury hepatic
isoflurane enflurane anesthetics associated allergic injury
Halothane hepatitis
halothane patients hepatitis
enflurane produce similar that hepatitis
halothane hepatitis
halothane administration subsequent produce similar that hepatitis
isoflurane / enflurane produce similar that hepatitis
Myocet improves index doxorubicin reducing neutropenia
doxorubicin reducing neutropenia
cyclophosphamide used provides improves index doxorubicin reducing neutropenia
puromycin aminonucleoside antithrombin effects nephrosis
aminonucleoside antithrombin effects nephrosis
puromycin aminonucleoside rats nephrosis
aminonucleoside rats nephrosis
apomorphine had induced erection penile
apomorphine had induced erection
epinephrine use associated bleeding intracranial
epinephrine use associated bleeding
Epinephrine has role arrest cardiac
Epinephrine has role arrest
oral contraceptives taking woman reported syndrome uremic hemolytic
oral contraceptives taking woman reported syndrome uremic
oral contraceptives taking woman reported syndrome
contraceptives taking woman reported syndrome uremic hemolytic
contraceptives taking woman reported syndrome uremic
contraceptives taking woman reported syndrome
oral contraceptives taking woman reported syndrome HUS
contraceptives taking woman reported syndrome HUS
verapamil fibrillation atrial
verapamil fibrillation
verapamil administered evaluate mechanisms promotion AF
Verapamil caused promotion AF
Verapamil caused increasing mean duration induced AF
verapamil shortened mean decreased AF
verapamil caused that similar produced affect ERP length AF
verapamil caused that similar produced affect ERP duration AF
verapamil failed promote AF
verapamil promoted AF
Verapamil AF
amphotericin Recurrent failure acute
amphotericin Recurrent failure renal
amphotericin Recurrent failure
amphotericin B administration developed failure acute
amphotericin B administration developed failure renal
amphotericin B administration developed failure
B administration developed failure acute
B administration developed failure renal
B administration developed failure
amphotericin activate contributing failure acute
amphotericin activate contributing failure renal
amphotericin activate contributing failure
pilocarpine reported seizures model epilepsy temporal
pilocarpine reported seizures model epilepsy lobe
pilocarpine reported seizures model epilepsy
cis predicted included hypercalcemia
RA levels cis predicted included hypercalcemia
lithium Ebstein
lithium Ebstein '
lithium anomaly s
lithium anomaly
cocaine nephritis Henoch related failure acute
cocaine nephritis Henoch related failure renal
cocaine nephritis Henoch related failure
cocaine expression critical induced anxiety
cocaine effects studied paid states anxiety
cocaine induced states anxiety
cocaine examine lack mice performance induced anxiety
cocaine dose anxiety
Cocaine induced attenuated anxiety
cocaine antagonist anxiety
cocaine required indicate induced anxiety
echothiophate drops use developed presented weakness muscle
echothiophate drops use developed presented weakness
iodide drops use developed presented weakness muscle
iodide drops use developed presented weakness
capsaicin induced effects ketamine lidocaine hyperalgesia
capsaicin induced administration hyperalgesia ketamine lidocaine brush pain
capsaicin induced administration hyperalgesia
levodopa pallidotomy dyskinesias
levodopa pallidotomy dyskinesias LID
levodopa responsiveness found was correlation improvement LID
levodopa responsiveness responsiveness found was correlation improvement LID
levodopa responsiveness outcome signs LID
levodopa responsiveness outcome correlations volume dyskinesias
levodopa responsiveness value indicate dyskinesias
vigabatrin patients electroretinography oculography Electro attributed constriction visual
vigabatrin patients electroretinography oculography Electro attributed constriction field
vigabatrin patients electroretinography oculography Electro attributed constriction
vigabatrin associated thought constriction visual
vigabatrin associated thought constriction field
vigabatrin associated thought constriction
vigabatrin patients fields attributed loss visual
vigabatrin patients fields attributed loss field
vigabatrin patients fields attributed loss
vigabatrin therapy associated appears constriction visual
vigabatrin therapy associated appears constriction field
vigabatrin therapy associated appears constriction
D caused syndrome nephrotic
D caused syndrome
Penicillamine caused syndrome nephrotic
Penicillamine caused syndrome
D caused proteinuria
Penicillamine caused proteinuria
fluoxetine hydrochloride induced hyperprolactinemia
hydrochloride induced hyperprolactinemia
fluoxetine hydrochloride induced hyperprolactinemia effects model adenomyosis
hydrochloride induced hyperprolactinemia effects model adenomyosis
fluoxetine hydrochloride induced induction adenomyosis
hydrochloride induced induction adenomyosis
fluoxetine caused hyperprolactinemia
fluoxetine caused adenomyosis
Fluoxetine given produce hyperprolactinemia
fluoxetine receiving group revealed cases adenomyosis
azidothymidine mice anemia
Azidothymidine anemia
AZT Azidothymidine anemia
dipivalyl thrombosis vein
dipivalyl thrombosis
epinephrine thrombosis vein
epinephrine thrombosis
dipivalyl epinephrine started day seeing acquired thrombosis vein
dipivalyl epinephrine started day seeing acquired thrombosis
epinephrine started day seeing acquired thrombosis vein
epinephrine started day seeing acquired thrombosis
verapamil therapy hypotension bradycardia
verapamil therapy hypotension adrenergic failure cardiac
verapamil therapy hypotension adrenergic failure
beta verapamil therapy hypotension bradycardia
adrenergic hypotension bradycardia
blocking developed failure adrenergic hypotension bradycardia
drugs blocking developed failure adrenergic hypotension bradycardia
verapamil therapy hypotension
beta verapamil therapy hypotension
adrenergic hypotension
blocking developed failure adrenergic hypotension
drugs blocking developed failure adrenergic hypotension
beta verapamil therapy hypotension adrenergic failure cardiac
beta verapamil therapy hypotension adrenergic failure
adrenergic failure cardiac
adrenergic failure
blocking developed failure cardiac
blocking developed failure
drugs blocking developed failure cardiac
drugs blocking developed failure
prazosin blockade 2 occurs hypotension Orthostatic
prazosin blockade 2 occurs hypotension
prazosin treated hypotension orthostatic
prazosin treated hypotension
prazosin dosing performed produce hypotension orthostatic
prazosin dosing performed produce hypotension
Abbott responses bradycardia
53693 Abbott responses bradycardia
noradrenaline i micrograms responses bradycardia
cirazoline responses bradycardia
cirazoline effects bradycardia
Abbott effects similar greater bradycardia
53693 Abbott effects similar greater bradycardia
noradrenaline accompanied bradycardia
iron dextran infusion associated syndrome Value methylprednisolone prevention arthralgia
dextran infusion associated syndrome Value methylprednisolone prevention arthralgia
amphetamine use setting woman syndrome left
amphetamine use setting woman syndrome ventricular
amphetamine use setting woman syndrome apical
amphetamine use setting woman syndrome ballooning
amphetamine use setting woman syndrome
amphetamine use setting woman syndrome cardiomyopathy Takotsubo
amphetamine use setting woman syndrome cardiomyopathy
amphetamine use occurring syndrome apical
amphetamine use occurring syndrome ballooning
amphetamine use occurring syndrome
flumazenil administration Seizure
flumazenil administration patient seizure occurrence tonic
flumazenil administration patient seizure clonic
flumazenil administration patient seizure
nitrendipine nephrosclerosis
nitrendipine treatment effect angiotensin converting pressure albuminuria
nitrendipine treated albuminuria
thiopentone 4 mg that Somewhat slower i found lasted occurred apnoea
midazolam mg effect inducing sleep kg found lasted occurred apnoea
midazolam group found lasted occurred apnoea
midazolam group occurred apnoea
amikacin receiving patients associated outcome nephrotoxicity
amikacin treated patients Data analyzed factors associated nephrotoxicity
Perhexiline maleate neuropathy peripheral
Perhexiline maleate neuropathy
maleate neuropathy peripheral
maleate neuropathy
perhexiline maleate noted neuropathy Peripheral
perhexiline maleate noted neuropathy
maleate noted neuropathy Peripheral
maleate noted neuropathy
malondialdehyde dependence oxypurines nucleosides ischemia cerebral
malondialdehyde dependence oxypurines nucleosides ischemia
levodopa Improvement dyskinesia
levodopa improve induced dyskinesia
nifedipine induced telangiectasia
nifedipine starting months developed telangiectasia
Adalat nifedipine starting months developed telangiectasia
amlodipine commenced recurrence telangiectasia
nondepolarizing blocking implicated cause weakness muscle
nondepolarizing blocking implicated cause weakness
neuromuscular nondepolarizing blocking implicated cause weakness muscle
neuromuscular nondepolarizing blocking implicated cause weakness
blocking implicated cause weakness muscle
blocking implicated cause weakness
agents implicated cause weakness muscle
agents implicated cause weakness
ND agents implicated cause weakness muscle
ND agents implicated cause weakness
NMBA ND agents implicated cause weakness muscle
NMBA ND agents implicated cause weakness
ND discontinuation weakness
NMBAs patients insufficiency developed weakness
ND likely junction pathology due weakness
NMBA ND likely junction pathology due weakness
ND likely junction pathology
ND likely junction at
ND likely junction both
ND likely junction the
ND likely junction neuromuscular
ND likely junction
NMBA ND likely junction pathology
NMBA ND likely junction at
NMBA ND likely junction both
NMBA ND likely junction the
NMBA ND likely junction neuromuscular
NMBA ND likely junction
doxorubicin cycle fibrillation atrial
doxorubicin cycle fibrillation
scopolamine improve decline cognitive
scopolamine improve decline
scopolamine overdosage
hyoscine overdosage
ouabain injection intermittent induced arrhythmia
adrenaline infusion induced arrhythmia Adrenaline
adrenaline infusion induced arrhythmia
adrenaline digitalis cibenzoline arrhythmias
adrenaline digitalis arrhythmias
adrenaline suppress needed dose - cibenzoline suppressed induced v arrhythmia
adrenaline arrhythmias
adrenaline digitalis arrhythmia
thiopental produced involvement reversal paralysis respiratory
thiopental produced involvement reversal paralysis
thiopental induced paralysis respiratory
thiopental induced paralysis
thiopental produced paralysis respiratory
thiopental produced paralysis
nitrazepam overdose
nitrazepam overdose
chlormethiazole intoxication those two patient conformed coma
nitrazepam overdose patient conformed coma
morphine modulators Effect increase
morphine modulators Effect increase activity in
morphine modulators Effect increase activity locomotor
morphine modulators Effect increase activity
morphine modulators increase
morphine modulators increase activity in
morphine modulators increase activity locomotor
morphine modulators increase activity
morphine kg administration produced increase
morphine kg administration produced activity in
morphine kg administration produced activity locomotor
morphine kg administration produced activity
morphine potentiated hyperactivity
scopolamine potentiated hyperactivity
morphine produced hyperactivity
chondroitin sulfate derivative elicit response hypotensive
sulfate derivative elicit response hypotensive
zonisamide associated hallucinations Visual
zonisamide associated hallucinations
zonisamide treatment begun experienced patients describe reported hallucinations visual
zonisamide treatment begun experienced patients describe reported hallucinations
zonisamide treatment begun experienced hallucinations visual
zonisamide treatment begun experienced hallucinations
Topiramate induced nephrolithiasis
topiramate cases nephrolithiasis
Phenobarbitone enlargement
Phenobarbitone enlargement liver of
Phenobarbitone enlargement liver the
Phenobarbitone enlargement liver
carbon tetrachloride yield cirrhosis
carbon tetrachloride yield cirrhosis liver of
carbon tetrachloride yield cirrhosis liver the
carbon tetrachloride yield cirrhosis liver
tetrachloride yield cirrhosis
tetrachloride yield cirrhosis liver of
tetrachloride yield cirrhosis liver the
tetrachloride yield cirrhosis liver
carbon tetrachloride dose giving increased primed given yield cirrhosis
carbon tetrachloride dose giving increased primed given yield cirrhosis liver of
carbon tetrachloride dose giving increased primed given yield cirrhosis liver the
carbon tetrachloride dose giving increased primed given yield cirrhosis liver
tetrachloride dose giving increased primed given yield cirrhosis
tetrachloride dose giving increased primed given yield cirrhosis liver of
tetrachloride dose giving increased primed given yield cirrhosis liver the
tetrachloride dose giving increased primed given yield cirrhosis liver
phenobarbitone given induced enlargement
phenobarbitone given induced enlargement liver of
phenobarbitone given induced enlargement liver the
phenobarbitone given induced enlargement liver
phenobarbitone peak giving increased primed given induced enlargement
phenobarbitone peak giving increased primed given induced enlargement liver of
phenobarbitone peak giving increased primed given induced enlargement liver the
phenobarbitone peak giving increased primed given induced enlargement liver
phenobarbitone given yield cirrhosis
phenobarbitone given yield cirrhosis liver of
phenobarbitone given yield cirrhosis liver the
phenobarbitone given yield cirrhosis liver
phenobarbitone peak giving increased primed given yield cirrhosis
phenobarbitone peak giving increased primed given yield cirrhosis liver of
phenobarbitone peak giving increased primed given yield cirrhosis liver the
phenobarbitone peak giving increased primed given yield cirrhosis liver
ceftriaxone induced hepatitis
ceftriaxone induced hepatitis anemia autoimmune
ceftriaxone induced hepatitis anemia hemolytic
ceftriaxone induced hepatitis anemia
ceftriaxone ingesting developed hepatitis
ouabain arrhythmia
levofloxacin associated Seizures
levofloxacin drug initiating developed seizures
levofloxacin drug levofloxacin induced seizures
levofloxacin drug initiating developed seizures
levofloxacin induced seizures
levofloxacin cases RESULTS induced reported seizures
ethinyl estradiol acid hydroxylation sulfation cholestasis
estradiol acid hydroxylation sulfation cholestasis
chlorthalidone phase associated frequency beats ventricular
chlorthalidone phase associated frequency beats ectopic
chlorthalidone phase associated frequency beats
amiodarone pneumonitis
amiodarone withdrawal need diagnosis pneumonitis
bupivacaine develop loss hearing
bupivacaine develop loss
prilocaine given Patients likely develop loss hearing
prilocaine given Patients likely develop loss
bupivacaine dB loss hearing
bupivacaine dB loss
prilocaine dB loss hearing
prilocaine dB loss
risperidone treated subjects observed Drug
risperidone treated subjects observed parkinsonism induced
risperidone treated subjects observed parkinsonism
haloperidol risperidone treated subjects observed Drug
haloperidol risperidone treated subjects observed parkinsonism induced
haloperidol risperidone treated subjects observed parkinsonism
tacrolimus cyclosporine known nephrotoxic
cyclosporine known nephrotoxic
pilocarpine model epilepsy temporal
pilocarpine model epilepsy lobe
pilocarpine model epilepsy
quinine ingestion associated syndrome Hemolytic
quinine ingestion associated syndrome uremic
quinine ingestion associated syndrome
quinine ingestion syndrome Hemolytic
quinine ingestion syndrome uremic
quinine ingestion syndrome
Quinine occurs associated hemolytic
Quinine occurs syndrome uremic
Quinine occurs syndrome
isoflurane function hypotension
isoflurane effect hypotension
isoflurane inspired concentration increasing min / 236 induced Hypotension
isoflurane induced hypotension
labetalol induced Effects hypotension
isoflurane induced Effects hypotension
labetalol induced hypotension
labetalol induced isoflurane group hypotensive
isoflurane induced hypotension
isoflurane group hypotensive
labetalol induced hypotension
isoflurane induced hypotension
phenacetin comparison use acetaminophen factor failure chronic
phenacetin comparison use acetaminophen factor failure renal
phenacetin comparison use acetaminophen factor failure
phenacetin use associated development failure chronic
phenacetin use associated development failure renal
phenacetin use associated development failure
phenacetin use associated development failure end
phenacetin use associated development failure disease stage
phenacetin use associated development failure disease renal
phenacetin use associated development failure disease
phenacetin use associated development failure disease ESRD
phenacetin contribute burden ESRD
terbutaline treatment abnormalities implications autism
Terbutaline associated concordance autism
ketoconazole treatment complication hypertension
ketoconazole treated syndrome patients Two developed hypertension
ketoconazole therapy achieved demonstrated hypertension
ketoconazole doses treatment induce blockade leading mineralocorticoid hypertension
ribavirin treatment interferon Development myasthenia ocular
ribavirin treatment interferon Development myasthenia
pegylated interferon Development myasthenia ocular
pegylated interferon Development myasthenia
interferon Development myasthenia ocular
interferon Development myasthenia
ribavirin alpha therapy associated myasthenia ocular
ribavirin alpha therapy associated myasthenia
pegylated alpha therapy associated myasthenia ocular
pegylated alpha therapy associated myasthenia
IFN alpha therapy associated myasthenia ocular
IFN alpha therapy associated myasthenia
alpha therapy associated myasthenia ocular
alpha therapy associated myasthenia
2 alpha therapy associated myasthenia ocular
2 alpha therapy associated myasthenia
b alpha therapy associated myasthenia ocular
b alpha therapy associated myasthenia
IFN therapy complications review present reported myasthenia ocular
IFN therapy complications review present reported myasthenia
asenapine % % occurred reported symptoms Extrapyramidal
asenapine % % occurred reported symptoms
haloperidol asenapine % % occurred reported symptoms Extrapyramidal
haloperidol asenapine % % occurred reported symptoms
asenapine similar indicated seen AEs symptoms extrapyramidal
asenapine similar indicated seen AEs symptoms
haloperidol asenapine similar indicated seen AEs symptoms extrapyramidal
haloperidol asenapine similar indicated seen AEs symptoms
amphetamine induced hyperactivity
fluvoxamine treatment potentiated amphetamine induced hyperactivity
nomifensine induced hyperactivity
fluvoxamine remained hyperactivity
clonidine undergoing arrest Cardiac
clonidine undergoing arrest
clonidine reports arrest cardiac
clonidine reports arrest
heparin Delayed induced thrombocytopenia
Heparin BACKGROUND presents thrombocytopenia
heparin exposure presents thrombocytopenia
heparin recognition contribute thrombocytopenia
heparin manifestations thrombocytopenia
heparin thrombocytopenia
heparin exposure included thrombocytopenia
heparin thrombocytopenia
heparin thrombocytopenia
heparin returns initiated thrombocytopenia
Verapamil withdrawal cause infarction myocardial
Verapamil withdrawal cause infarction
verapamil withdrawal introduction coincided infarction myocardial
verapamil withdrawal introduction coincided infarction
Nitroprusside induced ACTH evokes hypotension
nitroprusside secretion Suppression induced observed hypotension
isoniazid neuropathy
isoniazid dose caused neuropathy
pilocarpine treated analyze occurrence seizures
pilocarpine induced result seizures
KA / pilocarpine induced result seizures
alendronate proteinuria
alendronate proteinuria failure acute
alendronate proteinuria failure renal
alendronate proteinuria failure
alendronate sodium administration days increased g failure acute
alendronate sodium administration days increased g failure renal
alendronate sodium administration days increased g failure
sodium administration days increased g failure acute
sodium administration days increased g failure renal
sodium administration days increased g failure
dobutamine detection performance index Assessment induced ischemia myocardial
dobutamine detection performance index Assessment induced ischemia
dobutamine detecting ischemia myocardial
dobutamine detecting ischemia
dobutamine detecting ECG lead assess induced ischemia myocardial
dobutamine detecting ECG lead assess induced ischemia
Tiopronin due nephritis dermatitis
Tiopronin due due dermatitis
gold thiosulphate due dermatitis due due nephritis dermatitis
gold thiosulphate due dermatitis
Tiopronin due nephritis
Tiopronin group nephritis
puromycin aminonucleoside barrier proteins distribution changes nephrosis
aminonucleoside barrier proteins distribution changes nephrosis
puromycin rats nephrosis
aminonucleoside rats nephrosis
tolazamide Wernicke
tolazamide abnormality encephalopathy s
tolazamide abnormality encephalopathy
tolazamide treated encephalopathy Wernicke
tolazamide treated encephalopathy Wernicke '
tolazamide treated encephalopathy s
tolazamide treated encephalopathy
tolazamide patient syndrome similarity encephalopathy Wernicke
tolazamide patient syndrome similarity encephalopathy Wernicke '
tolazamide patient syndrome similarity encephalopathy s
tolazamide patient syndrome similarity encephalopathy
methyldopa effect hypotensive
methyldopa neurons microinjection elicits response hypotensive
methyldopa microinjection caused hypotension
methyldopa mediate hypotension
methyldopa mediate cells contribute action hypotensive
methyldopa action contribute cells mediate hypotension
methyldopa action hypotensive
isoproterenol severity infarction myocardial
isoproterenol severity infarction
Ximelagatran found efficient antagonist withdrawn tests abnormal
Ximelagatran found efficient antagonist withdrawn tests liver
Ximelagatran found efficient antagonist withdrawn tests function
Lamotrigine associated myoclonus
lamotrigine exacerbation appearance jerks myoclonic
lamotrigine exacerbation appearance jerks
lamotrigine exacerbation appearance jerks MJ
LTG exacerbation appearance jerks myoclonic
LTG exacerbation appearance jerks
LTG exacerbation appearance jerks MJ
LTG exacerbated MJ
LTG dose decreased disappeared MJ
LTG exacerbated MJ
LTG exacerbated status myoclonic
LTG exacerbated status
LTG withdrawal ceased status exacerbated MJ
LTG withdrawal ceased status myoclonic
LTG withdrawal ceased status
tizanidine initiation Hypotension
lisinopril treated chronically angiotensin converting control hypertension developed hypotension
tizanidine addition hypotension
FK Mechanisms hypertension
506 FK Mechanisms hypertension
FK utility complicated hypertension
506 FK utility complicated hypertension
FK mechanisms clarify hypertension
506 FK mechanisms clarify hypertension
FK effects studied hypertension
506 FK effects studied hypertension
FK FR antagonist studied hypertension
506 FK FR antagonist studied hypertension
FK induced hypertension
506 FK induced hypertension
carrageenan licking models induced hyperalgesia thermal
carrageenan licking models induced hyperalgesia
carrageenan licking models induced hyperalgesia mechanical
carrageenan licking models induced hyperalgesia
capsaicin hyperalgesia thermal
capsaicin hyperalgesia
capsaicin hyperalgesia induced models induced hyperalgesia mechanical
capsaicin hyperalgesia induced models induced hyperalgesia
reserpine hypothermia
d induced hyperactivity
amphetamine d induced hyperactivity
quinpirole amphetamine d induced hyperactivity
TRI increases locomotor induced hyperactivity
heparin enhanced volume hematoma
isoproterenol Development hypertrophy cardiac
isoproterenol Development hypertrophy
isoproterenol injections rats studied development hypertrophy cardiac
isoproterenol injections rats studied development hypertrophy
ISO isoproterenol injections rats studied development hypertrophy cardiac
ISO isoproterenol injections rats studied development hypertrophy
FK 506 consisted vacuolization glomerulosclerosis focal
FK 506 consisted vacuolization glomerulosclerosis segmental
FK 506 consisted vacuolization glomerulosclerosis
506 consisted vacuolization glomerulosclerosis focal
506 consisted vacuolization glomerulosclerosis segmental
506 consisted vacuolization glomerulosclerosis
Calcitriol therapy suppresses has hypercalcemia
Calcitriol therapy suppresses has hypercalcemia suppression
Calcitriol therapy suppresses has hypercalcemia suppression turnover of
Calcitriol therapy suppresses has hypercalcemia suppression turnover bone
Calcitriol therapy suppresses has hypercalcemia suppression turnover
Calcitriol therapy suppresses has hypercalcemia suppression turnover lead disease adynamic
Calcitriol therapy suppresses has hypercalcemia suppression turnover lead disease bone
Calcitriol therapy suppresses has hypercalcemia suppression turnover lead disease
OCT prevent occurrence hypercalcemia
trihexyphenidyl challenge allele slowing mental
trihexyphenidyl challenge allele slowing
trihexyphenidyl dose resulted ratings slowness mental
trihexyphenidyl dose resulted ratings slowness
trihexyphenidyl mg ratings slowness mental
trihexyphenidyl mg ratings slowness
trihexyphenidyl challenge associated slowing mental
trihexyphenidyl challenge associated slowing
sulindac therapy associated Hyperkalemia
indomethacin agents complication recognized Hyperkalemia
sulindac administration days developed hyperkalemia
sulindac hyperkalemia
Sulfasalazine induced erythematosus lupus
Sulfasalazine induced erythematosus
sulfasalazine therapy autoantibodies effusions Pneumonitis
sulfasalazine therapy autoantibodies effusions evidence tamponade cardiac
sulfasalazine therapy autoantibodies effusions evidence tamponade
sulfasalazine therapy autoantibodies effusions pleural
sulfasalazine therapy autoantibodies effusions
sulfasalazine lupus
sulfasalazine use Physicians aware lupus
sulfasalazine use Physicians aware lupus syndrome
sulfasalazine signs aware lupus
sulfasalazine signs aware lupus syndrome
metronidazole treatment syndrome Haemolytic
metronidazole treatment syndrome uraemic
metronidazole treatment syndrome
metronidazole developed syndrome haemolytic
metronidazole developed syndrome uraemic
metronidazole developed syndrome
metronidazole aetiology syndrome haemolytic
metronidazole aetiology syndrome uraemic
metronidazole aetiology syndrome
metronidazole involvement established suggest action drug evidence syndrome haemolytic
metronidazole involvement established suggest action drug evidence syndrome uraemic
metronidazole involvement established suggest action drug evidence syndrome
metronidazole involvement established suggest link cases syndrome haemolytic
metronidazole involvement established suggest link cases syndrome uraemic
metronidazole involvement established suggest link cases syndrome
metronidazole treatment link suggest established involvement metronidazole aetiology syndrome haemolytic
metronidazole treatment link suggest established involvement metronidazole aetiology syndrome uraemic
metronidazole treatment link suggest established involvement metronidazole aetiology syndrome
metronidazole treatment link suggest action drug evidence syndrome haemolytic
metronidazole treatment link suggest action drug evidence syndrome uraemic
metronidazole treatment link suggest action drug evidence syndrome
metronidazole treatment link cases syndrome haemolytic
metronidazole treatment link cases syndrome uraemic
metronidazole treatment link cases syndrome
clomiphene associated occlusion retinal
clomiphene associated occlusion vein
clomiphene associated occlusion
clomiphene citrate associated occlusion retinal
clomiphene citrate associated occlusion vein
clomiphene citrate associated occlusion
citrate associated occlusion retinal
citrate associated occlusion vein
citrate associated occlusion
CC citrate associated occlusion retinal
CC citrate associated occlusion vein
CC citrate associated occlusion
CC occlusion vein retinal
CC occlusion vein
CC occlusion
CC courses developed occlusion retinal
CC courses developed occlusion vein
CC courses developed occlusion
CC complications literature search include uncommon disturbance visual
CC complications literature search include uncommon disturbance
CC intake disturbance visual
CC intake disturbance
CC occlusion vein retinal
CC occlusion vein
CC occlusion
pemoline overdose
lithium therapy insipidus nephrogenic
lithium therapy insipidus diabetes
lithium therapy insipidus
lithium induced insipidus nephrogenic
lithium induced insipidus diabetes
lithium induced insipidus
lithium therapy discontinued diagnosed have lithium induced insipidus nephrogenic
lithium therapy discontinued diagnosed have lithium induced insipidus diabetes
lithium therapy discontinued diagnosed have lithium induced insipidus
lithium cessation remained thirsty polyuric
lithium cessation remained showed evidence insipidus nephrogenic
lithium cessation remained showed evidence insipidus diabetes
lithium cessation remained showed evidence insipidus
Lithium considered persisted polyuria
lithium stopped persisted polyuria
Lithium considered insipidus nephrogenic
Lithium considered insipidus diabetes
Lithium considered insipidus
lithium stopped persisted considered insipidus nephrogenic
lithium stopped persisted considered insipidus diabetes
lithium stopped persisted considered insipidus
lithium patients management implications mechanisms insipidus nephrogenic
lithium patients management implications mechanisms insipidus diabetes
lithium patients management implications mechanisms insipidus
Dapsone associated anemia hemolytic
Dapsone associated anemia
dapsone dose taking developed anemia hemolytic
dapsone dose taking developed anemia
dapsone cause anemia hemolytic
dapsone cause anemia
rifampin proteinuria
rifampin treated patients 9 found proteinuria
Sirolimus proteinuria
Sirolimus proteinuria dysfunction renal
Sirolimus proteinuria dysfunction
Sirolimus represents advance prevention rejection nephropathy
sirolimus share designated non drug nephrotoxic
sirolimus associated dysfunction proteinuria
sirolimus mechanisms multifactorial proteinuria
sirolimus effects knowledge minimised close monitoring function proteinuria
sirolimus effects knowledge minimised use occurs proteinuria
sirolimus use kidney sirolimus effects knowledge minimised close monitoring function proteinuria
sirolimus use kidney sirolimus effects knowledge minimised use occurs proteinuria
Clomipramine exposure hoarding
Clomipramine exposure include anxiety
Clomipramine exposure include anxiety impairment memory
Clomipramine exposure include anxiety impairment
hydralazine induced hypotension
nitroglycerin hydralazine induced hypotension
Glyburide induced hepatitis
glyburide exist sulfonylurea reports hepatotoxicity
glyburide therapy initiation developed syndrome acute
glyburide therapy initiation developed syndrome hepatitis
glyburide therapy initiation developed syndrome like
glyburide therapy initiation developed syndrome
Glyburide produce hepatitis acute
Glyburide produce hepatitis
Glyburide produce illness like
Glyburide produce illness
puromycin aminonucleoside subunits targeting expression syndrome nephrotic
puromycin aminonucleoside subunits targeting expression syndrome
aminonucleoside subunits targeting expression syndrome nephrotic
aminonucleoside subunits targeting expression syndrome
PAN treatment induced proteinuria hypoalbuminemia
PAN treatment induced proteinuria ascites
PAN treatment induced proteinuria
PAN associated syndrome nephrotic
PAN associated syndrome
PGE NGF increased patients OAB
2 PGE NGF increased patients OAB
PGF NGF increased patients OAB
2 alpha PGF NGF increased patients OAB
alpha PGF NGF increased patients OAB
PGE OAB
2 PGE OAB
PGF alpha correlate parameters patients OAB
2 alpha correlate parameters patients OAB
alpha correlate parameters patients OAB
iron dextran induced degeneration
iron dextran induced degeneration neurons of
iron dextran induced degeneration neurons dopaminergic
iron dextran induced degeneration neurons
dextran induced degeneration
dextran induced degeneration neurons of
dextran induced degeneration neurons dopaminergic
dextran induced degeneration neurons
iron animals content detection study degeneration
iron animals content detection study degeneration neurons of
iron animals content detection study degeneration neurons dopaminergic
iron animals content detection study degeneration neurons
dextran animals content detection study degeneration
dextran animals content detection study degeneration neurons of
dextran animals content detection study degeneration neurons dopaminergic
dextran animals content detection study degeneration neurons
iron dextran increase SN causes degeneration
iron dextran increase SN causes degeneration neurons of
iron dextran increase SN causes degeneration neurons dopaminergic
iron dextran increase SN causes degeneration neurons
dextran increase SN causes degeneration
dextran increase SN causes degeneration neurons of
dextran increase SN causes degeneration neurons dopaminergic
dextran increase SN causes degeneration neurons
carbimazole reactivity hepatitis Toxic
carbimazole reactivity hepatitis
carbimazole hepatitis
carbimazole mixed cholestatic
carbimazole replaced appeared hepatitis
alprazolam patients developed reactions depression
alprazolam patients developed reactions memory impaired
alprazolam patients developed reactions memory
alprazolam patients developed reactions memory ataxia
alprazolam patients developed reactions depression enuresis
alprazolam patients developed reactions memory loss weight
alprazolam patients developed reactions memory loss
everolimus prophylaxis Graft associated incidence syndrome microangiopathy
tacrolimus everolimus prophylaxis Graft associated incidence syndrome sinusoidal
tacrolimus everolimus prophylaxis Graft associated incidence syndrome obstruction
tacrolimus everolimus prophylaxis Graft associated incidence syndrome
tacrolimus everolimus prophylaxis Graft associated incidence syndrome microangiopathy
everolimus prophylaxis Graft associated incidence syndrome sinusoidal
everolimus prophylaxis Graft associated incidence syndrome obstruction
everolimus prophylaxis Graft associated incidence syndrome
mepivacaine 850 block performance mg observed increase
mepivacaine 850 block performance mg observed increase pressure in
mepivacaine 850 block performance mg observed increase pressure blood
mepivacaine 850 block performance mg observed increase pressure
adrenaline containing mg observed increase
adrenaline containing mg observed increase pressure in
adrenaline containing mg observed increase pressure blood
adrenaline containing mg observed increase pressure
mepivacaine 850 block performance mg observed increase accompanied fibrillation atrial
mepivacaine 850 block performance mg observed increase accompanied fibrillation
adrenaline containing mg observed increase accompanied fibrillation atrial
adrenaline containing mg observed increase accompanied fibrillation
epinephrine hydrocortisone dipyridamole Effects induced injury myocardial
epinephrine hydrocortisone dipyridamole Effects induced injury
epinephrine infusion injury myocardial
epinephrine infusion injury
sumatriptan use sensations Atypical
sumatriptan use sensations
T had effect locomotion irritability
T had increased preference aggression
enalapril assigned Patients RESULTS had likelihood function decreased
enalapril assigned Patients RESULTS had likelihood function renal
enalapril assigned Patients RESULTS had likelihood function
enalapril groups placebo associated function decreased
enalapril groups placebo associated function renal
enalapril groups placebo associated function
diuretic therapy age associated function decreased
diuretic therapy age associated function renal
diuretic therapy age associated function
enalapril group significantly % 32 1 52 associated risk developing function decreased
enalapril group significantly % 32 1 52 associated risk developing function renal
enalapril group significantly % 32 1 52 associated risk developing function
enalapril group significantly % 32 1 52 associated risk developing function decreased
enalapril group significantly % 32 1 52 associated risk developing function renal
enalapril group significantly % 32 1 52 associated risk developing function
enalapril 52 associated risk developing function decreased
enalapril 52 associated risk developing function renal
enalapril 52 associated risk developing function
enalapril group function decreased
enalapril group function renal
enalapril group function
Diuretic therapy associated risk function decreased
Diuretic therapy associated risk function renal
Diuretic therapy associated risk function
Enalapril use caused risk function decreased
Enalapril use caused risk function renal
Enalapril use caused risk function
enalapril group reduced associated risk impairment renal
enalapril group reduced associated risk impairment
capsaicin injection determined obtained stimuli hyperalgesia mechanical
capsaicin injection determined obtained stimuli hyperalgesia
capsaicin injection determined obtained stimuli hyperalgesia allodynia
capsaicin injection reduced hyperalgesia mechanical
capsaicin injection reduced hyperalgesia
capsaicin injection reduced hyperalgesia allodynia
losartan administration anuria
losartan administration developed episodes anuria
losartan mg dose resulted anuria
losartan prescribed developed episode anuria
omeprazole use associated anemia Hemolytic
omeprazole use associated anemia
omeprazole use reaction anemia hemolytic
omeprazole use reaction anemia
omeprazole starting days developed weakness lethargy
omeprazole starting days developed weakness shortness
omeprazole starting days developed weakness breath of
omeprazole starting days developed weakness breath
omeprazole caused anemia hemolytic
omeprazole caused anemia
beta selected carboline sensitive seizures
carboline sensitive seizures
methyl beta injection resistance seizures
beta injection resistance seizures
carboline injection resistance seizures
3 carboline injection resistance seizures
carboxylate injection resistance seizures
beta carboxylate injection resistance seizures
CCM beta carboxylate injection resistance seizures
picrotoxin states recording induced plus induced diazepam induced seizures
pentylenetetrazol picrotoxin states recording induced plus induced diazepam induced seizures
lopinavir related dilated
lopinavir related cardiomyopathy
ritonavir therapy agent lopinavir related dilated
ritonavir therapy agent lopinavir related cardiomyopathy
lopinavir related dilated developed block heart
lopinavir related dilated developed block
ritonavir therapy agent lopinavir related dilated developed block heart
ritonavir therapy agent lopinavir related dilated developed block
lopinavir agent developed bradycardia
ritonavir therapy agent developed bradycardia
nitric hypertension
oxide hypertension
NO synthesis Inhibition induces hypertension
NO ATPase response induced hypertension
NO rats induced hypertension
NO Inhibition synthase induced hypertension
venlafaxine overdose
venlafaxine overdose resulting Seizure
venlafaxine overdose
venlafaxine overdose
venlafaxine experienced seizure
venlafaxine overdose
venlafaxine overdose case resulted seizure
venlafaxine overdose
venlafaxine overdose patient resulted episode seizure
theophylline fenoldopam induced arteritis
fenoldopam induced arteritis
theophylline vasodilators induced Arteritis
fenoldopam vasodilators induced Arteritis
streptozotocin caused function reverse mellitus diabetes
streptozotocin caused function reverse mellitus
streptozotocin function investigated rats diabetic
streptozotocin diabetes
ketoconazole ingestion developed weakness extremities tremor
ketoconazole ingestion developed weakness
ketoconazole ingestion developed weakness extremities of
ketoconazole ingestion developed weakness extremities
ketoconazole ingestion developed weakness extremities paralysis legs
ketoconazole ingestion developed weakness extremities paralysis
ketoconazole ingestion developed weakness extremities dysarthria
gentamicin induced failure acute
gentamicin induced failure renal
gentamicin induced failure
GM gentamicin induced failure acute
GM gentamicin induced failure renal
GM gentamicin induced failure
gum rats treatment effect assessed Arabic failure acute
gum rats treatment effect assessed Arabic failure renal
gum rats treatment effect assessed Arabic failure
Arabic failure acute
Arabic failure renal
Arabic failure
tacrolimus Recovery associated neuritis brachial
tacrolimus Recovery associated neuritis
cocaine use delirium
cocaine toxicity mechanisms provide Fatal use delirium
cocaine induced delirium
cocaine induced delirium EDDs
cocaine registry compared EDDs
cocaine registry compared delirium
cocaine overdose victims compared EDDs
cocaine overdose victims compared delirium
cocaine concentrations had EDDs
cocaine use disrupts precipitate agitation death sudden
cocaine use disrupts precipitate agitation death
cocaine use coupled disrupts precipitate agitation death sudden
cocaine use coupled disrupts precipitate agitation death
cocaine use disrupts precipitate agitation rhabdomyolysis
cocaine use coupled disrupts precipitate agitation rhabdomyolysis
cocaine use disrupts precipitate agitation delirium
cocaine use coupled disrupts precipitate agitation delirium
levofloxacin warfarin interaction result appear cases complications bleeding
warfarin interaction result appear cases complications bleeding
tAMCA retains action convulsive
tAMCA caused activity associated behaviours convulsive
tAMCA concentration increased degree seizures
tAMCA evoked seizures generalized
tAMCA evoked seizures
tAMCA evoked mg correlated potentials convulsive
tAMCA concentration evoked evoked seizures generalized
tAMCA concentration evoked evoked seizures
tAMCA concentration evoked evoked mg correlated potentials convulsive
Tranexamic acid retains action convulsive
acid retains action convulsive
cocaine induce sensitization seizures
lidocaine appearance induced convulsions
lidocaine appearance induced convulsions
cocaine that decreased induced convulsions
cocaine that decreased induced appearance induced convulsions
lidocaine administration reversed changes activity convulsive
lidocaine activity convulsive
cocaine lidocaine activity convulsive
lidocaine convulsions
lidocaine seizures
cocaine administration resulting kindling distinct have sensitization seizures
Triazolam induced episodes mania
triazolam doses induced episodes mania
triazolam action duration coincident excitement Manic
pilocarpine induced epilepsy
succinylcholine induced myalgia postoperative
succinylcholine induced myalgia
succinylcholine used proven agent reduction myalgia postoperative
succinylcholine used proven agent reduction myalgia
NH 4 mmol CL intraperitonealinjection minutes rats produced coma
4 mmol CL intraperitonealinjection minutes rats produced coma
CL intraperitonealinjection minutes rats produced coma
lignocaine anaesthesia syndrome Cauda
lignocaine anaesthesia syndrome equina
lignocaine anaesthesia syndrome
lignocaine anaesthesia syndrome review cases syndrome cauda
lignocaine anaesthesia syndrome review cases syndrome equina
lignocaine anaesthesia syndrome review cases syndrome
Sulpiride induced dystonia tardive
Sulpiride induced dystonia
sulpiride therapy starting developed dystonia
sulpiride reports dystonia tardive
sulpiride reports dystonia
carboplatin dose using induced Anemia
carboplatin application days administered rHuEPO prevented development anemia
Nicotine potentiation catalepsy
morphine potentiation catalepsy
nicotine catalepsy
morphine induced catalepsy
nicotine Morphine induced dose catalepsy
Morphine induced dose catalepsy
nicotine reduced induced catalepsy
morphine combination reduced induced catalepsy
nicotine morphine induced catalepsy
morphine induced catalepsy
nicotine induced morphine potentiation mediated concluded elicited catalepsy
morphine catalepsy
morphine potentiation mediated concluded elicited catalepsy
N rats Production cancer prostate
N rats Production cancer
nitroso rats Production cancer prostate
nitroso rats Production cancer
N rats Production cancer prostate
N rats Production cancer
methylurea rats Production cancer prostate
methylurea rats Production cancer
N treatments adenocarcinomas prostate
N treatments adenocarcinomas
nitroso treatments adenocarcinomas prostate
nitroso treatments adenocarcinomas
N treatments adenocarcinomas prostate
N treatments adenocarcinomas
methylurea treatments adenocarcinomas prostate
methylurea treatments adenocarcinomas
N treatments adenocarcinomas PAs
nitroso treatments adenocarcinomas PAs
N treatments adenocarcinomas PAs
methylurea treatments adenocarcinomas PAs
testosterone methylurea treatments adenocarcinomas prostate
testosterone methylurea treatments adenocarcinomas
propionate CAS testosterone methylurea treatments adenocarcinomas prostate
propionate CAS testosterone methylurea treatments adenocarcinomas
testosterone methylurea treatments adenocarcinomas PAs
propionate CAS testosterone methylurea treatments adenocarcinomas PAs
TP CAS testosterone methylurea treatments adenocarcinomas prostate
TP CAS testosterone methylurea treatments adenocarcinomas
TP CAS testosterone methylurea treatments adenocarcinomas PAs
TP treated PA
TP acted development cancer prostate
TP acted development cancer
alfentanil anesthesia rigidity muscle
alfentanil anesthesia rigidity
alfentanil prevented MED D induced rigidity muscle
alfentanil prevented MED D induced rigidity
valproic acid reaction Confusion
acid reaction Confusion
valproic acid observed reaction Confusion
acid observed reaction Confusion
valproic acid reported cases confusion
acid reported cases confusion
valproic acid reported confusion
acid reported confusion
valproic exposure weeks occurred Confusion
acid exposure weeks occurred Confusion
valproic acid confusion
acid confusion
D treatment globulin induced anemia aplastic
D treatment globulin induced anemia
penicillamine globulin induced anemia aplastic
penicillamine globulin induced anemia
D due therapy anemia aplastic
D due therapy anemia
penicillamine therapy described patient received due therapy anemia aplastic
penicillamine therapy described patient received due therapy anemia
D induced anemia aplastic
D induced anemia
penicillamine D induced anemia aplastic
penicillamine D induced anemia
adriamycin nephrosis
adriamycin dose given divided groups matched albuminuria
adriamycin nephrosis
levodopa dyskinesias
Levodopa induced present dyskinesias
Levodopa induced present dyskinesias LIDs
MPTP types Using parkinsonism
levodopa therapy duration progression rate involved development LIDs
levodopa therapy onset exposure Monkeys developed dyskinesia
levodopa administration days dyskinesia
levodopa therapy duration monkeys resistant LIDs
levodopa therapy duration monkeys resistant LIDs e developed dyskinesia
levodopa administration e LIDs
levodopa administration e developed dyskinesia
levodopa develop LIDs
levodopa develop demonstrate studying pathophysiology LIDs
Etoposide infarction myocardial
Etoposide infarction
etoposide containing reported occurrence infarction myocardial
etoposide containing reported occurrence infarction
verapamil induced bradycardia
dipyridamole administration occurred Angina
levodopa effect hypotensive
levodopa mechanism hypotensive
tobramycin netilmicin treated patients proportion occurred Nephrotoxicity
netilmicin treated patients proportion occurred Nephrotoxicity
piperacillin netilmicin four occurred Ototoxicity
piperacillin tobramycin occurred Ototoxicity
tobramycin occurred Ototoxicity
netilmicin four occurred Ototoxicity
tobramycin severe ototoxicity
netilmicin severe ototoxicity
Capsaicin applied increases
Capsaicin applied flow in
Capsaicin applied flow dural
Capsaicin applied flow dural and
Capsaicin applied flow dural cortical
Capsaicin applied flow blood
Capsaicin applied flow
Thyroxine abuse case thyrotoxicosis
thyroxine abuse considered remains cause thyrotoxicosis
ketoconazole treatment associated deaths two continued onset symptoms hepatitis
ketoconazole treatment associated deaths two continued onset symptoms jaundice
ketoconazole treatment advised monitoring intervals evidence hepatitis
ketoconazole treatment advised prevent injury hepatic
ketoconazole treatment advised prevent injury
digitalis stage induced arrhythmias ventricular
digitalis stage induced arrhythmias
digitalis stage induced two Using examined determined concentration model arrhythmia
adrenaline stage induced arrhythmias ventricular
adrenaline stage induced arrhythmias
adrenaline stage induced two Using examined determined concentration model arrhythmia
digitalis ligation concentrations arrhythmias
digitalis ligation concentrations arrhythmias
adrenaline concentrations arrhythmias
adrenaline concentrations arrhythmias
adrenaline concentration higher arrhythmia
adrenaline concentration higher those types arrhythmias
scopolamine model amnesia
scopolamine amnesia
Ketoconazole induced torsades
Ketoconazole induced torsades pointes de
Ketoconazole induced torsades pointes
ketoconazole taking developed torsades
ketoconazole taking developed pointes de
ketoconazole taking developed pointes
ketoconazole taking developed pointes TdP
ketoconazole taking developed interval prolonged
ketoconazole taking developed interval QT
ketoconazole taking developed interval
ketoconazole prolong induce TdP
ketoconazole administered patients factors syndrome long
ketoconazole administered patients factors syndrome QT
ketoconazole administered patients factors syndrome
cyclosporine showed decrease therapy secondary nephrotoxicity
cyclosporine dosages cause nephrotoxicity
M % groups treated steroid showed reduction
M % groups treated steroid showed reduction intake of
M % groups treated steroid showed reduction intake food
M % groups treated steroid showed reduction intake
T M % groups treated steroid showed reduction
T M % groups treated steroid showed reduction intake of
T M % groups treated steroid showed reduction intake food
T M % groups treated steroid showed reduction intake
T showed IIa atrophy
T showed IIa atrophy
T C rats performed study showed pronounced atrophy muscle
T C rats performed study showed pronounced atrophy
T pronounced atrophy muscle
T pronounced atrophy
capsaicin intensity modulation induced hyperalgesia
capsaicin attention affected hyperalgesia
capsaicin that similar magnitude modulation hyperalgesia
capsaicin treatment interaction suggest capsaicin induced hyperalgesia
capsaicin induced hyperalgesia
scopolamine test induced amnesia
dicyclomine scopolamine test induced amnesia
Suxamethonium infusion fasciculations
apraclonidine significant effects ocular
apraclonidine significant effects hypotensive
apraclonidine administration significant treated significant effects ocular
apraclonidine administration significant treated significant effects hypotensive
puromycin aminonucleoside subunit syndrome nephrotic
puromycin aminonucleoside subunit syndrome
aminonucleoside subunit syndrome nephrotic
aminonucleoside subunit syndrome
puromycin aminonucleoside syndrome nephrotic
puromycin aminonucleoside syndrome
aminonucleoside syndrome nephrotic
aminonucleoside syndrome
PAN aminonucleoside syndrome nephrotic
PAN aminonucleoside syndrome
PAN dose treated studied courses excretion proteinuria
PAN model phase syndrome nephrotic
PAN model phase syndrome
azithromycin associated hiccups
azithromycin therapy associated hiccups
azithromycin beginning presented hiccups
azithromycin Discontinuation resolved hiccups
baclofen azithromycin Discontinuation resolved hiccups
azithromycin mediated mechanism pathogenesis hiccups
sirolimus administration proteinuria
sirolimus use linked proteinuria
sirolimus use associated proteinuria
sirolimus therapy proteinuria
sirolimus therapy commencement association implicated etiology proteinuria
sirolimus implicated association commencement therapy proteinuria
sirolimus implicated etiology proteinuria
sirolimus initiation association proteinuria
sirolimus therapy correlated Proteinuria
sirolimus discontinuation resulted decrease proteinuria
Sirolimus induces pre proteinuria
sirolimus withdrawn improve Proteinuria
tacrolimus receiving patients groups compared period year group comprising patients hypertensive
tacrolimus associated nephrotoxicity reducing nifedipine recipients impact factor selecting agent treat hypertension
Ketamine elicited psychosis
Fluoxetine induced akathisia
fluoxetine receiving patients developed akathisia
fluoxetine purposeless indistinguishable akathisia
fluoxetine symptoms identical reported akathisia
fluoxetine akathisia
fluoxetine effect appeared Akathisia
fluoxetine akathisia
fluoxetine caused identical pathophysiology jitteriness akathisia
fluoxetine jitteriness pathophysiology identical caused fluoxetine akathisia
fluoxetine jitteriness akathisia
verapamil ablation induced tachycardia atrioventricular
verapamil ablation induced tachycardia reentrant
verapamil ablation induced tachycardia
verapamil block caused QRS established attack AVRT
warfarin trends hemorrhage
warfarin incidence bleeding
prochlorperazine administration infusion affect incidence akathisia
prochlorperazine administration compare rate akathisia
prochlorperazine administered reduction incidence akathisia
valsartan % day mg dose higher incidence drug edema
valsartan % % % day mg dose higher incidence drug edema
amlodipine group higher incidence drug edema
amlodipine % % day mg dose higher incidence drug edema
amlodipine % % % day mg dose higher incidence drug edema
amlodipine % % day mg dose higher incidence drug edema
Ceftriaxone associated pseudolithiasis biliary
Ceftriaxone associated pseudolithiasis
ceftriaxone leads pseudolithiasis
ceftriaxone treatment receiving patients evaluated importance pseudolithiasis
5 flourouracil induced syndrome apical
5 flourouracil induced syndrome ballooning
5 flourouracil induced syndrome
flourouracil induced syndrome apical
flourouracil induced syndrome ballooning
flourouracil induced syndrome
nitroprusside CPAP shunt hypotension
nitroprusside infusion produced decrease
nitroprusside infusion produced pressure in
nitroprusside infusion produced pressure arterial
nitroprusside infusion produced pressure blood
nitroprusside infusion produced pressure
Nitroprusside caused decreases
Nitroprusside caused pressure in
Nitroprusside caused pressure arterial
Nitroprusside caused pressure blood
Nitroprusside caused pressure
fentanyl neurotransmission Involvement rigidity muscular
fentanyl neurotransmission Involvement rigidity
fentanyl anesthesia dose effect well rigidity muscular
fentanyl anesthesia dose effect well rigidity
fentanyl rigidity muscular
fentanyl rigidity
Isoproterenol induces loss correlation injury myocardial
Isoproterenol induces loss correlation injury
isoproterenol demand unknown damage myocardial
isoproterenol demand unknown damage
isoproterenol demand hypotension hyperactivity myocardial
isoproterenol demand hypotension hyperactivity
isoproterenol induced injury integrity alterations explain changes related injury ischaemic
isoproterenol induced injury integrity alterations explain changes related injury
flunitrazepam injection pain
cisplatin nephrotoxicity
pilocarpine evoked epilepticus status
pilocarpine evoked epilepticus
pilocarpine evoked Infarcts
pilocarpine evoked Infarcts reticulata in
pilocarpine evoked Infarcts reticulata substantia
pilocarpine evoked Infarcts reticulata nigra
pilocarpine evoked Infarcts reticulata pars
pilocarpine evoked Infarcts reticulata
creatine supplementation associated fibrillation atrial
creatine supplementation associated fibrillation
levodopa Tiapride movements involuntary
levodopa Tiapride movements
levodopa Tiapride induced movements involuntary
levodopa Tiapride induced movements
levodopa dyskinesias
Aspirin induces anomalies developmental
Aspirin induces anomalies
acetylsalicylic -RSB- Aspirin induces anomalies developmental
acetylsalicylic -RSB- Aspirin induces anomalies
acid -RSB- Aspirin induces anomalies developmental
acid -RSB- Aspirin induces anomalies
ASA -RSB- Aspirin induces anomalies developmental
ASA -RSB- Aspirin induces anomalies
ASA administered strains Dawley Sprague results compare test confounds detection malformations
ASA malformations
ASA induces focused suggested induce defects ventricular
ASA induces focused suggested induce defects septal
ASA induces focused suggested induce defects
ASA induces focused suggested induce defects VSDs
ASA induces focused suggested induce defects VSDs
ASA induces focused suggested induce defects defects rats hernia diaphragmatic
ASA induces focused suggested induce defects defects rats hernia
ASA induces focused suggested induce defects defects rats DH
ASA induces focused malformations
ASA induces low malformations
ASA administered similar Variations malformations
ASA induced titrating dose achieve dose malformations
Suxamethonium induced arrest cardiac
Suxamethonium induced arrest
suxamethonium use hyperkalaemia result death case arrest cardiac
suxamethonium use hyperkalaemia result death case arrest
suxamethonium use hyperkalaemia
suxamethonium arrest cardiac
suxamethonium arrest
suxamethonium bradycardia
suxamethonium administration hyperkalaemia
suxamethonium caused hypersensitivity
bromocriptine isoproterenol pretreatment Effects tachycardia
bromocriptine shown mediated tachycardia
bromocriptine tachycardia
Isoproterenol pretreatment caused hypertrophy cardiac
Isoproterenol pretreatment caused hypertrophy
bromocriptine induced hypotension
bromocriptine induced hypotension tachycardia
Bromocriptine induced unaffected hypotension
isoproterenol pretreatment unaffected reversed bradycardia
Bromocriptine induced unaffected reversed tachycardia
domperidone i reduced effect bradycardia
isoproterenol pretreatment abolished 15 induced bradycardia
bromocriptine reversed abolished 15 induced tachycardia
bromocriptine tachycardia
dexmedetomidine sedation associated incidence bradycardia
sulindac group experienced loss hearing
sulindac group experienced loss
sorafenib sunitinib inhibitors number found cause hemolysis
sunitinib inhibitors number found cause hemolysis
oral contraceptives women liver hyperplasia focal
oral contraceptives women liver hyperplasia nodular
oral contraceptives women liver hyperplasia
contraceptives women liver hyperplasia focal
contraceptives women liver hyperplasia nodular
contraceptives women liver hyperplasia
oral contraceptives women liver hyperplasia adenomas
contraceptives women liver hyperplasia adenomas
oral contraceptives use associated hyperplasia focal
oral contraceptives use associated hyperplasia nodular
oral contraceptives use associated hyperplasia
contraceptives use associated hyperplasia focal
contraceptives use associated hyperplasia nodular
contraceptives use associated hyperplasia
oral contraceptives use associated hyperplasia one adenoma
contraceptives use associated hyperplasia one adenoma
methamphetamine associated gene psychosis
methamphetamine psychosis
METH methamphetamine psychosis
METH gene 5 induced psychosis
METH patients psychosis
METH associated rs RESULTS patients psychosis
METH HTR association psychosis
METH pathophysiology play HTR CONCLUSION psychosis
tacrolimus induced hypertrophy myocardial
tacrolimus induced hypertrophy
tacrolimus induced Herein describe myocardial
tacrolimus induced hypertrophy
tacrolimus concentration reducing resolved hypertrophy Myocardial
tacrolimus concentration reducing resolved hypertrophy
tacrolimus induces hypertrophy myocardial
tacrolimus induces hypertrophy
ticlopidine developed treatment jaundice
ticlopidine mechanisms unclear cholestasis
gold caused anemia aplastic
gold caused anemia
D case caused anemia aplastic
D case caused anemia
penicillamine anemia aplastic
penicillamine anemia
methylprednisolone administration CONCLUSIONS related incidence effects nausea
methylprednisolone administration CONCLUSIONS related incidence effects nausea vomiting
methylprednisolone administration CONCLUSIONS related incidence effects nausea headache
gentamicin methylprednisolone administration CONCLUSIONS related incidence effects nausea headache
gentamicin methylprednisolone administration CONCLUSIONS related incidence effects nausea
gentamicin methylprednisolone administration CONCLUSIONS related incidence effects nausea vomiting
capsaicin skin stimulation nociceptive induced gabapentin induced hyperalgesia secondary
capsaicin skin stimulation nociceptive induced gabapentin induced hyperalgesia
dipyridamole hyperemia
dipyridamole resulted stenosis hyperemia
dipyridamole analyzed demonstrated Thallium induced hyperemia
lithium feeding Effects failure chronic
lithium feeding Effects failure renal
lithium feeding Effects failure
Lithium caused hypertension proteinuria
Lithium caused hypertension
Li associated proteinuria
Li associated proteinuria hypertension
bromocriptine induced psychosis
bromocriptine received seen psychosis
Bromocriptine associated psychosis
bromocriptine cause psychosis
appetite suppressants associated incidence hypertension primary
appetite suppressants associated incidence hypertension pulmonary
appetite suppressants associated incidence hypertension
suppressants associated incidence hypertension primary
suppressants associated incidence hypertension pulmonary
suppressants associated incidence hypertension
appetite drugs intake associated disease hypertension Primary
appetite drugs intake associated disease hypertension pulmonary
appetite drugs intake associated disease hypertension
suppressant drugs intake associated disease hypertension Primary
suppressant drugs intake associated disease hypertension pulmonary
suppressant drugs intake associated disease hypertension
appetite suppressants taken patients uncertain diagnosis hypertension primary
appetite suppressants taken patients uncertain diagnosis hypertension pulmonary
appetite suppressants taken patients uncertain diagnosis hypertension
suppressants taken patients uncertain diagnosis hypertension primary
suppressants taken patients uncertain diagnosis hypertension pulmonary
suppressants taken patients uncertain diagnosis hypertension
appetite suppressants prescription policy lead incidence hypertension primary
appetite suppressants prescription policy lead incidence hypertension pulmonary
appetite suppressants prescription policy lead incidence hypertension
suppressants prescription policy lead incidence hypertension primary
suppressants prescription policy lead incidence hypertension pulmonary
suppressants prescription policy lead incidence hypertension
cocaine Stroke
amphetamine cocaine Stroke
cocaine use stroke
amphetamine cocaine use stroke
cocaine stroke
amphetamine cocaine stroke
cocaine 8 using admitted women matched ratio stroke
amphetamine / cocaine 8 using admitted women matched ratio stroke
cocaine use factor stroke
amphetamine cocaine use factor stroke
busulfan cystitis
busulfan cystitis appearances radiation cystitis
pyrazinamide induced dysosmia
pyrazinamide related disorder olfactory
pyrazinamide related disorder
pyrazinamide withdrawal disappeared Dysosmia
lovastatin dose associated rare Myopathy
capsaicin elicited pain
capsaicin amount administered evoke sensation painful
ketoprofen administration decreased aggregation platelet
ketoprofen administration decreased aggregation
ketoprofen group patient developed hematoma
risperidone syndrome Neuroleptic
risperidone syndrome malignant
risperidone syndrome
risperidone developed syndrome neuroleptic
risperidone developed syndrome malignant
risperidone developed syndrome
risperidone observed effects protection ensure syndrome neuroleptic
risperidone observed effects protection ensure syndrome malignant
risperidone observed effects protection ensure syndrome
Quinidine phenylethylbarbiturate induced hepatitis
phenylethylbarbiturate induced hepatitis
quinidine phenylethylbarbiturate administration year patient affected hepatitis
phenylethylbarbiturate administration year patient affected hepatitis
phenylethylbarbiturate itself responsible hepatitis
cytosine treatment neuropathy Peripheral
cytosine treatment neuropathy
arabinoside treatment neuropathy Peripheral
arabinoside treatment neuropathy
cytosine arabinoside therapy play unclear mechanisms neuropathy peripheral
cytosine arabinoside therapy play unclear mechanisms neuropathy
arabinoside therapy play unclear mechanisms neuropathy peripheral
arabinoside therapy play unclear mechanisms neuropathy
Sorafenib induced due spasm coronary
Sorafenib induced due spasm artery
Sorafenib induced due spasm
sorafenib induced spasm coronary
sorafenib induced spasm artery
sorafenib induced spasm
acetaminophen overdose failure associated edema cerebral
acetaminophen overdose failure associated edema
acetaminophen overdose failure hepatic
acetaminophen overdose failure
acetaminophen patient present induced unresponsive failure signs edema cerebral
acetaminophen patient present induced unresponsive failure signs edema
acetaminophen patient present induced unresponsive failure fulminant
acetaminophen patient present induced unresponsive failure hepatic
acetaminophen patient present induced unresponsive failure
nitroglycerin application sided received patients migraine
nitroglycerin induced attacks migraine
nitroglycerin developed patients migraine
nitroglycerin effect inducing seems migraine
nitroglycerin effect inducing seems suggesting importance development crisis migraine
D treated cirrhosis case polymyositis
penicillamine case polymyositis
D complications one develop Polymyositis
penicillamine Polymyositis
D receiving developed polymyositis
penicillamine therapy D receiving developed polymyositis
D followed polymyositis
penicillamine therapy followed polymyositis
cocaine LR mice treatment pre induced convulsions
cocaine effects anti ligands involved validate shown attenuate effects convulsive
cocaine effects convulsive
isoproterenol A effect infarction myocardial
isoproterenol A effect infarction
isoproterenol induced infarction myocardial
isoproterenol induced infarction
isoproterenol induced infarction myocardial
isoproterenol induced infarction
vancomycin aminoglycoside receiving patients confined occurred Thrombophlebitis
vancomycin aminoglycoside receiving patients confined nephrotoxicity ototoxicity
flutamide intramuscularly -RSB- evaluated anemia
leuprolide acetate 3 -RSB- evaluated anemia
acetate 3 -RSB- evaluated anemia
LHRH acetate 3 -RSB- evaluated anemia
A LHRH acetate 3 -RSB- evaluated anemia
dobutamine related myocarditis
dobutamine related myocarditis hypersensitivity
dobutamine related myocarditis eosinophilic
Succinylcholine induced rigidity masseter
Succinylcholine induced rigidity muscle
Succinylcholine induced rigidity
succinylcholine administration describe case rigidity masseter
succinylcholine administration describe case rigidity muscle
succinylcholine administration describe case rigidity
succinylcholine administration describe case rigidity jaw
succinylcholine administration describe case rigidity jaw steel of
succinylcholine administration describe case rigidity jaw steel
Sch administration describe case rigidity masseter
Sch administration describe case rigidity muscle
Sch administration describe case rigidity
Sch administration describe case rigidity jaw
Sch administration describe case rigidity jaw steel of
Sch administration describe case rigidity jaw steel
Ranitidine induced nephritis interstitial
Ranitidine induced nephritis
ranitidine case nephritis interstitial
ranitidine case nephritis
diethylstilbestrol induced tumors Pituitary
diethylstilbestrol induced tumors
DES diethylstilbestrol induced tumors Pituitary
DES diethylstilbestrol induced tumors
amiodarone administration pain low
amiodarone administration pain back
amiodarone administration pain
amiodarone loading initiation experienced pain low
amiodarone loading initiation experienced pain back
amiodarone loading initiation experienced pain
pentazocine affected muscle due neuropathy compression
pentazocine affected muscle due neuropathy
pentazocine induced myopathy
Paracetamol associated coma acidosis metabolic
Paracetamol associated coma acidosis
paracetamol ingestion failure acidosis metabolic
paracetamol ingestion failure acidosis
Penicillamine induced glomerulonephritis
D months presented rapidly glomerulonephritis
penicillamine treatment woman arthritis presented rapidly glomerulonephritis
D months presented rapidly glomerulonephritis RPGN
penicillamine treatment woman arthritis presented rapidly glomerulonephritis RPGN
D course case RPGN
penicillamine treatment emphasizes case RPGN
D induced angiopathy
penicillamine D induced angiopathy
isoniazid pretreated induced bradycardia
isoniazid hypotension doses induced tachycardia bradycardia
isoniazid hypotension
isoniazid bradycardia
Isoniazid increased bradycardia
puromycin amino injection induced NS
amino injection induced NS
nucleoside amino injection induced NS
PAN amino injection induced NS
PAN injection observed established NS
PAN induced NS
Doxorubicin cardiomyopathy
doxorubicin bed experienced cardiomyopathy
doxorubicin interaction fact attributed cardiomyopathy
tacrolimus triggered dysfunction resulted dysfunction myopathy
tacrolimus triggered dysfunction resulted dysfunction tubular
tacrolimus triggered dysfunction resulted dysfunction
lamivudine augmented triggered dysfunction resulted dysfunction tubular
lamivudine augmented triggered dysfunction resulted dysfunction
lamivudine augmented triggered dysfunction resulted dysfunction myopathy
sertraline fluoxetine receiving women sexually
sertraline fluoxetine receiving women dysfunctional
paroxetine fluoxetine receiving women sexually
paroxetine fluoxetine receiving women dysfunctional
fluoxetine receiving women sexually
fluoxetine receiving women dysfunctional
magnesium administration presenting gravis Myasthenia
magnesium administration presenting gravis
magnesium administration paralysis described patients gravis myasthenia
magnesium administration paralysis described patients gravis
fat diet sensitive rats obese
fat diet induces obesity
doxorubicin dose administered day regimen led cardiotoxicity dysfunction cardiac
doxorubicin dose administered day regimen led cardiotoxicity dysfunction
risperidone hyperprolactinemia
risperidone treated % present Hyperprolactinemia
risperidone started occurred occurred hyperprolactinemia
risperidone link study induced treatment hyperprolactinemia
disulfiram intoxication fold vocal
disulfiram intoxication fold
disulfiram intoxication fold palsy
disulfiram overdose caused neuropathy rare is report leading fold vocal
disulfiram overdose caused neuropathy rare is report leading fold
disulfiram overdose caused neuropathy rare is report leading fold palsy
disulfiram overdose caused neuropathy peripheral
disulfiram overdose caused neuropathy
ketamine buffers decreases duration hallucinations
Warfarin induced accelerated calcification artery
Warfarin induced accelerated calcification
Warfarin doses given rats enhance extent calcification artery
Warfarin doses given rats enhance extent calcification
Warfarin calcification artery
Warfarin calcification
Warfarin weeks Treatment caused calcification
Warfarin weeks Treatment caused calcification media of
Warfarin weeks Treatment caused calcification media the
Warfarin weeks Treatment caused calcification media artery
Warfarin treatment weeks detected calcification artery
Warfarin treatment weeks detected calcification
Warfarin growth calcification artery
Warfarin growth calcification
Warfarin groups treatment produced calcification
Warfarin groups treatment produced calcification media of
Warfarin groups treatment produced calcification media the
Warfarin groups treatment produced calcification media artery
Warfarin groups treatment produced calcification rats calcification artery
Warfarin groups treatment produced calcification rats calcification
Warfarin resistant groups either fed levels was determined explanation association calcification artery
Warfarin resistant groups either fed levels was determined explanation association calcification
Warfarin resistant groups either fed levels was calcification artery
Warfarin resistant groups either fed levels was calcification
Warfarin resistant groups either fed levels induced calcification artery
Warfarin resistant groups either fed levels induced calcification
Warfarin increased suggests related calcification artery
Warfarin increased suggests related calcification
Warfarin D synergy examined calcification artery
Warfarin D synergy examined calcification
Warfarin doses known calcification
Warfarin doses known calcification media of
Warfarin doses known calcification media the
Warfarin doses known calcification media artery
Warfarin D treated rats found sites calcification artery
Warfarin D treated rats found sites calcification
sirolimus Proteinuria
sirolimus therapy consequence reported proteinuria
SRL conversion displayed proteinuria
SRL use common proteinuria
DFO reduction submitted Subjects SNHL
oxacillin associated vasculitis Cutaneous
oxacillin associated vasculitis leucocytoclastic
oxacillin associated vasculitis
oxacillin treated man year developed failure renal
oxacillin treated man year developed failure
Oxacillin included drugs cause vasculitis leucocytoclastic
Oxacillin included drugs cause vasculitis
amphetamine dose sensitization cross behavioral
amphetamine dose sensitization cross
amphetamine dose sensitization
amphetamine dose sensitization cross behavioral
amphetamine dose sensitization cross
amphetamine dose sensitization
amphetamine hyperactive
amphetamine injection followed libitum groups amphetamine hyperactive
amphetamine injection followed chow injection followed libitum groups amphetamine hyperactive
amphetamine sucrose chow injection followed chow injection followed libitum groups amphetamine hyperactive
sucrose experienced animals hyperactive
sucrose % followed libitum groups amphetamine hyperactive
sucrose chow injection followed chow injection followed libitum groups amphetamine hyperactive
DX treated those treated animals appeared proteinuria
doxorubicin treatment prolonged intense 2 appeared Proteinuria
DX DXNP difference 2 appeared Proteinuria
Cocaine use predisposed rupture aneurysmal
Cocaine use predisposed rupture
AraG attributable effects included 2 neuropathy
AraG attributable effects included 2 neuropathy pain musculoskeletal
AraG attributable effects included 2 neuropathy pain
AraG greater toxicity Haematological
AraG greater toxicity
AraG giving safety supports monitored toxicity neurological
AraG giving safety supports monitored toxicity
rilmenidine rats operated elicited hypotension
alpha rilmenidine rats operated elicited hypotension
methyldopa elicited hypotension
rilmenidine effect contrast methyldopa alpha hypotension enhanced response hypotensive
rilmenidine effect contrast methyldopa alpha hypotension
alpha hypotension enhanced response hypotensive
methyldopa alpha hypotension enhanced response hypotensive
alpha hypotension
methyldopa alpha hypotension
alpha hypotension
methyldopa hypotension
alpha interaction hypotension
methyldopa alpha interaction hypotension
sirolimus due proteinuria
sirolimus due remained observed proteinuria
sirolimus therapy observed remained due proteinuria
sirolimus therapy observed proteinuria
sirolimus received patients observed observed remained due proteinuria
sirolimus received patients observed observed proteinuria
raloxifene due thromboembolism risk venous
raloxifene due thromboembolism
nicotine receptors induced hyperactivity
Nicotine caused increase
Nicotine caused activity in
Nicotine caused activity locomotor
Nicotine caused activity
Nicotine blocked hyperactivity
nicotine PHNO induced hyperactivity
nicotine injection induces hyperactivity
Suxamethonium induced apnea
Suxamethonium causes apnea
organophosphorus deactivated poisons gets apnea
OP organophosphorus deactivated poisons gets apnea
poisons gets apnea
OP compound attempt information concealed ensued apnea
compound attempt information concealed ensued apnea
levodopa involved unclear dyskinesia
3 induced anaemia
azido 3 induced anaemia
3 dideoxythymidine understood induced anaemia
' 3 dideoxythymidine understood induced anaemia
dideoxythymidine understood induced anaemia
AZT dideoxythymidine understood induced anaemia
AZT anaemia
AZT produced anaemia
AZT treated increased number fold anaemia
AZT treated appropriate observed degree anaemia
AZT treated degrees anaemia
AZT observed anaemia
AZT induced anaemia
amisulpride mg doses man hypertension
tiapride mg mg doses man headache vomiting
tiapride mg mg doses man headache
amisulpride mg doses man headache
tiapride mg mg doses man hypertension
amisulpride mg doses man headache vomiting
amisulpride therapy crisis hypertensive
tiapride amisulpride therapy crisis hypertensive
amisulpride crisis hypertensive
tiapride amisulpride crisis hypertensive
AZT induced cardiomyopathy
zidovudine investigate triggers Fas pathway model DCM
3 azido zidovudine investigate triggers Fas pathway model DCM
' 3 azido zidovudine investigate triggers Fas pathway model DCM
- azido zidovudine investigate triggers Fas pathway model DCM
azido zidovudine investigate triggers Fas pathway model DCM
2 azido zidovudine investigate triggers Fas pathway model DCM
3 triggers Fas pathway model DCM
deoxythymidine 3 triggers Fas pathway model DCM
AZT 3 triggers Fas pathway model DCM
AZT concentrations containing libitum received triggers Fas pathway model DCM
AZT - treated developed dilation cardiac
AZT - treated developed dilation
ribavirin treatment b case parasitosis delusional
ribavirin treatment b case parasitosis
pegylated alpha patient parasitosis delusional
pegylated alpha patient parasitosis
interferon alpha patient parasitosis delusional
interferon alpha patient parasitosis
alpha patient parasitosis delusional
alpha patient parasitosis
2 b case parasitosis delusional
2 b case parasitosis
b case parasitosis delusional
b case parasitosis
ribavirin b year woman developed parasitosis delusional
ribavirin b year woman developed parasitosis
pegylated alpha developed parasitosis delusional
pegylated alpha developed parasitosis
interferon alpha developed parasitosis delusional
interferon alpha developed parasitosis
alpha developed parasitosis delusional
alpha developed parasitosis
2 b year woman developed parasitosis delusional
2 b year woman developed parasitosis
b year woman developed parasitosis delusional
b year woman developed parasitosis
MPTP rendered parkinsonian
lidocaine group % fatal fatal dose convulsions
lidocaine group % fatal fatal % bupivacaine induced seizures
chloroprocaine group % induced bupivacaine % fatal dose convulsions
chloroprocaine group % induced seizures
bupivacaine % fatal dose convulsions
bupivacaine induced seizures
5 presented pain chest
5 presented pain
fluorouracil administration metastasis presented pain chest
fluorouracil administration metastasis presented pain
5 administration metastasis presented pain chest
5 administration metastasis presented pain
FU 5 administration metastasis presented pain chest
FU 5 administration metastasis presented pain
paroxetine related syndrome neuroleptic
paroxetine related syndrome malignant
paroxetine related syndrome
alprazolam paroxetine related syndrome neuroleptic
alprazolam paroxetine related syndrome malignant
alprazolam paroxetine related syndrome
paroxetine occur presented symptoms syndrome malignant neuroleptic
paroxetine occur presented symptoms syndrome malignant
paroxetine occur presented symptoms syndrome
paroxetine occur presented symptoms syndrome NMS
paroxetine occur presented demonstrating NMS
alprazolam treatment paroxetine occur presented symptoms syndrome malignant neuroleptic
alprazolam treatment paroxetine occur presented symptoms syndrome malignant
alprazolam treatment paroxetine occur presented symptoms syndrome
alprazolam treatment paroxetine occur presented symptoms syndrome NMS
alprazolam treatment paroxetine occur presented demonstrating NMS
cocaine toxicity blockade observed H reduced up seizures
puromycin aminonucleoside injection induced urea syndromes proteinuria hypoalbuminemia
aminonucleoside injection induced urea syndromes proteinuria hypoalbuminemia
puromycin aminonucleoside injection induced urea syndromes proteinuria hypercholesterolemia
aminonucleoside injection induced urea syndromes proteinuria hypercholesterolemia
puromycin aminonucleoside injection induced urea syndromes proteinuria
aminonucleoside injection induced urea syndromes proteinuria
puromycin aminonucleoside injection induced urea syndromes nephrotic
puromycin aminonucleoside injection induced urea syndromes
aminonucleoside injection induced urea syndromes nephrotic
aminonucleoside injection induced urea syndromes
amikacin toxicity retinal
amikacin toxicity
amikacin treatment toxicity retinal
amikacin treatment toxicity
chloramphenicol administration anemia aplastic
chloramphenicol administration anemia
chloramphenicol beginning undergoing died anemia aplastic
chloramphenicol beginning undergoing died anemia
chloramphenicol associated pattern anemia aplastic
chloramphenicol associated pattern anemia
chloramphenicol treatment report anemia aplastic
chloramphenicol treatment report anemia
ifosfamide Hallucinations
ifosfamide effect Hallucinations
ifosfamide cases reported hallucinations
ifosfamide interviewed authors METHODS hallucinations
ifosfamide hallucinations
picrotoxin pentetrazol induced convulsions inhibitors effects induction seizure
picrotoxin pentetrazol induced convulsions
flurothyl pentetrazol induced convulsions inhibitors effects induction seizure
flurothyl pentetrazol induced convulsions
pentetrazol induced convulsions inhibitors effects induction seizure
pentetrazol induced convulsions
PTZ prostaglandins induction seizure
PTZ prostaglandins induction effects inhibitors convulsions
bicuculline electroshock evaluated investigate relationship prostaglandins induction seizure
bicuculline electroshock evaluated investigate relationship prostaglandins induction effects inhibitors convulsions
picrotoxin convulsions fluorthyl induced convulsions
picrotoxin convulsions
fluorthyl induced convulsions
fluorthyl convulsions
PTZ fluorthyl induced convulsions
PTZ fluorthyl convulsions
bicuculline picrotoxin convulsions fluorthyl induced convulsions
bicuculline picrotoxin convulsions
azidothymidine induced suppression marrow
azidothymidine induced suppression
AZT induced anemia leukopenia
AZT induced anemia
AZT administration rendered anemic leukopenic
AZT administration rendered reversed induced anemia leukopenia
AZT administration water drinking days reversed rendered anemic leukopenic
AZT administration water drinking days reversed induced anemia leukopenia
AZT induced reversed rendered anemic leukopenic
AZT induced anemia leukopenia
AZT administration rendered anemic
AZT administration rendered reversed induced anemia
AZT administration water drinking days reversed rendered anemic
AZT administration water drinking days reversed induced anemia
AZT induced reversed rendered anemic
AZT induced anemia
AZT coadministered reduced AZT induced toxicity marrow
AZT coadministered reduced AZT induced toxicity
AZT induced toxicity marrow
AZT induced toxicity
levodopa overflow dyskinesias
levodopa therapy complications assessed dyskinesias
levodopa therapy complications assessed dyskinesias LID
levodopa complications assessed dyskinesias
levodopa complications assessed dyskinesias LID
levodopa with LID
levodopa dyskinesias
levodopa dyskinesias disease LID
levodopa assessed lift score dyskinesia
levodopa increased LID
apomorphine Development induced behavior aggressive
apomorphine Development induced behavior
apomorphine induced behavior aggressive
apomorphine induced behavior
apomorphine treatment induced development behavior aggressive
apomorphine treatment induced development behavior
apomorphine treatment induced evidenced intensity aggressiveness
apomorphine induced behavior aggressive
apomorphine induced behavior
isoproterenol status mangiferin Role infarction myocardial
isoproterenol status mangiferin Role infarction
isoproterenol Anacardiaceae induced infarction myocardial
isoproterenol Anacardiaceae induced infarction
isoproterenol Anacardiaceae induced infarction MI
ISPH Anacardiaceae induced infarction myocardial
ISPH Anacardiaceae induced infarction
ISPH Anacardiaceae induced infarction MI
ISPH induced rats MI
ISPH exerts due MI
quipazine aggressiveness induced deprivation induced twitches head
quipazine aggressiveness induced deprivation induced twitches
apomorphine deprivation induced aggressiveness
quipazine increased reduced twitches head
quipazine increased reduced twitches
apomorphine increased induced aggressiveness
oestrogen Long increased risk disease embolism stroke
oestrogen Long increased risk disease embolism gallbladder
oestrogen Long increased risk disease
oestrogen Long increased risk thrombo venous
oestrogen Long increased risk thrombo
oestrogen Long increased risk disease embolism
cisplatin observed limited dose e g nephrotoxicity ototoxicity
cisplatin associated toxicities dose e g nephrotoxicity ototoxicity
cisplatin observed limited dose e g nephrotoxicity
cisplatin associated toxicities dose e g nephrotoxicity
cisplatin trials suggested reduced incidence cisplatin induced nephrotoxicity ototoxicity
cisplatin induced nephrotoxicity ototoxicity
cisplatin trials suggested reduced incidence cisplatin induced nephrotoxicity
cisplatin induced nephrotoxicity
cisplatin trials suggested reduced incidence cisplatin induced nephrotoxicity neuropathy
cisplatin induced nephrotoxicity neuropathy
amitriptyline less incidence frequency vision mouth dry
amitriptyline less incidence frequency vision mouth
amitriptyline less incidence frequency vision blurred
amitriptyline less incidence frequency vision
propylthiouracil administration caused observations patient hepatitis chronic
propylthiouracil administration caused observations patient hepatitis active
propylthiouracil administration caused observations patient hepatitis active aggressive
propylthiouracil administration caused observations patient hepatitis
adriamycin dose developed failure congestive
adriamycin dose developed failure heart
adriamycin dose developed failure
adriamycin 2 mg receiving developed leukemia myeloblastic acute
adriamycin 2 mg receiving developed leukemia myeloblastic
adriamycin 2 mg receiving developed leukemia
Antituberculosis therapy induced failure acute
Antituberculosis therapy induced failure liver
Antituberculosis therapy induced failure
Antituberculosis therapy failure acute
Antituberculosis therapy failure liver
Antituberculosis therapy failure
Antituberculosis therapy failure ATT ALF
Antituberculosis therapy failure ALF
fentanyl Omission reduce incidence nausea postoperative
fentanyl Omission reduce incidence nausea
fentanyl Omission reduce incidence nausea and
fentanyl Omission reduce incidence nausea vomiting
fentanyl % discharge moderate reduce did reduce incidence nausea postoperative
fentanyl % discharge moderate reduce did reduce incidence nausea
fentanyl % discharge moderate reduce did reduce incidence nausea and
fentanyl % discharge moderate reduce did reduce incidence nausea vomiting
fentanyl fentanyl % discharge moderate reduce did reduce incidence nausea postoperative
fentanyl fentanyl % discharge moderate reduce did reduce incidence nausea
fentanyl fentanyl % discharge moderate reduce did reduce incidence nausea and
fentanyl fentanyl % discharge moderate reduce did reduce incidence nausea vomiting
fentanyl groups Combining revealed reducing nausea postoperative
fentanyl groups Combining revealed reducing nausea
fentanyl groups Combining revealed reducing nausea and
fentanyl groups Combining revealed reducing nausea vomiting
Fentanyl reduce increased depression hypotension
Fentanyl reduce increased depression bradycardia
Fentanyl reduce increased respiratory
Fentanyl reduce increased depression
fentanyl exacerbated nausea postoperative
fentanyl exacerbated nausea
fentanyl exacerbated nausea and
fentanyl exacerbated nausea vomiting
carrageenan model writhing
carrageenan model writhing induced acid paw model edema
